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2DE   2D gel electrophoresis
aa   amino acid
ACN   acetonitrile
AD   Alzheimer’s disease
AMPA   α-amino-3-hydroxy-5-methylisoxazole-4- propionic acid
α-CCA   α-cyano-4-hydroxycinnamic acid
AK   adenosine kinase
ASAPRatio  automated statistical analysis of protein abundance ratio
CHAPS   3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate
CID   collision-induced dissociation
CNS   central nervous system
DAB   diaminobenzidine tetrahydrochloride
DTT   DL-Dithiothreitol
EAAT2   excitatory amino acid transporter 2
ECM   extracellular matrix
EDTA   ethylenediaminetetraacetic acid
EtOH   ethanol
ER   endoplasmatic reticulum
Erk   extracellular regulated kinase
ESI-MS   electrospray ionization mass spectrometry
FT ICR   Fourier transform ion cyclotron resonance
GO   gene ontology
GFAP	 	 	 glial	fibrillary	acidic	protein
GluR2   glutamate receptor 2
Grp   glucose-regulated protein
GS   glutamine synthetase
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
hNT   human neurotrypsin
HRP   horseradish peroxidase
ICAT	 	 	 isotope-coded	affinity	tag
IEF   isoelectric focusing
IgG   immunoglobulin
IPG   immobilized pH gradient
kDa   kilo Dalton
KO   knock-out
L-LTP   late long-term potentiation
LTD   long term depression
µLC    microcapillary liquid chromatography
MALDI-TOF	 	 matrix-assisted	laser	disorption/ionization	time-of-flight
MAPK   mitogen-activated protein kinase
MPT   minimal probability threshold
mNT   mouse neurotrypsin
MetOH   methanol
m/z   mass-to-charge ratio
NMJ   neuromuscular junction
NMDAR  N-methyl-D-aspartic acid receptor
PAR   protease-activated receptor
PBS   phosphate buffered saline
PAK1   p21-activated kinase 1
PCR   polymerase chain reaction
PKC   protein kinase C
PSD   post-synaptic density
PVDF	 	 	 polyvinylidene	fluoride
ppm   parts per million
RF   radio frequency
RP   reversed phase
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis
SCX   strong cation exchange
SIC   single ion chromatogram
TAMRA   carboxytetramethylrhodamine
TBS   Tris buffered saline
TCEP   tris(2-carboxyethyl)phosphine hydrochloride
TFA	 	 	 triflouracetic	acid
tPA   tissue-type plasminogen activator
uPA   urokinase-type plasminogen activator
VDAC   voltage-dependent anion channel
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Summary 
Summary
Neurotrypsin is a multi-domain serine peptidase expressed in the developing and adult nervous 
system. Based on expression analysis we hypothesized that neurotrypsin is implicated in processes 
such as memory formation and learning. A four base-pair deletion in the human gene causes 
non-syndromic mental retardation. Recently the synapse organizer agrin, a large extracellular 
proteoglycan,	was	identified	as	a	specific	substrate	for	neurotrypsin	both,	in	vitro	and	in	vivo.	
Neurotrypsin cleaves agrin at two positions resulting in the generation of three products. Two 
fragments, the C-terminal 22-kDa LG3 domain and the 90-kDa intermediate fragment, are 
enriched in supernatants and soluble fractions and are therefore thought to be released into 
the ECM where they might freely diffuse. Probably the N-terminal fragment remains associated 
to the plasma membrane. No cleavage products are found in the neurotrypsin knock-out mice, 
suggesting an exclusive catalytic processing of agrin by neurotrypsin. Furthermore, it was shown 
by Hilgenberg et al. that the C-terminal LG3 fragment released after the cleavage can bind 
to the a3 subunit of Na+/K+-ATPase and is therefore capable to inactivate the ion pump and 
trigger a downstream signaling cascade, thereby regulating presynaptic excitability. However, 
the molecular function of the proteolytic cleavage and the fate of the newly generated 
fragments remain to be shown. To shed light on the molecular function and cellular processes 
that	are	affected	by	neurotrypsin	activity	we	performed	a	quantitative	protein	profiling.	We	
compared the protein composition of hippocampi and synapses from whole brains from 
wild-type	with	neurotrypsin-overexpressing	mice.	We	mainly	found	changed	proteins	that	are	
involved in exo- and endocytosis of synaptic vesicles, reorganization of the cytoskeleton, cell 
adhesion, termination of synaptic signaling, and energy metabolism. For example, we showed 
that the expression level of the synaptic protein kinase α-CaMK II was reduced in transgenic 
mice	by	about	10%.	We	found	elevated	levels	of	proteins	such	as	PAK1,	Cdc42,	and	p21-Rac,	
all of which regulate actin cytoskeleton polymerization and/or depolymerization. Moreover, 
the cell adhesion molecules L1 and NrCAM were decreased in soluble fractions by 20%. 
Changed abundance was also found for EAAT2 and glutamine synthetase, both of which 
were down regulated in membrane fractions by 25%. Finally, expression levels of PKC-α and -ε 
were decreased by 40%, whereas MAPK1 was increased by 20 – 40%. These results support the 
notion that neurotrypsin, together with agrin, is a crucial factor in synapse organization and they 
provide the basis for further studies demonstrating a functional role of neurotrypsin in synaptic 
signal transmission.
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Zusammenfassung
Neurotrypsin ist eine Multi-Domänen Serin Peptidase, welche am stärksten in dem sich 
entwickelnden und im adulten Nervensystem exprimiert ist. Basierend auf Expressionsanalysen 
geht man davon aus, dass Neurotrypsin in Gedächtnisbildung und Lernprozessen involviert 
ist. Eine Deletion von vier Basen im menschlichen Gen ruft eine schwere geistige Behinderung 
hervor. Kürzlich wurde gezeigt, dass Agrin, bekannt als grosses extrazelluläres Proteoglykan 
und	als	Organisator	 von	 Synapsen,	 ein	 spezifisches	 Substrat	 für	Neurotrypsin	 ist.	 Neurotrypsin	
spaltet Agrin an zwei Positionen und generiert so drei neue Agrin-Fragmente. Zwei davon, 
nämlich die C-terminale 22-kDa LG3-Domäne und das mittlere 90-kDa grosse Fragment, 
waren in Zellüberständen und löslichen Fraktionen angereichert. Demzufolge werden sie  in die 
extrazelluläre	Matrix	abgegeben	und	sind	darin	möglicherweise	frei	diffusionsfähig.	Wahrscheinlich	
bleibt der N-terminale Teil mit der Plasmamembran assoziert. In der Neurotrypsin knock-out Maus 
wurden bisher keine Agrin Spaltprodukte gefunden, was sehr für eine einzigartige katalytische 
Proteolyse von Agrin durch Neurotrypsin spricht. Zudem konnte kürzlich von Hilgenberg et al. 
gezeigt werden, dass die LG3-Domäne nach ihrer Freisetzung an die α3 Untereinheit der Na+/
K+-ATPase binden kann und somit via dieser Ionenpumpe eine nachgeschaltete Signalkaskade 
auslöst, welche schliesslich die präsynaptische Reizbarkeit steuert. Allerdings kennt man 
bis heute weder die molekulare Funktion dieser Interaktion noch das Schicksal der daraus 
entstehenden Produkte. Um über die molekularen Funktionen und zellulären Porzesse, welche 
durch die Aktivität von Neurotrypsin in Gang gesetzt werden, Aufschluss zu geben, wurde ein 
quantitatives	Proteinprofil	erstellt.	Wir	verglichen	die	Proteinzusammensetzung	von	Hippocampi	
und von gereinigten Synapsen aus dem Gesamtgehirn aus wildtyp Mäuse mit Neurotrypsin 
überexprimierenden Mäusen. Dabei wurden vor allem Proteine gefunden die in der Exo- und 
Endozytose von synaptischen Vesikeln, Neuorganisierung des Zytoskeletts sowie Zelladhäsion, 
der Beendigung von synaptischen Signalen und Energiemetabolismus involviert sind. Zum 
Beispiel konnten wir zeigen, dass der Grad der Expression von α-CaMK II in den trangsenen 
Tieren	um	etwa	10%	 reduziert	 ist.	Wir	 fanden	eine	erhöhte	 Expression	 von	PAK1,	Cdc42	und	
p21-Rac, Proteine, die alle die Polymerisierung und Depolymerisierung des Aktin Zytoskeletts 
regulieren. Des weiteren waren die Zelladhäsionsmoleküle L1 und/oder NrCAM in der löslichen 
Fraktion 20% herunter reguliert. Relativ veränderte Proteinmengen konnten auch für EAAT2 
und	die	Glutamin	 Synthetase	 gezeigt	werden.	 Die	 beiden	waren	 etwa	 25%	weniger	 häufig	
in den Membranfraktionen der transgenen Tieren. Zu guter Letzt war die Expression von PKC-
α and -ε um 40% herunter und die von MAPK1 um 20 – 40% herauf reguliert. Diese Resultate 
unterstützen die Hypothese, dass Neurotrypsin, zusammen mit Agrin, wichtige Faktoren sind, die 
für die Organisation von Synapsen witchtig sind, und zur sogenannten synaptischen Plastizität 
wesentlich	dazu	beitragen.	Des	Weiteren	bieten	sie	die	molekulare	Grundlage	für	zukünftige	
Studien, welche die funktionelle Rolle von Neurotrypsin in der synaptischen Signalübermittlung 
aufzeigen sollen.
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1. Introduction
1.1 Proteolytic enzymes
A fundamental condition for life is that organisms are provided with enzymes that are able to 
catalyze	chemical	 reactions	efficiently	and	 selectively.	Without	catalysis	chemical	 reactions	
such as hydrolytic cleavage could not occur on a useful time scale, and thus could not support 
life.
One important class of enzymes is the class of hydrolases and among them the hydrolases of 
peptide	bonds,	 the	peptidases.	 They	 form	 the	 subclass	3.4	of	 the	enzyme	classification	 (EC)	
system,	 the	 internationally	 recognized	scheme	 for	 the	classification	and	nomenclature	of	all	
enzymes. Since the EC system places each peptidase in one of just 13 subclasses, it inevitably 
pools together peptidases that are very different. About 1992, N. D. Rawlings and A.J. Barret 
started	to	develop	a	new	form	of	classification	system	for	peptidases,	grouping	them	in	a	way	
that	reflects	structural	features	and	evolutionary	relationships.	In	1996	the	system	was	published	
on the world wide web as the MEROPS database (URL: http://www.merops.sanger.co.uk).
The MEROPS	database	uses	a	hierarchical,	structure-based	classification	of	peptidases.	On	the	
basis of similarities in amino acid sequence each peptidase is assigned to a family, and families 
that are thought to be homologous are grouped together in a clan (Rawlings et al., 2006). The 
residue of the catalytic centre that mediates the nucleophilic attack on the peptide bond or 
the	metal	 ion	 required	for	catalytic	activity	defines	 the	classification:	At	present,	39	different	
clans and 183 families are registered; 14 aspartic peptidase families (A), 60 cysteine peptidase 
families (C), 1 glutamic peptidase family (G), 53 families of metallo peptidases (M), 42 serine 
peptidase families (S), 4 threonine peptidase families (T) and 9 families of unknown catalytic 
type (U). The importance of peptidases and their inhibitors is illustrated by the fact that ~2% of 
all genes encode peptidases and their homologs in all kinds of organisms, and that there are 
over 550 putatively active peptidases in the human genome.
1.1.1 Serine peptidases
Almost	one-third	of	all	peptidases	are	classified	as	 serine	peptidases.	 They	are	named	after	
their nucleophilic serine residue at the active site. Four different families of serine peptidases are 
known with ‘classic’ catalytic triads consisting of histidine, asparagine, and serine. The prototypic 
serine peptidases of the four families are chymotrypsin (S1), subtilisin (S8), carboxypeptidase Y 
(S10), and Clp protease (S14). The major difference among them is the order of the amino acid 
residues from the catalytic triad. To date the members of these families represent by far the vast 
majority of all known serine peptidases. The remainder of the serine peptidases bear ‘novel’ 
catalytic triads or dyads including Ser–His–Glu, Ser–His/Lys, His–Ser–His, and N-terminal Ser.
Serine peptidases can be found in eukaryotes, prokaryotes, archae, and viruses. They are 
involved in physiological processes including digestion, hemostasis, apoptosis, cell proliferation, 
reproduction, synaptic plasticity, and immune responses. Even cascades of sequential activation 
of	serine	peptidases	are	known,	e.g.	in	the	blood	coagulation,	where	they	were	first	observed	
and	characterized	complement	fixation,	matrix	remodeling,	and	differentiation.	These	diverse	
biological	processes	demand	a	wide	variety	of	specificities,	ranging	from	digestive	peptidases	
that	cleave	after	a	hydrophobic	or	positively	charged	residues	to	proteases	that	recognize	a	five	
amino	acid	stretch	or	even	hydrolyze	a	single	protein	only.	Specificity	can	often	be	presumed	
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from the topology of the substrate binding sites and the exosites, whose conformation often 
have striking consequences on the rates of proteolytic kinetics.
1.1.2 S1 family peptidases and their catalytic mechanism
Based on the nomenclature of chymotrypsin numbering the structure of the S1 family peptidases, 
also called chymotrypsin-like peptidases, is generally divided into catalytic, substrate recognition 
and zymogen activation domains. In addition to the proteolytic function, many serine peptidases 
are also modular proteins containing non-catalytic regulatory domains.
The catalytic triad spans the active site cleft, with the Ser195 on one side and the Asp102 and the 
His57 on the other side. The catalytic triad is part of an extensive hydrogen-bonding network (Fig. 
1.1). The oxyanion hole is formed by the backbone NHs of the amide bond of Gly193 and Ser195. 
These atoms form a pocket of positive charges that activates the carbonyl carbon of the scissile 
peptide bond and stabilizes the negatively charged oxyanion of the tetrahedral intermediate. 
Figure 1.1 shows schematically the mechanism of the proteolytic cleavage of peptide bonds. 
To hydrolyze a peptide bond, all peptidases must overcome three obstacles: i) Amide bonds 
are generally very stable due to electron donation from the amide nitrogen to the carbonyl. 
Thus, peptidases usually activate the amide bond via the interaction of the carbonyl oxygen 
of the substrate with the main chain NHs of Gly193 and Ser195. Only now comes the nucleophilic 
attack of the Ser195 oxygen on the carbonyl carbon. Assisted by His57, acting as a general base, 
a tetrahedral intermediate is formed. The resulting His57-H+ is stabilized by a hydrogen bond to 
Asp102, and the oxyanion of the tetrahedral intermediate is stabilized by an interaction with 
the main chain NHs of the oxyanion hole. ii) Amines are poor leaving groups, thus peptidases 
protonate the amine prior to expulsion: His57-H+ protonates the leaving amine and the tetrahedral 
intermediate collapses with the expulsion of R’NH2, the new N-terminal portion of the cleaved 
polypeptide chain, resulting in the acylenzyme intermediate. The leaving group will be replaced 
by water from the solvent. iii) But H2O	is	a	poor	nucleophile;	serine	peptidases	first	activate	H2O 
via a His57 activates water and the water molecule undergoes a nucleophilic attack to the 
carbon of the acylenzyme to form a second tetrahedral intermediate. The deacylation of the 
acylenzyme is essentially the reversal of the previous steps. The second tetrahedral intermediate 
collapses, by the release of the carboxylate product (the new C-terminal portion of the cleaved 
polypeptide chain) to yield the active enzyme. As the reaction proceeds, changes in bonding 
and charges at the scissile bond will propagate to more remote enzyme – substrate interactions 
and vice versa (Hedstrom, 2002).
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1.2 Peptidases are capable to modulate brain function
Peptidases and their natural inhibitors have been implicated in both physiological and 
pathophysiological processes in the central nervous system (CNS). They are involved in almost 
every aspect of neuronal development. Some are crucial for cell proliferation, neuronal 
migration,	neurite	outgrowth	and	path	finding,	synaptogenesis	and	synaptic	plasticity.	Others	
are required for neuronal death, tumor growth and invasion. They also contribute to a variety 
of neuropathologies, including neurodegenerative diseases (e.g. Alzheimer’s disease (AD), 
Parkinsons’s disease), demyelination diseases (e.g. multiple sclerosis), brain tumors and cerebral 
ischemia, hemorrhagic stroke, and epileptic seizures.
Four major classes of peptidase are present in the CNS. Those are the (1) serine peptidases, with 
the well-known members tPA, plasmin, thrombin, and neuropsin. Many different S1 family serine 
peptidases,	peptidase	receptors,	and	specific	inhibitors	are	expressed	in	the	brain	(Table	1.1);	
(2) matrix metalloproteases (MMPs), which consist of more than 20 members that all require 
Zn2+ for their enzymatic activity; (3) aspartic peptidases, such as the lysosomal peptidases 
cathepsins; and (4) cysteine peptidases, which include 14 caspases involved in distinct steps of 
the apoptotic pathway, as well as the intracellular active calpains.
A measurement for the persistent increase in the synaptic strength that last for minutes to 
several days is called long-term potentiation (LTP). It is widely accepted being one of the 
major mechanisms by which memory is formed and stored in the brain. Several peptidases 
are involved in the regulation of LTP (Fig. 1.2). From studies with transgenic animals lacking or 
overexpressing one or the other peptidase it was suggested that functional redundancy or 
compensation	among	different	members	and	their	inhibitors	do	exist.	Normally,	specific	inhibitors	
tightly regulate peptidase activity to prevent disastrous proteolysis. Imbalances in the catalytic 
activity of peptidases and their inhibitors compromises neural homeostasis and can result in 
neuropathological changes.
The following sections provide an overview of the functional mechanisms through which some of 
the peptidases contribute to the physiological and pathophysiological processes in the CNS.
Figure 1.1     The catalytic mechansim of chymotrypsin-like serine peptidases
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1.2.1 Plasminogen activators play a crucial role in the CNS
Plasminogen activators (PAs) are best known for their thrombolytic action to dissolve blood clots 
in	the	vasculature.	They	specifically	cleave	the	Arg-Val	bond	in	plasminogen.	Plasmin	 is	then	
able	to	digest	fibrin	polymers.	In	addition	to	that,	plasmin	has	a	wide	spectrum	of	substrates	in	
the	CNS,	including	extracellular	matrix	(ECM)	proteins,	such	as	fibronectin	and	laminin.
Two types of plasminogen activators (PAs) are known: tissue-type plasminogen activator (tPA) 
and urokinase-type plasminogen activator (uPA). They are encoded by two different genes 
and share similar enzymology, but differ in their domain organization and properties of the 
non-catalytic regions (Vassalli et al., 1991) (Fig. 1.3). In the normal CNS, tPA is the predominant 
PA whereas uPA is more relevant in the context of brain tumor biology (Levicar et al., 2003; 
Mohanam et al., 1994).
1.2.1.1 Tissue-type plasminogen activator
tPA is a secreted S1 serine peptidase that converts plasminogen to proteolytically active 
plasmin.	 Structurally,	 tPA	consists	 of	 an	N-terminal	 fibronectin	 type	 I	 domain	 (FN1),	 followed	
by an epidermal growth factor-like domain (EGF), two kringle domains (KR), and a C-terminal 
Figure 1.2     Schematic  representation of  peptidases  involved in  long-term potentiation (LTP).
AC: adenylate cyclase; AMPAR: α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor; D1: Dopamine 1-like 
receptor; DAG: diacylglycerol; IP3: inositol 1,4,5-triphosphate; LRP-1: low-density lipoprotein receptor-related protein-
1; NCAM L1: neural cell adhesion molecule L1; NMDAR: N-methyl-D-aspartic acid receptor; PAR-1: protease-activated 
receptor 1; PIP2: phosphatidylinositol (4,5)-bisphosphate; PLC: phospholipase C; PKA: cAMP-dependent kinase A; PKC: 
protein kinase C; PSD-95: postsynaptic density protein 95.
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catalytic domain consisting of Ser, His and Asp residues (Fig. 1.3). The presence of multiple non-
catalytic domains is critical in mediating protein-protein and cell-cell interactions. For instance, 
tPA	binds	to	fibrin	with	high	affinity	and	subsequently	has	an	increased	affinity	to	plasminogen.	
This	 interaction	 leads	 to	 an	 elevated	 catalytic	 efficiency	 on	 the	 activation	 of	 plasminogen	
between	100	and	1000-fold.	Hence,	poorly	active	tPA	is	released,	binds	to	fibronectin	or	laminin	
and is subsequently potentiated to activate plasminogen. However, the single chain, almost 
fully active enzyme, can further be processed into a two-chain, fully active form. The cleavage 
occurs proximal to the protease domain after Arg310 and is catalyzed by plasmin, kallikreins or 
factor	Xa.	tPA	chains	A	and	B	are	linked	via	an	interchain	disulfide	bond.
Within	the	CNS,	the	spatial	and	temporal	localization	of	tPA	presents	a	candidate	modulator	
of neurotransmission (Table 1.1). Upon neural activity tPA the transcript is regulated as an 
immediate-early gene (Qian et al., 1993). Both intracellular tPA protein and mRNA deposits have 
been localized to the synapse and various depolarizing agents promote exocytosis of tPA from 
neuronal stores (Gualandris et al., 1996). Moreover, its synthesis is increased in processes such as 
synaptic plasticity, motor learning and seizures (Qian et al., 1993; Seeds et al., 1995). On the other 
hand, tPA is also involved in pathological events, such as excitotoxic cell death. It was observed 
that	genetic	deficiency	of	tPA	(Tsirka	et	al.,	1995;	Tsirka	et	al.,	1997)	and	infusion	of	the	specific	
inhibitor	neuroserpin	(Yepes	et	al.,	2002)	results	in	a	significant	resistance	to	cell	death	induced	
either by direct injection of an excitotoxin or by generation of a seizure. In cerebral ischemia, 
tPA	seems	to	have	both	beneficial	(Marler	and	Goldstein,	2003)	and	deleterious	(Wang	et	al.,	
1998) effects. Early after onset of cerebral ischemia the associated neuronal depolarization in 
vivo leads to an increased secretion of tPA from neurons and microglial cells, followed by a 
compensatory expression of neuroserpin. If the ischemic insult is prolonged, the effect of tPA 
overcomes the balancing action of its inhibitor, and the unopposed neurotoxic effect results in 
cell death (Yepes et al., 2000). Most likely an abnormal high level of tPA-mediated plasmin activity 
induces	the	neurotoxic	 lesions,	 thereby	acting	on	non-fibrinogenic	substrates	to	compromise	
cell viability. It is very important to better understand the function of tPA, because recombinant 
tPA	is	now	used	as	treatment	for	occlusive	stroke	due	to	its	ability	to	dissolve	fibrin	clots	and	to	
allow	reperfusion	of	ischemic	brain	areas	(del	Zoppo	et	al.,	1997;	Hacke	et	al.,	1995;	Wardlaw	
et	al.,	1997).	However,	in	animal	models,	administered	tPA	can	penetrate	brain	tissue	(Wang	et	
al., 1998) and thus therapeutic thrombolytic treatment with tPA could have fatal consequences 
due to the production of excessive plasmin, which may elicit neuronal cell death. Another 
pathological situation where the tPA-plasmin system has been suggested to play a role is AD 
(Selkoe, 2001). In vitro experiments have shown that amyloid-ß (Aß) peptide can stimulate tPA 
activity, resulting in plasmin generation and subsequent Aß degradation (Kingston et al., 1995; 
Ledesma et al., 2000; Tucker et al., 2000). Recently, the contribution of the tPA-plasmin system in 
the clearance of Aß has also been shown in vivo (Melchor et al., 2003). These data suggest that 
tPA,	through	plasmin	generation,	could	have	beneficial	effects	for	AD	treatment.
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Neurotrypsin
Plasminogen
tPA
uPA
Thrombin
Neuropsin
Calpain M-type
H2N
H2N
H2N
H2N
H2N
H2N
H2N
COOH
COOH
COOH
COOH
COOH
COOH
COOH
SP PB PAN FN1 EGF GLA EFh KR
SRCR calpain III CysPcTryp_SPc
Figure 1.3     Comparison of the domain  structure of  neurotrypsin, plasminogen,  tPA, thrombin, uPA, neuropsin
and calpain M-type.
SP: Signal peptide; PB: Proline-rich basic segment, might mediate binding to components of cell surface and ECM; PAN: 
Apple domain, 6 conserved cysteines forming three disulphide bonds. Binds to kininogen, factor XIIa, factor IX, platelets, 
and heparin; FN1: Fibronectin type I domain, in tPA together with the EGF-like domain is involved in fibrin-binding; EGF: 
Epidermal grwoth factor-like domain is a repeat pattern involving a number of conserved Cys residues, thought to be 
important for its recognition by receptors and other molecules. Frequently found in extracellular proteins; GLA:Vitamin K-
dependent carboxylation/gamma-carboxyglutamic domain. Responsible for the high-affinity binding of Ca2+; EFh: EF-hand, 
Ca2+-binding motif that occurs at least in pairs. EF-hands undergo a conformational change upon Ca2+-binding; KR: Kringle 
domain, are triple-looped, disulfide cross-linked domains found in a varying number of copies, in some serine peptidases 
and plasma proteins. Thought to play a role in binding mediators, such as phospholipids and other proteins, and in the regu-
lation of proteolytic activity; SRCR: Scavanger receptor cysteine-rich domain, disulphide rich extracellular domains. Found 
in several extracellular receptors and may be involved in protein-protein interactions; CalpainIII: Calpain large subunit, 
with currently unknown function. Calpains participate in intracellular signaling pathways mediated by Ca2+-ions; Tryp_SPc: 
Trypsin-like serine peptidase with the catalytic traide Ser, Asp, His; Cys_Pc: Calpain-like thiol protease family (peptidase 
family C2). Ca2+-activated by the large subunit.
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1.2.1.2 Urokinase-type plasminogen activator
uPA	is	a	S1	serine	peptidase	first	 isolated	from	the	urine.	 It	exists	either	as	a	54	kDa	monomer	
or	as	a	homodimer	linked	by	an	interchain	disulfide	bridge	(Fig.	1.3).	uPA	is	a	member	of	the	
plasminogen activation system, which facilitates nerve regeneration by digesting adhesive cell 
contacts and by activation of other peptidases, thereby initiating a proteolytic cascade. The 
expression level of uPA seems to be much lower than that of tPA (Meiri et al., 1994). Both tPA and 
uPA activate some MMPs, either indirectly via plasminogen activation or directly, such as the uPA 
activation	of	MMP-2	(Siconolfi	and	Seeds,	2003).	It	is	synthesized	as	a	proenzyme	with	little	or	no	
activity and can be activated by various peptidases, including its immediate substrate plasmin, 
generating a positive feedback loop of self-activation (Levicar et al., 2003). It has been clearly 
shown	that	a	specific	glycosylphosphatidyl-inositol	(GPI)-anchored	receptor	for	uPA	(uPAR)	 is	
expressed on the surface of many cell types (Roldan et al., 1990) (Table 1.1). The uPA-uPAR 
interaction occurs between the EGF-like domain of uPA and the N-terminus of the receptor with 
high	specificity	and	affinity.	The	interaction	induces	conformational	changes	in	uPAR,	which	is	
then able to bind plasmin(ogen), integrin, and the ECM protein vitronectin. This multi protein 
complex formation facilitates local proteolysis, ECM degradation, and eventually neurite 
outgrowth or cell migration. Considering the necessity of cell movement and tissue invasion 
during tumor progression it is not surprising that uPA-uPAR is closely related to the growth and 
dissemination of various tumors, including those originating in the brain (Mohanam et al., 1994; 
Schmitt et al., 1997). Both mRNA and protein levels of uPA and uPAR are dramatically enriched 
in malignant brain tumors (Kinder et al., 1993; Landau et al., 1994). High levels of uPAR and uPA 
activity correlate with cellular degradation of the ECM, cell migration, and Matrigel invasion in 
a dose-dependent manner. Therefore, blocking the uPA-uPAR interaction is being targeted as 
a novel strategy to inhibit growth and spread of malignant brain tumors that are refractory to 
conventional therapy (Reuning et al., 2003). E.g. down regulation of uPAR by antisense RNA or 
blockage	of	uPA-uPAR	interaction	by	specific	ligands	inhibits	glioblastoma	cell	migration	in vitro 
and in vivo (Mohan et al., 1999; Mohanam et al., 2002). However, given the fact that uPA and 
uPAR are synthesized by many cell types throughout the body and are critical in maintaining 
ECM	turnover,	it	is	conceivable	that	nonspecific	inhibition	might	have	harmful	consequences.
1.2.2 tPA modulates neurotransmission and synaptic plasticity
Via proteolytic remodelling of cell-cell and cell-matrix molecules and non-proteolytic 
mechanisms tPA is engaged in the formation of LTP, neurite outgrowth, cell migration, and 
microglia activation. Several lines of evidence indicate multiple mechanisms by which tPA 
could exert its modulatory effect on neurotransmission and synaptic plasticity.
1.2.2.1 tPA interacts with NMDA receptors
Controversial evidence suggests that tPA might be involved in the modulation of NMDA 
receptor (NMDAR) function. A physical interaction between tPA and the glutamate receptor 
NR1 subunit was demonstrated. The tPA cleavage, which could enhance NMDA-evoked rise 
in free intracellular calcium (∆[Ca2+]i), was localized to the C-terminal side of Arg260 of the NR1 
subunit (Fernandez-Monreal et al., 2004; Liot et al., 2004; Nicole et al., 2001) (Fig. 1.4, left). A 
role for plasmin in tPA-mediated NR1 proteolysis was considered unlikely because incubation 
of recombinant NR1 with plasmin led to complete degradation (Fernandez-Monreal et al., 
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2004;	Matys	and	Strickland,	2003).	The	specific	tPA-NR1	interaction	was	defined	from	embryonic	
neuronal cultures, whereas others, utilizing lysates from adult mouse brain, failed to detect the 
tPA-mediated cleavage of NR1 (Kvajo et al., 2004; Liu et al., 2004; Matys and Strickland, 2003). 
Furthermore, the fact that co-immunoprecipitation of tPA with NR2B but to a lesser extent with 
NR1 was observed in three month old wild-type mice (Pawlak et al., 2005a) strongly suggests 
that the type of action of tPA on NMDA receptor subunits depends on the developmental 
stage. However, direct evidence that NR1 cleavage has an electrophysiological consequence 
is lacking. Since ∆[Ca2+]i	is	not	a	reflection	of	NMDA-mediated	excitatory	postsynaptic	current	
(EPSCs), it is conceivable that the potentiation of ∆[Ca2+]i by tPA may lie downstream of other 
receptor-mediated signaling events. This hypothesis is emphasized by the fact that in primary 
hippocampal neurons tPA promotes a proteolytic-independent activation of the Erk1/2 signal 
transduction pathway through NMDA receptors, possibly NR2B, G proteins and PKC. The 
activation of this signaling pathway results in glycogen synthetase kinase 3 (GSK3) activation, 
a process that requires de novo protein synthesis, and leads to tau hyperphosphorylation, 
microtubule destabilization and apoptosis. Similar effects are produced by amyloid aggregates 
in a tPA-dependent manner. Consistently, it was shown that tPA co-localizes with amyloid-rich 
areas, activated Erk1/2 and phosphorylated tau in senile plaques of AD human brains (Medina 
et al., 2005).
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1.2.2.2 tPA induces late-LTP through the association with LRP-1
Extracellular tPA activity is controlled by neuroserpin and plasminogen activator inhibitor 
(PAI)-1. It is targeted to cell surfaces by association with Annexin II and lipoprotein receptor-
related protein (LRP)-1. LRP-1 is a member of the low-density lipoprotein receptor (LDLR) family 
of endocytic receptors. LRP-1 is widely expressed throughout the CNS where it mediates the 
signaling and catabolism of many ligands. Indeed, LRP-1 endocytoses free tPA as well as 
inhibitory	complexes	 tPA:PAI-1	 (Makarova	et	al.,	2003).	Mice	deficient	 in	 tPA	 (tPA-/-) exhibit a 
selective reduction in late LTP (L-LTP) in hippocampal slices in both the Schaffer collateral-CA1 
Figure 1.4     Mechanism by which tPA 
influences glutamatergic transmis-
sion.
Left: tPA cleavage of the glutamate re-
ceptor NR1 subunit increases NMDAR-
dependent Ca2+-flux and excitotoxic cell 
death. Right: Lipoprotein receptor-re-
lated protein 1 (LRP-1) is tethered to the 
NMDA receptor via PSD-95. tPA facili-
tates NMDAR-dependent late-LTP at the 
CA1 synapse by binding to LRP-1 and 
transducing a signal that elevates PKA 
levels. For simplicity, only the exocytosis 
of tPA from presynaptic stores is depict-
ed. However, tPA stores within the post-
synapse have also been demonstrated.
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and	mossy	fiber-CA3	pathways	(Huang	et	al.,	1996).	Application	of	tPA	restored	L-LTP	along	the	
CA1 pathway and increased protein kinase A (PKA) activity (Zhuo et al., 2000). Interestingly, 
co-application of tPA together with the LDLR ligand blocker receptor-associated protein, RAP, 
ablated both the restoration of L-LTP and the activation of PKA. Although other LDLR family 
members are crucial for LTP, LRP-1 is the most intriguing in this respect given its known association 
with tPA. In addition, other LRP-1 ligands – α-2-macroglobulin, lactoferrin, apoε4 – can also 
modulate NMDA receptor-evoked ∆[Ca2+]i (Qiu et al., 2003). To this end, LRP-1 is tethered to the 
NMDA receptor via postsynaptic density protein 95, PSD-95, in an activity-dependent manner 
(May et al., 2004). Altogether, free tPA and tPA:LRP-1 complexes are ideally suited to be NMDA 
receptor modulators (Fig. 1.4).
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1.2.2.3 tPA facilitates late-LTP via the dopaminergic system
The striatum is heavily innervated by dopaminergic neurons. Dopamine is a slow-acting 
neuromodulatory transmitter that exerts its effect on two classes of receptors: D1-like receptors 
that couple to Gs proteins and elevate cAMP and D2-like receptors that couple to Gi proteins 
and suppress cAMP. Substantial evidence for tPA involvement in dopaminergic transmission has 
been obtained in the synaptic plasticity paradigms of LTP and drug addiction. Despite unaltered 
physiological and pharmacological EPSPs, tPA-/- mice showed impairment in corticostriatal 
LTP (Centonze et al., 2002). Mimicking D1-receptor activation by an elevation of cAMP could 
restore LTP. It was therefore postulated that tPA facilitates D1-mediated signaling. In addition a 
reduced level of D2 receptor was found in tPA-/-	striatum,	which	seems	to	reflect	an	adaptation	
to attenuated high levels of cAMP and activated PKA (Fig. 1.5, left). Nevertheless, whether and 
how tPA acts on D1 receptor signaling and thus elevates the level of postsynaptic cAMP remains 
to be shown. Connections between tPA and dopaminergic transmission in LTP has also been 
made along the CA1 and CA3 circuits (Huang et al., 1996). These two forms of hippocampal 
LTP can also be evoked by the pharmacological elevation of cAMP. However, in tPA-/- mice, LTP 
induced by D1 agonist was abolished in CA1, and forskolin, a cAMP agonist could also reduce 
Figure 1.5     Mechanism by which 
tPA influences dopaminergic trans-
mission.
The D1 class of dopamine receptors 
couples to Gs protein and elevates 
cAMP/PKC levels upon activation of 
adenylate cyclase (AC). Left: In the 
striatum, tPA-/- mice have impaired 
D1receptor-mediated signaling that 
impedes corticostriatal LTP induction. 
Right: In the nucleus accumbens, 
tPA-mediated generation of plasmin 
triggers dopamine release upon mor-
phine injection. This underlies the 
plasticity-related behavioral sensitiza-
tion brought on by morphine adminis-
tration.
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L-LTP in CA3. Huang and colleagues speculated that dopamine-induced rise in cAMP might 
initiate immediate-early gene tPA that dramatically facilitates L-LTP in the hippocampus. In line 
with	LTP	being	a	molecular	correlate	for	learning	and	memory,	formation	of	cognitive	deficits	
in striatum-dependent but not in hippocampus-dependent tasks have been documented. 
Hence,	the	dopamine-dependent	deficiencies	in	hippocampal	L-LTP	in	tPA-/- mice may have 
an impact on behavioral processes such as anxiety and addiction and cannot be translated 
into	deficits	in	spatial	learning	and	memory.
1.2.2.4 tPA is involved in drug addiction
Drug abuse triggers cellular and behavioral changes that are long lasting, experience 
dependent, and strengthened by repetition. Synaptic plasticity is a crucial event that takes 
place in drug addiction. Furthermore, psychomotor stimuli, such as cocaine, morphine, and 
amphetamines are known to rely on dopaminergic transmission. It is therefore not surprising 
that tPA plays a prominent role in drug abuse. Morphine treatment altered the tPA expression 
via the generation of plasmin-induced dopamine release in the nucleus accumbens (NAcc) 
(Nagai et al., 2004) (Fig. 1.5, right). However, the plasmin-sensitive target remains unknown. 
Morphine-induced	 conditioned	 place	 preference	 and	 hyperlocomotion	 were	 significantly	
reduced in tPA-/- and plasminogen-/- (plg-/-) mice, being accompanied by a loss of dopamine 
release in the NAcc. Either exogenous tPA or plasmin reversed the defect of dopamine release 
and	hyperlocomotion	in	tPA-/-	mice.	These	findings	demonstrate	a	function	of	the	tPA-plasmin	
system in regulating dopamine release, which is involved in the rewarding effects of morphine.
Taken together, tPA is a multifaceted modulator of neuronal transmission and synaptic plasticity 
by both proteolytic and non-proteolytic type of action. As a peptidase it is capable to 
cleave two known important substrates in the brain: NR1 to alter ion channel properties and 
plasminogen to degrade ECM molecules. tPA can increase cell surface receptor activity and 
trigger intracellular signaling cascades, such as PKA and MAPK. Further, tPA can act as a ligand 
of LRP-1 in order to be desensitized and thereby facilitating NMDA receptor-dependent L-LTP 
in CA1. It can interact in an as yet unknown manner with D1-like receptors and increase L-LTP 
in	 the	striatum.	Generally,	 tPA	 is	accepted	as	crucial	 factor	 in	the	CNS	but	unidentified	non-
plasminogen substrates for tPA as well as the precise mechanism through which tPA exerts its 
function on dopaminergic transmission, LTP, and memory formation remain to be determined.
1.2.3 Plasminogen in the brain – a versatile peptidase activated by tPA and uPA
Plasminogen is the zymogen of S1 serine peptidase plasmin. It is a 92 kDa glycoprotein 
consisting	 of	 seven	 structural	 domains:	 a	 N-terminal	 preactivation	 peptide	 (PAN),	 five	 KR	
domains, and a C-terminal catalytic domain. (Fig. 1.3). The multiple kringle domains are crucial 
for substrate recognition, membrane association, and inhibitor binding (Syrovets and Simmet, 
2004). Plasmin can be cleaved and activated by both tPA and uPA, as well as by kallikrein and 
several coagulation factors. The activation of plasminogen occurs at the Arg561–Val562 peptide 
bond.	 This	 cleavage	gives	 rise	 to	 a	 two-chain	 protein	 linked	by	a	disulfide	bond.	 Plasmin	 is	
an important enzyme present in blood that degrades many blood plasma proteins, most 
notably	fibrin	clots.	Apart	from	fibrinolysis,	plasmin	proteolyses	proteins	in	various	other	systems:	
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it activates collagenases, some mediators of the complement system and weakens the wall of 
the	Graafian	follicle,	leading	to	ovulation.	It	cleaves	fibrin,	fibronectin,	thrombospondin,	laminin	
and	von	Willebrand	factor	and	can	activate	MMPs.	Plasmin	also	mediates	the	release	of	the	
guidance molecule F-spondin from the ECM (Tzarfaty-Majar et al., 2001). Furthermore, a 150 kDa 
neural cell adhesion molecule (N-CAM) L1 fragment released by plasmin could stimulate cell 
migration (Mechtersheimer et al., 2001). In contrast to the dual cellular source of tPA in the CNS, 
plasminogen is exclusively synthesized by neurons with highest expression in the hippocampus, 
cerebellum, and the cerebral cortex (Tsirka et al., 1997; Zhang et al., 2002) (Table 1.1). Thus in the 
CNS, plasmin acts as a downstream effector of tPA in processes such as cell migration, neurite 
outgrowth and synapse elimination. In this respect it was demonstrated that the tPA/plasmin 
system	induces	mossy	fiber	sprouting.	The	chondroitin	sulfate	proteoglycan	phosphacan,	an	ECM	
component	associated	with	inhibition	of	neurite	outgrowth,	was	identified	as	one	physiological	
target	of	plasmin	(Wu	et	al.,	2000).	Unexpectedly,	mice	lacking	tPA	displayed	decreased	mossy	
fiber	 outgrowth	but	 plg-/-	mice	 showed	normal	mossy	 fiber	 outgrowth.	 This	 strongly	 suggests	
that tPA functions both through a plasmin-depended and a plasmin-independent pathway 
to	mediate	mossy	fiber	reorganization.	Another	chondroitin	sulfate	proteoglycan,	NG2,	which	
inhibits neurite outgrowth, can bind to the kringle domains of plasminogen and enhances 
plasmin generation by uPA (Goretzki et al., 2000). Consequently, the plasminogen activator/
plasmin system works in concert to promote ECM degradation and remodeling (Lijnen, 2001).
On the other hand the tPA/plasmin system also promotes excitotoxic cell death. This action is 
dependent on the proteolytic activity of plasmin, which can degrade laminin, an early step in 
the neuronal death pathway. The plg-/- mice exhibit decreased microglial migration to the site 
of excitotoxic cell death and are more resistant to excitotoxic injuries (Chen and Strickland, 
1997; Tsirka et al., 1997). Furthermore, repeated stress can impair hippocampal function. Both 
pre- and postsynaptic effects of chronic stress result in a reduction in the number of NMDAR and 
dendritic spines in the CA1 region. Strikingly, the stress-induced decrease in NMDA receptors 
coincides spatially with sites of plasminogen activation. Consistent with this, tPA-/- and plg-/- 
mice are protected from stress-induced decrease in NMDAR and reduction in dendritic spines 
(Pawlak et al., 2005b). On the other hand, plasmin seems to be neuroprotective in the case of 
AD. As mentioned above, the tPA/plasmin proteolytic cascade accelerates Aß degradation 
and inhibits Aß-induced neurodegeneration (Melchor et al., 2003). The opposing roles of plasmin 
in neuronal survival versus death emphasize the functional complexity of this peptidase that is 
determined by particular cellular settings and various stimuli.
1.2.4 Thrombin is involved in brain development
Thrombin is a secreted S1 serine peptidase that cleaves peptide bonds after Arg and Lys, converts 
fibrinogen	to	fibrin	and	activates	factors	V,	VII,	VIII,	XIII	and,	in	complex	with	thrombomodulin,	
protein C. It is heavily involved in blood coagulation and tissue repair of many different origins. 
Prothrombin is composed of an N-terminal gamma carboxyglutamic acid-rich (GLA) domain 
that	is	responsible	for	high	affinity	binding	of	Ca2+ ions, followed by two KR domains and a C-
terminal trypsin-like serine protease domain (Fig. 1.3). Prothrombin is activated on the surface 
of phospholipid membranes, which bind the N-terminus of prothrombin as well as factors Va 
and Xa in a Ca2+-dependent manner. The activity of factor Xa is greatly enhanced by binding 
to factor Va. Factor Xa removes the activation peptide of prothrombin including the second 
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KR domain and cleaves the remaining part into light and heavy chains. Prior to its activation 
by factor Xa thrombin itself can cleave the N-terminal fragment of prothrombin including the 
GLA	and	the	first	KR	domain.	The	activation	process	starts	slowly	because	factor	V	has	to	be	
activated by the initially small amounts of thrombin.
Apart from other tissues prothrombin mRNA was also detected in the brain and in cell lines of 
neuronal and glial origin (Dihanich et al., 1991) (Table 1.1).
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1.2.4.1 Proteolytic activation of thrombin receptors
Protease-activated receptors (PARs) belong to the superfamily of G protein-coupled receptors 
(GPCRs).	The	central	step	of	human	PAR-1	activation	by	peptidases	is	the	specific	cleavage	of	
the extracellular N-terminus of the receptor after Arg41, unmasking a new N-terminus (SFLLRN) 
that functions as a tethered ligand and binds intramuscularly to the receptor. By this new 
interaction with the extracellular loop 2 a signal is transduced intracellular via G proteins. Gq 
is associated to intracellular loops 2 and 3 (Hollenberg and Compton, 2002) and G12/13 was 
shown to bind to the cytosolic C-terminal tail of PAR-1 (Pai et al., 2001). Synthetic PAR-activating 
peptide (PAR-AP) that mimic the tethered ligand can also activate PARs (Fig. 1.6).
Until	now	four	members	of	the	PAR	family	have	been	identified.	PAR-1,	-3	and	-4	are	considered	
as thrombin receptors, while PAR-2 is activated by serine proteases other than thrombin, such as 
trypsin and mast cell tryptase. Two thrombin interaction sites have been proposed on hPAR-1: 
one is the cleavage site, and the other one is between residue 53 and 64 and is involved in the 
thrombin anion-binding exosite (Rydel et al., 1991). Apart from thrombin other peptidases such 
as Factor Xa, tissue factor/factor VIIa complex, granzyme A, and trypsin can activate PARs as 
well. Although, PARs are constitutively activated by proteolysis, they are rapidly desensitized 
by a variety of mechanisms, including phosphorylation and internalization through coated pits 
(Brass et al., 1994; Ishii et al., 1994). Furthermore, PARs can also be inactivated by peptidases 
Figure 1.6     Activation of Protease-Activated Receptor 1 (PAR-1).
Following irreversible proteolytic cleavage of PAR a new N-terminus is unmasked (SFLLRN) acting as a tethered ligand that 
can interact with the extracellular loop 2 of the receptor. A synthetic peptide derived from the N-terminal sequence of PAR-1 
(PAR-AP) is able to activate the receptor in the absence of peptidases. Different peptidases may act on the extracellular 
N-terminus, either exposing the tethered ligand to activate, or disabling the tethered ligand to inactivate PARs by cleaving at 
a site downstream of the tethered ligand sequence. The intracellular loops 2 and 3 have been proposed to play a role in G 
protein coupling for PAR-1.
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such as cathepsin G and thermolysin, which are capable of cleaving within the tethered ligand 
(Ubl and Reiser, 2000; Ubl et al., 2000).
It is now widely accepted that activated thrombin signals through the family of protease-
activated receptors (PARs). Four different thrombin receptors have found to be widely 
distributed in brain tissue. PAR-1, -2, -3 and -4, which are expressed in neuronal cells at various 
densities	in	numerous	brain	regions	(Striggow	et	al.,	2001),	have	also	been	identified	in	glial	cell	
culture	(Wang	et	al.,	2002a)	(Table	1.1).	The	co-expression	suggests	distinct	functions	or	cross-
talk among the PAR family members. Ample evidence point to the idea that thrombin changes 
the morphology of neurons and astrocytes, induces glial cell proliferation, and even exerts, 
depending on the concentration, either apoptotic or cytoprotective effects on neural cells.
1.2.4.2 Thrombin elicits proliferative and pathophysiological changes in the brain
One of the most pronounced effects of thrombin is the induction of morphological changes in 
neural cells (Gebbink et al., 1997; Jalink and Moolenaar, 1992; Pai and Cunningham, 2002; Turnell 
et al., 1995) and astrocytes (Grabham and Cunningham, 1995; Majumdar et al., 1998). Both the 
application of PAR-AP and thrombin causes a rapid neurite retraction in neuronal cells and a 
reversal of stellation in astrocytes. These processes rely on cytoskeletal rearrangements that in 
turn	require	induction	of	specific	signaling	pathways	activated	through	PAR.	The	downstream	
signaling cascades involved here are discussed later in this work. However, a well-controlled 
balance between thrombin and its inhibitors is essential to regulate neuronal connections 
through the modulation of neurite outgrowth. Moreover, thrombin has been shown to potentiate 
NMDAR responses in CA1 pyramidal cells (Gingrich et al., 2000). It is known to enhance neural 
growth factor (NGF) and endothelin-1, and to induce astrocyte proliferation (Ehrenreich et al., 
1993; Grabham and Cunningham, 1995; Neveu et al., 1993). Furthermore, thrombin has been 
reported to induce secretion of Aß precursor in astrocytes (Davis-Salinas et al., 1994). Notably, 
at low concentrations thrombin promotes cell survival, while at high concentrations it induces 
apoptosis,	e.g.	thrombin	significantly	protected	hippocampal	neurons	against	ischemic	insults	
but caused degeneration at high concentrations in vivo and in vitro (Striggow et al., 2000). 
The	 finding	 that	 PARs	 are	 expressed	 in	microglia	 cells	 also	 suggests	 that	 thrombin	might	 be	
a	 mediator	 of	 brain	 inflammation.	 First,	 thrombin	 stimulates	 proliferation	 of	 microglial	 cells	
and second, thrombin leads to the release of the cytokines tumor necrosis factor-α (TNF-α), 
interleukin-6 (IL-6), interleukin-12 (IL-12), the chemokine KC, and the soluble TNF-α receptor II 
(Moller et al., 2000; Suo et al., 2002). Conversely, another group found no increase in IL-6 and 
TNF-α secretion. However, they found a PAR-1-induced release of the chemokine GRO (growth-
regulated oncogene)/CINC-1 (cytokine-induced neutrophil chemoattractant-1) that was 
mainly mediated by c-Jun N-terminal kinase (JNK) activation and preserved astrocytes from 
toxic	 insults.	 Importantly,	a	 specific	JNK	 inhibitor	 significantly	abolished	 the	protective	action	
of	PAR-1	(Wang	et	al.,	2006).	PAR	agonists	provoked	and	thrombin	inhibitors	blocked	all	these	
effects on astrocytes and neurons. The different physiological roles of PAR-2, -3, and -4 are still 
not clear. However, the fact that PAR-4 activation requires high concentrations of thrombin (Xu 
et al., 1998) raises the possibility that the deleterious effects of high thrombin concentrations 
may be mediated by PAR-4.
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1.2.4.3 Activated PAR-1 signaling in the CNS
Depending on the cell type PAR-1 activation by thrombin is coupled to heterotrimeric G 
proteins including Gi, G12/13, and Gq. Subsequent intracellular events involve activation of 
phospholipase C (PLC), generation of inositol triphosphate (IP3) and diacylglycerol (DAG), 
followed by intracellular increase of Ca2+ concentration and protein kinase C (PKC) activation. 
Non-receptor tyrosine kinases Src and focal adhesion kinase (FAK) are phosphorylated in 
response to thrombin. Ras and Ras-related protein Rho are also implicated in thrombin-induced 
response. Moreover, the activation of phosphatidylinositol 3-kinase (PI3-kinase) and MAPK by 
thrombin stimulation as been observed as well (Macfarlane et al., 2001) (Fig 1.7). Thrombin 
induced cellular shape changes like neurite retraction or reversal of stellation in astrocytes, 
do not underlay the same signaling pathways. In mammalian cells it is the highly conserved 
Rho family of small GTPases that plays a key role in signal transduction pathways, which link 
plasma membrane receptors to the reorganization of the actin cytoskeleton, resulting in neurite 
retraction.	Specifically,	the	cytoskeletal	effects	of	thrombin	appear	to	be	mediated	by	the	G12/13 
subunits	that	act	upstream	of	RhoA.	The	signals	are	believed	to	be	transduced	by	Rho-specific	
guanine nucleotide exchange factors (Rho-GEFs) Lbc and p115 (Majumdar et al., 1998). Heat 
shock protein 90 (Hsp90) might help to couple G12/13 to the PAR cytoplasmic C-terminus (Pai et 
al., 2001) (Fig. 1.7).
The signaling pathway underlying thrombin-induced astrocyte proliferation mainly takes place 
through	PAR-1	(Wang	et	al.,	2002b).	Thrombin	stimulates	Erk1/2	phosphorylation	in	a	time-	and	
concentration-dependent	manner.	This	effect	can	be	fully	mimicked	by	the	specific	activation	
Figure 1.7     Thrombin-induced signaling events via PAR-1 activation in the brain.
Activated PAR-1 may couple to G12/13 with association of Hsp90, leading to activation of RhoA. Subsequently, activated 
RhoA translocates to the membrane where it can transduce a signal through downstream factors to the  actin cytoskeleton. 
Potential effector proteins of RhoA involved in both cytoprotective and toxic effects include phosphatidylinositol 4-phosphate 
5-kinase (PtdIns 4P, 5 kinase), which in turn increases available PIP2. PAR-1 coupled to Gq activates PLC to produce DAG 
and IP3 from PIP2, resulting in Ca2+-mobilization and activation of PKC. As a Ser/Thr kinase, PKC has been implicated in 
protection and apoptosis. However, it is still necessary to define the links upstream of caspases released for apoptosis and 
extracellular signal-regulated kinase 1/2 (Erk1/2) activation for neuroprotection. In astrocytes however, activation of PAR-1 
results in the activation of both Gi/G0 and Gq, mediating activation of Erk1/2 cascades leading to proliferation. PI3-K: phos-
phatidylinositol 3-kinase.
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peptide PAR-AP. The stimulation is mainly transduced via two branches: 1) the Gi-mediated PI3-
kinase branch, and 2) the Gq - PLC/Ca2+ - PKC pathway (Fig. 1.7).
Furthermore, thrombin can evoke phosphorylation of proline-rich tyrosine kinase (Pyk2), a linker 
between GPCRs and Erk1/2 activation via PAR-1 (not shown). Pyk-2 links PAR-1-dependent 
increase in cytosolic Ca2+. PKC activation initiates MAPK pathway by recruiting the adaptor 
protein	growth	 factor	 receptor-bound	protein	2	 (Grb2)	 (Wang	and	Reiser,	2003).	 In	addition,	
an involvement of Hsp27 and Erk1/2 in the neuroprotective effects was also shown (Xi et al., 
2001; Xi et al., 1999). Finally, activation of both PAR-1 and PAR-2 resulted in the release of the 
GRO/CINC-1, but PAR-2-induced GRO/CINC-1 release was independent of PKC, PI3-kinase and 
Erk1/2 activation. However, these three kinases were involved in PAR-1-induced GRO/CINC-1 
release.	Despite	 such	differences	between	PAR-1	and	PAR-2	 signaling,	 JNK	was	 identified	 in	
both signaling pathways to play a pivotal role. It was demonstrated that different JNK isoforms 
mediated GRO/CINC-1 secretion, when it was induced by either PAR-1 or PAR-2 activation 
(Wang	et	al.,	2007).	Taken	together,	these	data	suggest	that	PAR-1	and	PAR-2	have	overlapping	
functions, but can activate separate pathways under certain conditions to rescue neural cells 
from cell death.
As mentioned earlier, in hippocampal neurons and astrocytes, thrombin has been shown to 
exhibit	 both	 beneficial	 and	 harmful	 effects	 in	 a	 concentration	 dependent	 manner.	 Similar	
profiles	are	involved	in	protective	and	apoptotic	functions,	e.g.	involvement	of	tyrosine	kinases,	
Ser/Thr kinases, RhoA, and the cytoskeleton (Donovan and Cunningham, 1998; Donovan et 
al., 1997). For the induction of the apoptotic pathway a continual presence of thrombin was 
beyond doubt more important than high concentrations per se. Hence, it was suggested that 
in both responses the same pathway is activated. The cell death pathway, however, may result 
from an over-activation of PAR-1 and over-activation of the connected pathway. Additionally, 
caspase-3 and caspase-1 were activated following PAR-1 stimulation to initiate apoptosis 
(Smirnova et al., 1998).
Taken together it is now apparent that activation of PARs by thrombin does not always produce 
the same pattern of cellular responses. Irrespective of the endeavor to push the understanding of 
the thrombin-signaling forward, it will be of great importance to study the activation mechanism 
for converting prothrombin into thrombin in brain under physiological conditions in more detail. 
Similarly, there is little knowledge about the function of PAR-2, -3, and -4 in neurons. Independent 
of the missing pieces in the puzzle, the mediators, including thrombin activation, involved in the 
signaling cascades might be potential targets for treatment of brain injury and diseases.
1.2.5  Neuropsin – a neural activity-dependent serine peptidase
The neuropsin gene, also called kallikrein-8, is encoded in a gene cluster as a member of the big 
kallikrein-like multigene family in humans (Yoshida et al., 1998). It is a simple S1 serine peptidase 
with an apparent Mr of 30 kDa that is composed of one polypeptide chain containing 260 amino 
acids (Chen et al., 1995) (Fig. 1.3). There is no characteristic domain other than a serine protease 
domain. Proneuropsin has a predicted signal peptide and is secreted via both regulated and 
constitutive	pathways	(Chen	et	al.,	1995;	Oka	et	al.,	2002).	In	the	hippocampal	CA1-3	subfields	
and amygdala, the gene shows activity dependent expression evoked by neuronal stimuli 
such as epilepsy or LTP. The non-active proneuropsin protein is stored in extracellular spaces, 
probably in the synaptic cleft and remains inactive until stimulation (Shimizu et al., 1998). Indeed, 
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increased neural activity triggered the rapid, transient activation of the zymogen of neuropsin 
in an NMDA-dependent manner. Inhibition of the MAPK, PKA, PKC or CaMK II signaling pathway 
indicated that the activation of neuropsin may lie downstream of one of these generic signaling 
cascades (Matsumoto-Miyai et al., 2003). In addition, various concentrations of recombinant 
neuropsin resulted in a dose-dependent increase of the amplitude of the tetanic stimulation-
induced early phase of LTP (E-LTP) via its proteolytic action (Komai et al., 2000). The brief increase 
(< 30 min) in neuropsin activity following neural potentiation of excitatory presynapses in CA1 
immediately processed the extracellular domain of L1 resulting in a freely diffusible extracellular 
fragment of 180 kDa. Subsequently, the magnitude of Schaffer collateral E-LTP is diminished 
(Matsumoto-Miyai et al., 2003). In spite of the marked changes L1 immunoreactive synapses, 
neuropsin	null-mutant	mice	exhibited	no	significant	impairment	in	hippocampal	LTP	(Davies	et	
al., 2001). This speaks in favor of the fact that other peptidases such as plasmin also proteolyse 
N-CAM L1 and thus can compensate for the absence of neuropsin. Ankyrins and syntenin-
1 bind to the cytoplasmic tail of N-CAMs and thus serve as adaptors that link cell adhesion 
molecules to the cytoskeleton. Thus, the cleavage of L1 by neuropsin may induce a dynamic 
rearrangement of the submembrane cytoskeleton and membrane protein clustering to induce 
changes in the synaptic morphology.
1.2.6  Calpains act in the pre- and postsynaptic boutons
Calpains, Ca2+-dependent cysteine peptidases that act intracellular, are expressed as 
proenzymes that undergo autocatalytic processing to yield the mature form. Two ubiquitous 
calpains, μ-calpain and m-calpain, are highly expressed in the CNS. Calpain substrates such as 
membrane receptors, postsynaptic density proteins, kinases, and phosphatases are localized 
intracellularly. It has been shown that calpain has direct proteolytic activity on NMDAR 2 (NR2) 
subunits and thus modulates the NMDAR function and turnover (Guttmann et al., 2001). PSD-95 
clustering and direct association of NR2A to PSD-95 mediate the blockade of calpain-induced 
cleavage of NR2A (Dong et al., 2004). Moreover, several lines of evidence suggest that calpain 
activation in the synapse is necessary for LTP. Fodrin cleavage by calpain causes increased 
LTP putatively through the insertion of NMDAR into the post-synaptic membrane (Lynch and 
Baudry, 1984). The molecular mechanism however, how calpain activity induces LTP, remains 
to be determined. Furthermore, both long-term depression (LTD) and cleavage of protein 
kinase C (PKC) -ζ are prevented by calpain inhibitors (Hrabetova and Sacktor, 1996). Calpain-
mediated proteolytic cleavage of PKC-ζ gives rise to constitutively active PKM resulting in burst 
firing	 in	 dopaminergic	 neurons	 (Liu	 et	 al.,	 2007).	 In	 addition,	 glutamate	 receptor-interacting	
protein (GRIP) is also a substrate of calpains. Calpain activation results in the disruption of GRIP 
binding to the GluR2 subunit of AMPA receptors. Because GRIP has been proposed to function 
as an AMPA receptor-targeting and stabilizing protein, degradation of GRIP and disruption 
of AMPA receptor anchoring are likely to play important roles in the structural and functional 
reorganization	accompanying	synaptic	modifications	in	LTP	and	LTD	(Lu	et	al.,	2001).
It is obvious that the calpains are the only peptidases addressed in this work that do not belong to 
the	S1	peptidase	family.	Nevertheless,	it	exemplifies	the	enormous	diversity	by	which	peptidases	
in general exert their functions in the brain.
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1.3	 Neurotrypsin	–	a	brain	specific	extracellular	serine	peptidase
Using RT-PCR, Gschwend et al. searched for novel serine peptidases that are expressed in the 
nervous system. Degenerated primers complementary to the conserved region around the 
His/Ser residues of the catalytic triad of known serine peptidases, such as trypsin, tPA, uPA or 
thrombin were used. The approach resulted in the cloning of a novel murine cDNA, which 
encodes a multidomain trypsin-like serine peptidase with a unique domain composition. Since it 
exhibits a highly intriguing neuronal expression pattern in the adult murine nervous system, it was 
termed neurotrypsin (Gschwend et al., 1997). Neurotrypsin is the peptidase under investigation 
in this work.
The structural composition deduced from the amino acid sequence revealed a multidomain 
protein of 761 amino acids with a typical C-terminal S1 type serine protease domain (PD). N-
terminally it starts with a putative signal peptide for secretion, followed by a proline-rich basic 
(PB) segment and one kringle domain. In case of human there are four (Proba et al., 1998), and 
in case of mouse and rat there are three scavenger receptor cysteine-rich (SRCR) domains. In 
fact,	the	first	copy	of	the	SRCR	domains	(exons	2	–	3)	is	missing	in	the	murine	protein.	Since	all	
other species tested so far bear four intact SRCR domains, the rodent lineage must have lost 
exons 2 and 3 during evolution. The functional consequences, however, are not known (Xu and 
Su, 2005). The next region is the zymogen activation (ZA) site that is located proximal to the C-
terminal PD with the conserved catalytic triad of serine peptidases (Fig. 1.3). To gain proteolytic 
activity, an activation cleavage, similar to tPA, must occur at the ZA site that separates the 
protein	into	two	chains	that	are	connected	by	a	disulfide	bond.	This	activation	cleavage	is	in	all	
probability carried out by furin, a member of the subtilisin superfamily. Furin is a ubiquitous Ca2+-
dependent endopeptidase active within the constitutive secretory pathway and capable to 
cleave at Arg-X-Lys/Arg-Arg motifs. Thus, neurotrypsin is most likely activated during its secretion. 
The non-catalytic domains are thought to mediate binding of neurotrypsin to cell surfaces or 
ECM molecules, navigating the peptidase to its site of action or bring it into proximity to its 
substrates.
1.3.1 Neurotrypsin is a trypsin-like serine peptidase
An	alignment	of	the	amino	acid	sequence	classifies	neurotrypsin	into	the	S1	family	of	trypsin-
like serine peptidases (Fig. 1.8). The sequences of chymotrypsin, trypsin, neurotrypsin, tPA and 
uPA are shown. In the chymotrypsin index, His57, Asp102, and Ser195 form the catalytic triad and 
residues 189 – 195, 214 – 220, and 225 – 228 form the primary substrate-binding pocket called 
S1 binding pocket. Residues 185 – 188 and 221 – 224 form two loops near the S1 pocket, called 
L1 and L2, respectively (Fig. 1.8). Catalytic mechanisms of trypsin and chymotrypsin as well as 
of the other serine peptidases are similar, but their substrate specificities	are	different.	 Trypsin	
favors cleavage after basic residues like lysine and arginine; chymotrypsin favors aromatic 
residues like phenylalanine, tyrosine, and tryptophan (Vajda and Szabo, 1976). The S1 binding 
pocket in trypsin and chymotrypsin are almost identical in primary sequences and backbone 
tertiary structures (Fig. 1.8). An important difference is that residue 189 is a negatively charged 
Asp in trypsin and a polar Ser in chymotrypsin. This residue lies at the bottom of the S1 binding 
pocket and determines different S1 pocket chemical properties. It was once used to explain the 
different	substrate	specificity	of	trypsin	and	chymotrypsin	(Steitz	et	al.,	1969;	Vajda	and	Szabo,	
1976). But the mechanism is not that simple. Mutation of Asp189 in trypsin (D189S) did not change 
the	 substrate	 specificity from trypsin-like to chymotrypsin-like (Graf et al., 1988; Hedstrom, 
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1996; Hedstrom et al., 1992); instead the enzyme just lost its activity. And mutation of S189D in 
chymotrypsin did	not	convert	its	specificity	into	that	of	trypsin	either	(Venekei	et	al.,	1996).	When	
the two loops L1 and L2 of trypsin were replaced by those of chymotrypsin in addition to the 
D189S mutation, the new protein showed an increase of chymotrypsin activity up to 1000-fold 
against the D189S mutant alone. These experiments imply that in addition to the S1 substrate-
binding pocket, loop regions of trypsin	and	chymotrypsin	have	 significant	effect	on	enzyme	
activity and	substrate	specificity.	
A	significant	finding	important	for	the	development	of	trypsin-like	serine	peptidase	inhibitors	is	
that	considerable	specificity	can	be	achieved	at	the	S1	pocket	alone	(Katz	et	al.,	2000;	Yang	
et al., 1990; Zeslawska et al., 2000). Despite the high structural similarity in the S1 binding site of 
trypsin-like serine peptidases, these sites are differentiated from one another by two important 
features that can be targeted for selectivity development of inhibitors – their depth, and the 
identity of residue 190 (Fig. 1.8). Simple amidine inhibitors tend to be selective for Ser190 peptidases 
(uPA, trypsin, neurotrypsin, and factor VIIa) rather than Ala190 peptidases (tPA, thrombin, and 
factor Xa), because of an additional hydrogen bond between the amidine and OγSer190 in the 
former class (Katz et al., 2000).
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Figure 1.8     Sequence alignment of human neurotrypsin catalytic domain with other serine peptidases.
The alignment shows the sequence similarities of chymotrypsin, trypsin, neurotrypsin, uPA and tPA in chymotrypsin number-
ing. The alignment is grouped into three categories: i) identical amino acid residues in all serine peptidases are highlighted 
in yellow, ii) the residues, which are identical in more than 50% are shown in blue, and iii) green indicates similarities in 
chemical properties of the amino acid residues. Substrate-binding pocket S1 and two loops L1and L2 are displayed above 
the sequences. The amino acids of the catalytic triad are shown in red. Ser189 and Asp189 in the S1 pocket of chymotrypsin 
and trypsin, respectively, are important determinants for substrate specificity (orange asterisk). Ser190 or Ala190 define two 
different classes of trypsin-like serine proteases (magenta asterisk). This residue strongly influences the conformation of the 
S1 substrate binding pocket and thus may change the substrate specificity of the peptidase.
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1.3.2 The role of neurotrypsin in the CNS – some evidence for a function in 
synaptic plasticity
Northern blot analysis of neurotrypsin mRNA isolated from liver, intestine, spleen, lung, brain, and 
cerebral cortex of adult mice revealed strongest signals in the brain and lungs, whereas only 
small quantities were detected in the intestine and spleen. No neurotrypsin transcripts were found 
in the liver. The expression of neurotrypsin mRNA in the CNS of adult mouse brain was studied 
in more detail by in situ hybridization.	 In	 the	nervous	system	mRNA	was	confined	to	neurons.	
In the forebrain, labeling was exclusively detected in distinct subsets of neurons of the cortex, 
the hippocampus, the amygdala, and the olfactory bulb (Figs. 1.9a – c). Neurotrypsin mRNA in 
the neocortex was most intensive in neurons of layers V and VI (Fig. 1.9b). In the hippocampus, 
neurotrypsin expression was strongest in the subiculum and in pyramidal cells of the CA1 region 
(Fig. 1.9c). Moderate expression was observed in granule cells of the dentate gyrus. In addition, 
there was strong expression in neurons from the brain stem motor nuclei (Figs. 1.9d and e) 
and the motor columns of the spinal cord (Fig. 1.9f). Expression of neurotrypsin mRNA was also 
found in the peripheral nervous system. In the dorsal root ganglia (DRG) a subpopulation of 
neurons expressed neurotrypsin mRNA (not shown) (Gschwend et al., 1997). The expression of 
neurotrypsin mRNA in the mouse during prenatal and postnatal development was examined for 
different	brain	regions	(Wolfer	et	al.,	2001).	Neuronal	expression	of	neurotrypsin	mRNA	correlates	
best with periods of target invasion and maturation of synaptic contacts (Fig. 1.10). Together 
with the ongoing expression in the adult CNS, there is substantial support for the idea that 
neurotrypsin is involved in synaptic plasticity both during synapse formation and maintenance. 
In conjunction with its structural homologies to PAs and the anatomical distribution led us come 
to the prediction that the extracellular proteolytic action of neurotrypsin subserves structural 
reorganization processes. Immunoelectron microscopy on adult human brain sections revealed 
that neurotrypsin is located in presynaptic nerve endings, in particular close to the presynaptic 
membrane lining the synaptic cleft. Furthermore, a genetic analysis of four mentally retarded 
and four healthy siblings disclosed that a mutation in the neurotrypsin gene is associated with 
cognitive impairment and low IQ (<50) in the four affected individuals. The 4-base pair deletion 
results in a truncated form of neurotrypsin, missing the catalytic domain. The data emphasize 
the crucial role of neurotrypsin for synaptic proteolysis in higher brain function, the ablation of it 
leading to non-syndromic mental retardation (Molinari et al., 2002).
In order to investigate the functional role for neurotrypsin in more detail transgenic mice 
overexpressing neurotrypsin were generated (Fig 5.1). Observations of brush-like structures in 
the	diaphragm	immunostained	for	neurofilament	revealed	a	degenerated	nerve	innervation	
of	the	end-plate	band	and	deficient	synapse	formation.	A	similar	phenotype	has	been	found	
in  agrin-/- mouse (Gautam et al., 1996), which lead to the assumption that neurotrypsin can 
proteolytically process agrin. 
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Figure 1.9     In situ hybridization for neurotrypsin transcripts in 
adult mouse brain.
(A) Labeling is seen in distinct layers throughout the neocortex (Te, 
temporal cortex; Oc, occipital cortex) with a more widespread labeling 
in the transition zones between iso- and allocortex (Ic, insular cortex; 
RS, retrosplenial cortex). In the allocortex, labeling is detected in the 
piriform cortex (Pir), with a strong signal in the endopiriform nucleus 
(arrow), and in the hippocampal formation. Neurotrypsin expression is 
also seen in the lateral amygdala (arrowhead). Bar, 1 mm. (B) Coronal 
section of the parietal cortex. Large positive neurons are seen in the 
lower half of layer V. In layer VI, positive cells are found throughout the 
layer. Weak labeling is associated with cells scattered in layers II and 
III. No mRNA is detected in layers I and IV. Bar, 100 μm. (C) Coronal 
section of the hippocampus. Labeling is detected in neurons of the
Figure 1.10     Time course of neurotrypsin mRNA expression in neural tissues during pre- and postnatal develop-
ment.
Columns represent developmental stages. Rows represent cell populations, regions, or tissues. The shading pattern of 
each box indicates the average signal intensity, assigned to one of the four staining levels listed in the legend. E: embryonic 
stage, P: postnatal.
subiculum (S), in pyramidal neurons of CA1 and CA3, and in granule neurons of the dentate gyrus (DG). Bar, 300 μm. (D) 
Coronal section of the pons. Labeling is seen in neurons of the facial nucleus (fc). Bar, 500 μm. (E) Coronal section of the 
medulla. Labeling in neurons of the dorsal motor nucleus of dorsal vagus (dv) and the hypoglossal nucleus (hg). Bar, 300 
μm. (F) Cross-section of the cervical spinal cord. Large cells are labeled in the motor columns (arrowheads). Labeling is also 
detected in the DRG  (arrow). Bar, 300 μm. (4V) Forth ventricle.
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1.3.3	 Cleavage	of	agrin	by	co-expression	with	neurotrypsin	in	cell	culture	and	in 
vivo in the hippocampus
The	 finding	 that	 neurotrypsin	 overexpression	 in	 mice	 showed	 a	 brush-like	 structure	 in	 the	
diaphragm resembling the phenotype of agrin -/- lead to the hypothesis that agrin is a substrate 
for neurotrypsin in vivo. To test this hypothesis, agrin and neurotrypsin were co-expressed in HeLa 
cells and supernatants and cell lysates were immunoblotted with antibodies raised against 
the 90-kDa agrin intermediate fragment and the C-terminal laminin globular domain 3 (LG3 
domain),	 respectively.	When	membrane-bound	 TM-agrin-y4z8 was expressed alone and the 
cell lysate was immunoblotted, a smeary signal was detected above 250 kDa, whereas in the 
supernatant	the	signal	was	absent	(Fig.	1.11a).	However,	Western	blotting	of	the	supernatant	
after 48h of co-expression of TM-agrin-y4z8 and neurotrypsin, three bands were detected. The 
upper band represents the 112- kDa C-terminal fragment after the α-cleavage, the intermediate 
90 kDa band, is the fragment resulting after cleavage at both, the α- and the β-sites, and the 
lower band is the very C-terminal LG3 domain produced by the β-cleavage (Fig. 1.11a, c). In 
fact, upon cleavage by neurotrypsin the C-terminal agrin fragments were released into the 
supernatant. The cell lysate was negative for agrin immunodetection, indicating a complete 
processing of agrin. The membrane bound N-terminal part of agrin could not be detected due 
to inexistent antibodies against this part of the protein. Even more convincing evidence for a 
specific	proteolytic-dependent	interaction	of	neurotrypsin	with	agrin	is	given	by	the	following	
experiment (Fig. 1.11a): Co-expression of agrin with an inactive form of neurotrypsin, where 
Ser825 was mutated to an Ala (S/A), and subsequent immunoblotting resulted in the detection of 
the full-length agrin in the cell lysate as if neurotrypsin was absent. Consequently, no cleavage 
product in the supernatant was found either. A similar pattern for the agrin bands was found 
in vivo in the hippocampus homogenate (Fig. 1.11b). The cleavage products were enriched in 
transgenic samples and absent in the KO, whereas full-length agrin was reduced in transgenic, 
and accumulated in KO samples. The amino acid sequence of the α- (PIER | ASCY) and β-
cleavage site (LVEK | SVGD) were determined by N-terminal sequencing (Fig. 1.11c) (Reif et 
al., 2007). So far, no other homologous cleavage site was found in any target sequences of 
other potential substrates. The cleavages are presumed to take place at the neuromuscular 
junction	(NMJ)	as	well	as	in	the	CNS.	Two	findings	suggest	a	very	high	specificity	of	neurotrypsin	
for substrate recognition and cleavage of agrin. Firstly, the fact that the basic residues Arg 
or Lys at P1 and acidic Glu at the P2 positions of agrin are highly conserved and thus, point 
mutations to alanine basically abolished cleavage. Secondly, typical serine protease inhibitors, 
such	as	aprotinin,	leupeptin,	and	(4-amidinophenyl)	methanesulfonyl	fluoride	(APMSF),	as well 
as	specific	inhibitors	for	trypsin,	plasmin,	uPA	and	thrombin	could not or only very little affect the 
proteolytic activity of neurotrypsin. Furthermore, sequence alignments do not imply neurotrypsin 
activation cleavage on other serine peptidases such as plasminogen, uPA, tPA, or prothrombin. 
It is believed that substrate diversity is limited and no participation in ECM degradation through 
plasminogen activation cascade is implicated. It is assumed that neurotrypsin catalytically 
processing of agrin is restricted to extracellular areas of the brain in close vicinity to synapses. 
Finally, very recent data suggest a neuronal activity- dependent release of neurotrypsin into the 
synaptic cleft (unpublished data). Nevertheless, the scope of neurotrypsin function in the CNS 
is far from being fully disclosed. For instance, a direct interaction of neurotrypsin with agrin is yet 
to be shown in vivo. And, neurotrypsin catalytic or non-catalytic activity has not been coupled 
to any of the generic signaling pathways to elicit cellular responses. Altogether, this data speak 
in	favor	of	the	fact	that	the	neurotrypsin	–	agrin	interaction	is	highly	specific.
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1.4	 Agrin	–	an	extracellular	matrix	heparan	sulfate	proteoglycan
Agrin	was	purified	 from	the	basal	 lamina	 from	the	synapse-rich	electric	organ	of	 the	pacific	
electric ray Torpedo californica in 1987 (Nitkin et al., 1987). Over a decade later the ‘agrin 
hypothesis’, which postulates that agrin is a nerve-derived trophic factor responsible for the 
assembly	of	the	postsynaptic	apparatus	at	the	neuromuscular	junction,	has	been	confirmed.	
First,	 agrin-deficient	mice	do	 not	 form	 functional	 postsynaptic	 structures	 and	die	perinatally	
(Gautam	et	al.,	1996).	And	second,	agrin	could	activate	synapse-specific	gene	expression	and	
establish fully functional and mature synapses on innervated rodent muscles in non-synaptic 
regions (Bezakova et al., 2001; Jones et al., 1997).
1.4.1 Alternative splicing of agrin
In	all	species	in	which	agrin	has	been	identified,	the	gene	encodes	a	protein	of	more	than	2000	
amino acids with a predicted molecular mass of 225 kDa (Fig. 1.11). The extensive N- and O-
linked glycosylation of the N-terminal half increases the apparent molecular mass of agrin to 
∼600 kDa. At least three of the O-linked carbohydrate attachment sites serve as docking sites 
for heparan sulfate glycosaminoglycan (HS-GAG) side chains and assign agrin to the family
Figure 1.11     Neurotrypsin cleaves agrin at two positions in vitro and in vivo.
(A) In vitro digestion of agrin by co-expression with neurotrypsin in HeLa cells. Agrin and wild-type (wt) or inactive (S/A) 
neurotrypsin were coexpressed for 48h. Supernatants (S) and cell lysates (CL) were immunoblotted with R132, directed 
against the 90-kDa fragment, together with R139, directed against the laminin globular domain 3 (LG3 domain), antibodies. 
Uncleaved membrane-bound full-length agrin expressed alone was detected in the CL. Co-expression with neurotrypsin 
resulted in the secretion of three agrin C-terminal agrin fragments. In S, one band represents the 112-kDa and the other the 
90-kDa fragment. The lower band represents the LG3 domain. Full-length agrin in the cell lysate is fully digested and thus 
has vanished. S/A neurotrypsin could not cleave agrin, resulting in the detection of full-length agrin in the CL. The lower 
panel shows the presence of wt and S/A neurotrypsin in the co-expression detected with G93 (The Western blot was kindly 
provided by R. Reif and S Sales). (B) In vivo cleavage of agrin in the hippocampus homogenate. A similar pattern for agrin 
processing is observed. The upper panel is incubated with R132 antibody. Full-length agrin is detected in three distinct major 
bands above 250 kDa. The signals in transgenic (tg), primarily the two upper bands, are slightly reduced as compared to 
wild-type (wt) littermates. Consequently, there is an accumulation of the 90-kDa cleavage product in tg. Only a little effect 
is observed for the 112-kDa fragment. For the knock-out (KO) the upper two full-length agrin bands are most prominent, 
whereas the lowest one is very weak. No cleavage product, neither of 112 kDa nor for the 90 kDa, is detectable. The mid-
dle panel, incubated with R139, reveals an augmentation of the LG3domain in tg. KO is devoid of the C-terminal cleavage 
product. The lower panel shows the loading control with β-actin. (C) A schematic representation of the agrin domain struc-
ture. Indicated above the diagram are the calculated molecular masses of agrin cleavage products as a consequence of 
neurotrypsin activity. The cleavage sites were determined by N-terminal sequencing. The α-cleavage site is PIER | ASCY, at 
which the cleavage occurs after the Arg, resulting in a C-terminal 112-kDa fragment. The β-cleavage site is LVEK | SVGD. 
Here, the hydrolysis occurs after the Lys, resulting in C-terminal 22-kDa fragment consisting of the LG3 domain including the 
z-site. Upon cleavage at both sites the 90-kDa middle fragment is produced.
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of heparan sulfate proteoglycans (Tsen et al., 1995). Two different agrin isoforms resulting 
from alternative mRNA splicing are known (Fig. 1.11). One isoform encodes a cleaved signal 
sequence (SS) followed by the N-terminal agrin (NtA) domain (SS-NtA). The other isoform contains 
a shorter amino terminus with a type II transmembrane (TM) domain (TM-agrin). They affect the 
association of agrin to either the ECM, as only SS-NtA-agrin isoform can bind to laminins, or the 
membrane (TM-agrin) (Burgess et al., 2000; Neumann et al., 2001). Both isoforms can additionally 
be alternatively spliced in at least two more positions, which are known as the A/y and B/z sites (A 
and B and y and z are used to denote the sites in chicken or mammals, respectively). The splice 
sites are located in the C-terminal laminin-globular (LG) domains LG2 and LG3, respectively 
(Fig. 1.11). Splicing at the y-site gives rise to protein variants that can contain 0 or 4 amino acids. 
Insertion of 4 amino acids is required for heparin binding and modulates the binding of agrin to 
α-dystroglycan (Gesemann et al., 1996; Hopf and Hoch, 1996). On the other hand, splicing at 
the z-site (agrin-z+) results in the insertion of 0, 8, 11 or 19 (8+11) amino acids. Inserts at the z-site 
are crucial for agrin-induced acetylcholine receptor (AChR) aggregation (Burgess et al., 1999). 
Interestingly,	splicing	at	this	site	is	regulated	in	a	tissue-specific	manner.	The	main	source	for	the	
‘active’ agrin form (agrin-z+) is neuronal, including motoneurons. Transcripts from all other non-
neuronal cells, except adult Schwann cells, encode ‘inactive’ agrin-z-.
1.4.2 Agrin is an important organizer of the neuromuscular junction
Although, binding of NtA-agrin to laminins in the basal lamina of the NMJ is essential for 
maintaining the postsynaptic apparatus in vivo, the AChR-aggregating activity of agrin is 
retained in a soluble, 95 kDa fragment of the C-terminal part. Surprisingly, a 21 kDa fragment 
of agrin-z+ that consists of the LG3 domain (LG3-z+) still induces the maximal number of AChR 
aggregates in vitro, albeit with several-hundred-fold lower potency than full-length agrin or the 
95 kDa fragment (Gesemann et al., 1995). This implies that agrin-z+ interacts with its receptor 
through the LG3-z+ domain. The 95 kDa agrin fragment binds to α-dystroglycan and activates the 
Figure 1.12     Schematic representation of agrin.
The structural domains, the sites of alternative mRNA splicing, and the binding regions of some of the most important part-
ners for agrin are illustrated. The signal sequence (SS) and amino (N)-terminal agrin domain (NtA) are present in an agrin 
isoform that is localized to the NMJ. These two regions are responsible for the secretion of agrin (SS) and the binding to lam-
inins in the basal lamina (NtA). The alternatively spliced type II transmembrane segment (TM) of agrin anchors this isoform 
at places that are devoid of basal laminae such as the ECM of the brain. The N-terminal half of agrin is highly glycosylated 
at Ser/Thr (S/T) attachment sites. These regions are involved in binding to NCAM L1 and heparin-binding growth factors. 
The C-terminal 95 kDa, a part of agrin is fully active in AChR aggregation and contains binding sites for ɑ-dystroglycan, 
heparin some integrins and an as yet unidentified agrin receptor. The four amino acid-long insert at the A/y site is encoded 
by a separate exon. Similarly, the different inserts at the B/z site of 8, 11, and 19 amino acid are also encoded by separate 
exons. The most C-terminal 21-kDa LG3 domain is sufficient to induce AChR aggregation although at much lower potency. 
Its activity requires the eight amino acid insert. FS, follistatin-like domain; LE, laminin EGF-like domain; LG, laminin globular 
domain; SEA, sperm protein enterokinase and agrin domain.
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muscle-specific	receptor	tyrosine	kinase	(MuSK).	Originally,	α-dystroglycan was proposed to be 
a functional agrin receptor that mediates downstream signaling leading to AChR aggregation 
(Bowe et al., 1994; Campanelli et al., 1994; Gee et al., 1994). But, α-dystroglycan also binds to 
the agrin-z-	with	high	affinity.	Conversely,	LG3-z+ does not bind to α-dystroglycan. (Gesemann 
et al., 1996; Hopf and Hoch, 1996; Sugiyama et al., 1994). And the NMJ is formed even in the 
absence of α-dystroglycan (Cote et al., 1999; Grady et al., 2000; Jacobson et al., 2001) although 
their morphology is altered. Thus, α-dystroglycan does not seems to be involved in the primary 
formation of postsynaptic structures, although it might be involved in their consolidation. MuSK, 
on	the	other	hand,	is	crucial	for	agrin-triggered	signaling	at	the	NMJ.	MuSK-deficient	mice	lack	
any postsynaptic specializations at the nerve–muscle contact and die perinatally, as do agrin-
deficient	mice	(DeChiara	et	al.,	1996).	Cultured	myotubes	devoid	of	MuSK	do	not	aggregate	
AChR in response to agrin, and the ability of myotubes to aggregate AChRs recovers after MuSK 
expression is restored (Herbst et al., 2002). Agrin-z+, but not agrin-z-, induces MuSK phosphorylation 
and, as observed for AChR aggregation, the minimal activation fragment comprises the LG3-z+ 
domain (Glass et al., 1996). Nevertheless, no direct interaction for agrin with neither MuSK nor 
AChR was shown. Thus, differentiated muscle cells contain yet another entity that functions as 
an ‘agrin receptor’, the identity of which is unknown until now.
1.4.3 The function of agrin in the brain
In addition to motor neurons, agrin mRNA has been detected in embryonic rat and chicken brains 
and in adult marine ray, suggesting that this molecule may also be involved in the formation of 
synapses between neurons. Northern blot and in situ hybridization indicated that agrin mRNA 
is expressed predominantly by neurons broadly distributed throughout the adult CNS. All four 
agrin-z transcripts are expressed in the adult CNS. z0, z8, and z19 were broadly expressed, z11 was 
detected only in the forebrain. Both the level of expression and the pattern of the alternative 
splice variants are differentially regulated in the brain (O’Connor et al., 1994). Notably, the 
structure with the highest agrin immunoreactivity in the brain is the microvasculature, in which 
agrin could bind to α-dystroglycan and laminin, and thus, stabilize the specialized basal 
lamina, which builds the blood–brain barrier. Furthermore, an increase in agrin protein levels 
precedes synaptogenesis in cultured hippocampal neurons. This increase in agrin expression is 
accompanied by its extracellular deposition along the distal third of the axon (Ferreira, 1999). The 
organizing role of agrin at the NMJ and its expression pattern in the brain indicate that it might 
orchestrate synaptogenesis in the entire nervous system. Indeed, agrin is important in regulating 
the formation of cholinergic interneuronal synapses in the superior cervical ganglion (SCG). 
Here,	agrin-deficient	embryos	show	a	mismatch	between	pre-	and	postsynaptic	structures	and	
have defective synaptic transmission (Gingras et al., 2002). Importantly, soluble agrin-z+ (but not 
agrin-z-)	restored	the	wild-type	phenotype	in	cultured	agrin-deficient	SCGs.	Agrin	expressed	in	
the SCG is TM-agrin (Gingras and Ferns, 2001) and could affect synaptogenesis through MuSK, 
which is expressed in neural tissue (Ip et al., 2000). The suppression of agrin expression in cultured 
hippocampal neurons by antisense oligonucleotide treatment resulted in the impairment of 
dendritic development and the formation of fewer synapses than in non-treated or sense 
treated neurons (Bose et al., 2000; Ferreira, 1999).
Agrin could function as a signaling molecule that interacts with a receptor other than MuSK. 
For instance, Hilgenberg (Hilgenberg et al., 1999; Hilgenberg and Smith, 2004) proposed that in 
neurons agrin signals via a receptor tyrosine kinase, which is coupled to the immediate-early 
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gene c-fos. The expression of c-fos was induced by agrin in a concentration-dependent and 
saturable manner. They further suggested that agrin binding to its receptor is associated with a 
rise in intracellular Ca2+, a ubiquitous second messenger capable of mediating a wide range 
of intracellular effects such as activation of CaMK II or MAPK. The agrin-induced increase in 
intracellular Ca2+ is characterized by an initial release from intracellular stores, supplemented 
by	an	extracellular	 influx	through	voltage-gated	calcium	channels	and	was	 indistinguishable	
when agrin-z+ or-z- were applied. Consequently, the same group recently presented the α3 
subunit of the Na+/K+-ATPase (NKA) as a neuronal receptor for agrin (Hilgenberg et al., 2006). 
They showed that the C-terminal agrin released after cleavage could bind and inhibit the ion 
pump activity and thus regulate presynaptic excitability. An increase in intracellular Na+ due 
to an impaired NKA function depolarizes synaptic membranes and triggers Ca2+	influx	through	
voltage-gated channels. Finally, increased cytoplasmic Ca2+ activates CaMK II and other Ca2+ 
effectors known to regulate a variety of synaptic functions such as neurotransmitter release and 
neurotransmitter receptor turnover.
To analyze the function of agrin in neurite outgrowth, TM-agrin was clustered on neurons using 
anti-agrin antibodies (Annies et al., 2006). On axons and dendrites from mouse hippocampal 
neurons anti-agrin antibodies induced a dose and time-dependent formation of numerous 
filopodia-like	processes	within	minutes.	These	data	provide	evidence	for	a	specific	role	of	TM-
agrin in shaping the cytoskeleton of neurites. In agreement with this, overexpression of TM-
agrin	caused	the	formation	of	filopodia	on	neurites	of	hippocampal	neurons	cultured	for	1–6	
days and increased Cdc42 activation (McCroskery et al., 2006). Conversely, suppression of 
agrin	expression	by	siRNA	reduced	the	number	of	filopodia.	The	N-terminal	half	of	agrin	was	
necessary	for	the	induction	of	filopodia.	By	positively	regulating	filopodia	in	developing	neurons,	
TM-agrin	may	influence	the	pattern	of	neurite	outgrowth	and	synapse	formation	by	increasing	
their initiation and stability.
In	cultured	agrin-deficient	neurons,	glutamatergic	and	GABAergic	synapses	still	form	(Serpinskaya	
et al., 1999). Moreover, electrophysiological analysis demonstrates that functional GABAergic 
synapses form between mutant neurons (Li et al., 1999). The frequency and amplitude of 
miniature postsynaptic glutamatergic and GABAergic currents are similar in mutant and age-
matched	wild-type	 neurons	 in	 culture.	 These	 results	 demonstrate	 that	 neuron-specific	 agrin	
is not required for the formation and early development for functional synaptic contacts 
between CNS neurons, and suggest that mechanisms of interneuronal synaptogenesis are 
distinct from those regulating synapse formation at the NMJ. Hence, synapses still form in the 
absence of agrin, albeit their stabilization seems to be agrin-dependent. Similarly, targeting any 
single molecule that has been implicated to have a function in vitro in synaptogenesis does not 
severely compromise the formation of synapses in the brain in vivo. It is therefore conceivable 
that several signaling systems provide compensatory mechanisms at central synapses. Such 
functional	redundancy	could	also	explain	why	synapses	still	form	in	the	brain	of	agrin-deficient	
mice.
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1.5 Mass spectrometry and protein analysis
Proteomics generally deals with the large-scale determination of cellular function directly at the 
protein level. Mass spectrometry (MS) has increasingly become the method of choice for the 
analysis of complex protein samples. MS-based proteomics is made possible by the availability 
of gene and genome sequence databases and technical and conceptual advances in 
many areas, most notably the discovery and development of protein ionization methods, as 
recognized by the 2002 Nobel prize in chemistry.
MS was restricted for a long time to small and thermostable compounds because of the lack 
of effective techniques to softly ionize and transfer the ionized molecules from the condensed 
phase into the gas phase without excessive fragmentation. In the late 1980s two techniques 
were developed that dramatically changed this situation and made polypeptides accessible 
to MS analysis — electrospray ionization (ESI) (Fenn et al., 1989) and matrix assisted laser 
desorption/ionization (MALDI) (Karas and Hillenkamp, 1988). Today mass spectrometers are 
used either to measure simply the molecular mass of a polypeptide or to determine additional 
structural	features	including	the	amino	acid	sequence	and	posttranslational	modifications.	In	
the former case, single-stage mass spectrometers are used, acting essentially as balances to 
weigh molecules. In the latter case, after the initial mass determination of precursor ions has 
occurred,	specific	ions	are	selected	and	subjected	to	fragmentation	through	collision-induced	
dissociation (CID). In such experiments, referred to as tandem mass spectrometry (MS/MS), 
detailed structural features of the peptides can be inferred from the analysis of the masses of 
the resulting fragments. In the context of proteomics, the key parameters for a mass analyzer 
are sensitivity, resolution, mass accuracy and the ability to generate information-rich ion mass 
spectra from peptide fragments (CID spectra). There are four basic types of mass analyzer 
currently	used	in	proteomics	research.	These	are	the	ion	trap,	time-of-flight	(TOF),	quadrupole	or	
linear ion trap and Fourier transform cyclotron (FT-MS) analyzers. These mass spectrometers can 
be stand-alone or, in some cases, put together in tandem to take advantage of the strengths 
of each other (Fig. 1.12).
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1.5.1 Quadrupole ion trap vs. Fourier transform ion cyclotron mass 
spectrometry
The quadrupole ion trap (QIT) mass spectrometer was developed in parallel with the quadrupole 
mass	analyzer	by	the	Nobel	prize	winning	mass	spectrometry	pioneer,	Wolfgang	Paul.	His	work	
in the early 1950’s lead to the development of the basic parameters of today’s benchtop 
instruments, however it took breakthroughs in design at Finnigan (MAT) in the 1980’s to make the 
QIT-MS the simple to use practical instrument it is today. Commercial QIT instruments are today very 
amenable being coupled to ESI and MALDI ionization as well as to liquid chromatography.
The ions, produced in the source of the instrument, enter into the trap through the inlet and 
are trapped through action of the three hyperbolic electrodes: the ring electrode and the 
entrance and exit endcap electrodes. The ions are trapped in the space between these three 
electrodes by (alternating current) AC ~1 MHz and (direct current) DC, non-oscillating, static 
electric	fields.	The	ring	electrode	radio	frequency	(RF)	potential,	an	AC	potential	of	constant	
Figure 1.13     Mass spectrometers used in proteome research.
The left and right upper panels depict the ionization and sample introduction process in electrospray ionization (ESI) and 
matrix-assisted laser desorption/ionization (MALDI). The different instrumental configurations (a–f) are shown with their 
typical ion source. a) In reflector time-of-flight (TOF) instruments, the ions are accelerated to high kinetic energy and are 
separated along a flight tube as a result of their different velocities. The ions are turned around in a reflector, which com-
pensates for slight differences in kinetic energy, and then impinge on a detector that amplifies and counts arriving ions. b) 
The TOF-TOF instrument incorporates a collision cell between two TOF sections. Ions of one mass-to-charge (m/z) ratio 
are selected in the first TOF section, fragmented in the collision cell, and the masses of the fragments are separated in the 
second TOF section. c) Quadrupole mass spectrometers select by time-varying electric fields between four rods, which 
permit a stable trajectory only for ions of a particular desired m/z. Again, ions of a particular m/z are selected in a first sec-
tion (Q1), fragmented in a collision cell (q2), and the fragments are separated in Q3. In the linear ion trap, ions are captured 
in a quadruple section, depicted by the red dot in Q3. They are then excited via resonant electric field and the fragments 
are scanned out, creating the tandem mass spectrum. d) The quadrupole TOF instrument combines the front part of a 
triple quadruple instrument with a reflector TOF section for measuring the mass of the ions. e) The (three-dimensional) 
ion trap captures the ions, fragments ions of a particular m/z, and then scans out the fragments to generate the tandem 
mass spectrum. f) The FT-MS instrument also traps the ions, but does so with the help of strong magnetic fields. The figure 
shows the combination of FT-MS with the linear ion trap for efficient isolation, fragmentation and fragment detection in the 
FT-MS section.
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frequency	but	variable	amplitude,	produces	a	3D	quadrupolar	potential	field	within	the	trap.	
This traps the ions in a stable oscillating trajectory. The exact motion of the ions is dependent 
on the voltages applied and their individual mass-to-charge (m/z) ratios. For detection of the 
ions, the potentials are altered to destabilize the ion motions resulting in ejection of the ions 
through the exit endcap. The ions are usually ejected in order of increasing m/z by a gradual 
change in the potentials. This ‘stream’ of ions is focused onto the detector of the instrument to 
produce the mass spectrum. The very nature of trapping and ejection makes a quadrupolar 
ion trap especially suited to performing MSn experiments in structural elucidation studies. It is 
possible to selectively isolate a particular m/z in the trap by ejecting all the other ions from the 
trap. Fragmentation of this isolated precursor ion can then be induced by CID experiments. The 
isolation and fragmentation steps can be repeated a number or times and is only limited by the 
trapping	efficiency	of	the	instrument.	MS5 experiments are fairly routine with this set-up as is the 
coupling of liquid chromatography to perform LC-MSn studies (March 2000).
Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry is a type mass spectrometer 
for determining the mass-to-charge ratio (m/z) of ions based on the cyclotron frequency of the 
ions	in	a	fixed	magnetic	field	(Fig.	1.12f).	In	the	basic	FT-MS	instrument,	the	ions	are	generated	
in the source as usual and then pass through a series of pumping stages at increasingly high 
vacuum.	When	the	ions	enter	the	cell	(ion	trap)	pressures	are	in	the	range	of	10-10 to 10-11 mBar 
with temperatures close to absolute zero. The cell is located inside a spatial uniform static 
superconducting	high	field	magnet	cooled	by	liquid	helium	and	liquid	nitrogen.	When	the	ions	
pass	into	the	magnetic	field	they	are	bent	into	a	circular	motion	in	a	plane	perpendicular	to	the	
field	by	the	Lorentz	Force	(see	equation	1,	below).	They	are	prevented	from	processing	out	of	
the cell by the trapping plates at each end. The frequency of rotation of the ions is dependent 
on their m/z ratio (equation 2). At this stage, no signal is observed because the radius of the 
motion is very small. A RF pulse achieves excitation of each individual ion across the excitation 
plates of the cell. Each individual excitation frequency will couple with the ions natural motion 
and excite them to a higher orbit where they induce an alternating current between the 
detector plates. The frequency of this current is the same as the cyclotron frequency of the ions 
and	the	intensity	is	proportional	to	the	number	of	ions.	When	the	RF	goes	off	resonance	for	that	
particular m/z value, the ions drop back down to their natural orbit (relax) and the next m/z 
packet is excited. Although the RF sweep is made up of a series of stepped frequencies, it can 
be considered as all frequencies simultaneously. These results in the measurement of all the ions 
in one go producing a complex frequency vs. time spectrum containing all the signals – the 
free induction decay (FID). Deconvolution of the FID by FT methods results in the deconvoluted 
frequency vs. intensity spectrum, which is then converted to the mass vs. intensity spectrum (the 
mass spectrum) by equation 3. Due to the ion-trap nature of FT-MS, it is possible to measure the 
ions without destroying them; this enables further experiments to be performed on the ions. 
The most common of these would be some kind of fragmentation study (MS/MS) for structural 
elucidation experiments.
Introduction 
(1)	 f = zv X b
(2) ωc = 
(3) m/z = 
FT-ICR mass spectrometry is a very high-resolution technique in that masses can be determined 
with very high accuracy. Mass accuracy of better than 2 ppm with external calibration is 
common for most applications. Many applications of FT-ICR MS use this mass accuracy to help 
determine the composition of molecules based on accurate mass. Another place where FT-ICR 
MS is useful is in dealing with complex peptide mixtures since the resolution (narrow peak width) 
allows the signals of two ions of similar m/z to be detected as distinct ions. A maximum resolution 
of better than 500,000 can be achieved. Peptides with multiple charges can be produced by 
electrospray ionization. These peptides contain a distribution of isotopes that produce a series 
of	isotopic	peaks,	which	can	be	resolved	by	ICR.	FT-ICR	MS	differs	significantly	from	other	mass	
spectrometry techniques in that the ions are not detected by hitting a detector such as an 
electron multiplier but only by passing near detection plates. Additionally the masses are not 
resolved in space or time as with other techniques but only in frequency. Thus, the different ions 
are not detected in different places as with sector instruments or at different times as with time-
of-flight	instruments	but	all	ions	are	detected	simultaneously	over	some	given	period	of	time.
The	technique	of	 ICR-MS	was	first	published	 in	 the	1950’s	where	 it	was	demonstrated	for	 the	
measurement of very small mass differences at very high precision by Hipple JA. The technique 
remained a largely academic tool until the application of FT methods by Alan Marshall and 
Melvin Comisarow in the early 1970’s when it has become more widely used (Comisarow and 
Marshall, 1996).
1.5.2 Interpretation of MS/MS spectra
In mass spectrometry, CID is a mechanism by which molecular ions are fragmented in the gas 
phase. The ions are usually accelerated by some electrical potential to high kinetic energy in 
the vacuum of a mass spectrometer and then allowed to collide with neutral gas molecules 
(often helium, nitrogen or argon). In the collision some of the kinetic energy is converted into 
internal energy, which results in bond breakage and the fragmentation of the molecular ion 
into smaller fragments. These fragment ions can then be analyzed by a mass spectrometer. The 
fragment ions produced by CID are used for several purposes. Partial or complete structural 
determination	can	be	achieved.	Another	use	is	in	simply	achieving	more	sensitive	and	specific	
detection. CID is used as part of tandem mass spectrometry for many experiments in proteomics. 
The CID mass spectra of peptides are very well suited	for the determination of their amino acid 
sequence. 
In	a	triple	quadrupole	mass	spectrometer	there	are	three	quadrupole	mass	analyzers.	The	first	
quadrupole	termed	“Q1”	can	act	as	a	mass	filter	that	transmits	a	selected	ion	and	accelerates	
it towards “q2” which is termed a collision cell (Fig. 1.12c). The pressure in q2 is higher and 
the ions collide with neutral gas in the collision cell and fragments by CID. The fragments are 
•	 f is the Lorentz Force observed by the ion when 
entering	the	magnetic	field
•	 b	is	the	magnetic	field	strength	(constant)
•	 v is the incident velocity of the ion
•	 ωc is the induced cyclotron frequency
•	 m is the mass of the ion
•	 z is the charge on the ion
zb
2πm
b
2πωc
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then accelerated out of the collision cell and enter Q3, which scans through the mass range, 
analyzing the resulting fragments (as they hit a detector). This produces a mass spectrum of the 
CID fragments from which structural information or identity can be gained.
CID spectra in proteomics usually derive from tryptic peptides. It is generally accepted that 
usable CID spectra can only be obtained from peptides of less than 2 – 3 kDa, and trypsin 
produces peptides of this size or smaller. It seems that the easiest spectra to interpret are those 
generated from doubly charged precursors, where the resulting fragment ions mostly are singly 
charged with only a few doubly charged fragments. Doubly charged precursors also fragment 
such that most of the peptide bonds break with comparable frequency, increasing the likelihood 
to derive a complete sequence. Another reason for using trypsin proteolysis has to do with the 
desirability of placing basic residues, notably lysine and arginine, at the C-terminus of a peptide. 
It is a general observation that in low energy CID the presence of an arginine in the middle of a 
peptide will often result in the absence of fragmentations at several contiguous peptide bonds 
adjacent to the arginine. By putting the basic residues at the C-terminus, peptides fragment in 
a more predictable manner throughout the length of the peptide is achieved.
The types of fragment ions observed in a CID spectrum depend on many factors including 
primary sequence, the amount of internal energy, how the energy was introduced, charge 
state,	etc.	The	accepted	nomenclature	for	fragment	ions	was	first	proposed	by	Roepstorff	and	
Fohlman	(Roepstorff	and	Fohlman,	1984),	and	subsequently	modified	by	Johnson	et al. (Johnson 
et al., 1987). Low energy CID of peptides results in a limited number of fragment ions. The key 
sequence-specific	fragment	ions	are	the	y-type	and	b-type	ions,	and	both	of	these	can	lose	
water (18.011u) or ammonia (17.027u). Usually, the y-type and b-type ions are more abundant 
than their corresponding losses of water or ammonia (Fig. 1.13). In addition to losing water or 
ammonia, the b-type ions can also lose CO (27.995 u) to give the so-called a-type ion, although 
these ions seem to occur most commonly for the lower mass fragments containing two, three, 
or four of the N-terminal residues. The prototypical CID spectrum of a tryptic peptide using a 
triple quadrupole contains a continuous series of y-type ions. The b-type ions are usually seen 
only at lower masses below the precursor m/z value and contain only a few of the N-terminal 
amino	acids.	 Ion	 trap	CID	data	of	 tryptic	peptides	 is	a	bit	different	 in	 that	one	often	finds	a	
continuous series of both b-type and y-type ions throughout the spectrum. This difference in 
intensity of b-type ions compared to triple quadrupoles is presumably due to precursor ions 
falling out of resonance with the excitation frequency in the trap. Once the molecule breaks 
Figure 1.14      Sequence ions generated by collision induced dissociation (CID).
Fragments will only be detected if they carry at least one charge. If this charge is retained on the N terminal fragment, 
the ion is classed as either a, b or c. If the charge is retained on the C terminal, the ion type is either x, y or z. A subscript 
indicates the number of residues in the fragment.
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apart in the trap it ceases to undergo further fragmentations. This is in contrast to quadrupole 
collision cells where fragment ions continue to bump into neutral gas atoms with higher collision 
energy. Presumably, b-type ions are less stable than y-type ions, and when they form in a triple 
quadrupoles further collisions involving these fragments cause them to break down into smaller 
bits.
The bonds N-terminal to a proline residue seem to be particularly labile, whereas the bond on 
the C-terminal side is not. For peptides containing proline(s) this has the effect of producing 
a pattern where a y-type series of ions may have a particularly abundant y-type ion due to 
cleavage on the N-terminal side of proline, but the y-type ion resulting from cleavage on the 
C-terminal side of proline has a much reduced abundance or is sometimes absent. A similar 
phenomenon may be observed for peptides containing glycine, where the cleavage on the 
C-terminal side results in ions of reduced abundance (partially extracted from http://www.abrf.
org/ResearchGroups/MassSpectrometry/EPosters/ms97quiz/SequencingTutorial.html).
1.5.3	 MS	analysis	of	partially	purified	proteins
Virtually	every	mass	spectrometry–based	proteomic	workflow	consists	of	three	distinct	stages:	(i)	
Protein	samples	are	isolated	from	their	biological	source	and	optionally	fractionated.	The	final	
protein sample is then digested and the resulting peptide sample is further fractionated. (ii) The 
peptides are subjected to qualitative and optionally to quantitative MS analysis. (iii) The large 
data sets generated are analyzed by suitable software tools to deduce the amino acid sequence 
and, if applicable, the quantity of the proteins in a sample. The peptide identity is assigned to 
the CID spectra through database searching (Baldwin, 2004). A subsequent statistical analysis 
of	 the	search	 results	 is	critical	 to	ensure	confidence	 in	 the	 identifications	 (Keller	et	al.,	2002).	
Using subcellular fractionation in combination with multi-dimensional mass spectrometry a lot 
of	effort	has	been	taken	to	determine	proteomes	of	diverse	organisms,	organelles,	body	fluids,	
such	as	the	cerebral	spinal	fluid	(Pan	et	al.,	2007;	Yuan	and	Desiderio,	2005;	Zhang	et	al.,	2005a;	
Zhang et al., 2005b) and urinary (Adachi et al., 2006), and even protein complexes (Husi et al., 
2000). For the large-scale analysis of yeast proteome, tryptic peptides of different fractions of 
S. cerevisiae whole cell-lysates were loaded onto a biphasic microcapillary column packed 
with	strong	cation	exchange	(SCX)	and	reverse-phased	(RP)	materials	(Washburn	et	al.,	2001).	
The column was directly coupled to a Finnigan LCQ ion trap mass spectrometer and peptides 
were	first	displaced	from	the	SCX	to	the	RP	by	a	salt	gradient	followed	by	elution	from	the	RP	
into the MS. The tandem mass spectra acquired were correlated to theoretical mass spectra 
generated from protein or DNA databases by the SEQUEST algorithm (Eng et al., 1994). A total of 
1,484	proteins	were	detected	and	identified.	Categorization	of	the	hits	demonstrated	the	ability	
of this technology to detect and identify proteins rarely seen in proteome analysis, including 
low abundance proteins like transcription factors and protein kinases. In addition, 131 proteins 
with three or more predicted transmembrane domains were detected. Furthermore, the high 
throughput	protein	profiling	of	another	frequently	used	model	organism,	C. elegans, resulted 
in	the	identification	of	1616	proteins,	including	110	secreted	and	242	transmembrane	proteins	
(Mawuenyega et al., 2003). Very recently a high-quality catalog of the proteome of Drosophila 
Melanogaster	 was	 published	 (Brunner	 et	 al.,	 2007).	 They	 identified	 63%	 of	 the	 predicted	D. 
Melanogaster proteome by detecting 9124 proteins from 498000 redundant and 72281 distinct 
peptide	 identifications.	 This	 was	 achieved	 by	 combining	 sample	 diversity,	 multidimensional	
biochemical fractionation and analysis-driven experimentation feedback loops. The collection 
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of the data was guided by statistical analysis of prior data.
In addition subcellular fractions were subjected to MS-based proteome analysis. To investigate 
the protein composition of the postsynaptic density (PSD), synaptosomal preparations were 
enriched from brain homogenates by differential and density gradient centrifugation followed 
by an extraction with 0.5% Triton-X 100. Proteins were then separated by SDS-PAGE and the in-
gel	digested	gel	slices	were	analyzed	by	either	MALDI-TOF	(Walikonis	et	al.,	2000)	or	LC-ESI-MS	
(Peng	et	al.,	2004).	Over	370	different	proteins	that	copurified	with	the	PSD	structure	and	thirteen	
phosphorylated	sites	 from	eight	proteins	were	discovered.	These	proteins	were	classified	 into	
numerous functional groups, revealing crucial information about the molecular diversity in the 
PSD, and provided a basis for further studies on the molecular mechanisms of synaptic function 
and plasticity. Moreover, molecules associated with or inserted into the synaptic plasma 
membrane	were	identified	using	analogous	techniques	(Stevens	et	al.,	2003).	 In	general,	the	
analysis	of	organelles	with	proteomic	methods	 is	an	active	 field	of	 research,	and	 significant	
progress	has	been	made	in	defining	the	proteomes	of	multiple	organelles.	Hence,	organelles	
and other large cellular structures have been analyzed, (e.g. plasma membrane, ER, lipid 
rafts, mitochondria, exosomes, clathrin-coated vesicles, lysosomes, centrosome/spindle poles, 
midbodies, cytoskeleton, phagosomes, peroxisomes, Golgi, nuclear pores, nucleolus, nuclear 
envelope (Yates et al., 2005)).
To dig deeper into even smaller entities of multi-protein structures, constituents of protein 
complexes were investigated by MS. So far, the number and identities of proteins in each 
subunit of the 80S ribosomes from S. cerevisiae have been determined primarily by isolating the 
ribosomal particles, electrophoretically separating the proteins and sequencing the proteins by 
Edman degradation. The effort of several groups was needed to estimate that the yeast 80S 
ribosome complex contains 78 different proteins present at unimolar amounts (32 proteins in 
the 40S and 46 in the 60S subunits). Now, multi-dimensional mass spectrometry was applied to 
isolated	ribosomes	resulting	in	the	identification	of	75	of	the	78	predicted	ribosomal	proteins	and	
of one novel protein component (YMR116p) of the yeast and human 40S subunit (Link et al., 
1999). Another fundamental study that reveals the protein composition of the NMDA receptor-
signaling (NRC) complex underscores the tremendous potential of multi-dimensional LC-ESI-MS/
MS. The receptor complex was isolated from mouse forebrain extracts using covalently coupled 
NR1	 immunoaffinity	 resins,	 immunoprecipitation	 with	 NR1	 specific	 antibody,	 and	 peptide-
affinity	 chromatography	with	 a	 hexapeptide	 of	 the	NR2B	C-terminus	 (Husi	 et	 al.,	 2000).	 The	
NRC comprised 77 proteins organized into receptor, adaptor, signaling, cytoskeletal and novel 
proteins, of which 30 are known from binding studies and another 19 participate in NMDAR 
signaling. NMDAR and metabotropic glutamate receptor subtypes were linked to cadherins 
and L1 cell-adhesion molecules in complexes lacking AMPA receptors. These neurotransmitter–
adhesion receptor complexes were bound intracellularly to kinases, phosphatases, GTPase-
activating proteins and Ras with effectors including components of the MAPK pathway.
1.5.4 Strategies for quantitative peptide analysis
To add a quantitative dimension to peptide LC-MS/MS experiments, the technique of stable-
isotope labeling has been applied. This method makes use of the fact that pairs of chemically 
identical analytes of different stable-isotope composition can be differentiated in a mass 
spectrometer thanks to their mass difference. The ratio of signal intensities for such analyte 
pairs accurately indicates the abundance ratio for the two analytes (Fig. 1.14). To this end, 
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stable-isotope tags have been introduced to proteins via metabolic labeling using heavy salts 
or amino acids (Conrads et al., 2002), enzymatically via transfer of 18O from water to peptides 
(Mirgorodskaya et al., 2000; Yao et al., 2001), or via chemical reactions using isotope-coded 
affinity	tags	(ICAT)	or	similar	reagents	(Gygi	et	al.,	1999b;	Zhou	et	al.,	2002).	Post-isolation	chemical	
isotope tagging of proteins is currently the most versatile and most commonly used labeling 
method. An attractive feature of this approach is that the selectivity of the labeling reactions 
can	be	used	 to	direct	 the	 isotopes	and	attached	affinity	 tags	 to	 specific	 functional	groups	
or protein classes, thus enabling their selective isolation and analysis. So far, isotope-tagging 
chemistries	have	been	described	that	are	specific	for	sulphhydryl	groups	(Gygi	et	al.,	1999b;	
Zhou et al., 2002), amino groups (Munchbach et al., 2000), the active sites for serine (Liu et al., 
1999) and cysteine hydrolases (Greenbaum et al., 2000), for phosphate ester groups (Oda et al., 
2001; Zhou et al., 2001) and for N-linked carbohydrates (Zhang et al., 2003). Recently, a method 
called ‘stable-isotope labeling with amino acids in cell culture’, or SILAC, has been described 
(Ong et al., 2002). In this method, one cell state is metabolically labeled with light and the other 
with heavy form of a particular amino acid, for example, 13C-labeled arginine. Potentially all 
peptides can be labeled and the absence of any chemical steps make the method easy to 
apply	as	well	as	compatible	with	multistage	purification	procedures.
In	summary,	quantitative	proteomics	provide	a	tool	for	the	identification	and	quantification	of	
hundreds and thousands of proteins from complex mixtures simultaneously. Despite the high 
sensitivity of the today’s mass spectrometers, a detailed validation of the enormous amount 
of data acquired is needed. Nonetheless, proteomics is a useful technique for high throughput 
profiling	of	protein	regulation	and	screening	for	candidate	molecules	in	a	perturbed	system.
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1.5.5	 Isotope-coded	affinity	tag	(ICAT)
Protein	labeling	with	isotope-coded	affinity	tags	(ICAT)	followed	by	tandem	mass	spectrometry	
allows	sequence	identification	and	accurate	quantification	of	proteins	in	complex	mixtures	(Fig.	
1.15). It has been applied to the analysis of global protein expression changes in yeast (Gygi et 
al., 1999b; Smolka et al., 2001), to identify protein changes in subcellular fractions comparing 
the PSD proteome from rat forebrain and cerebellum, identifying the alterations in protein 
expression in the synaptic plasma membrane of hippocampal PSD proteins after morphine 
administration (Cheng et al., 2006; Moron et al., 2007; Prokai et al., 2005). Components of 
Figure 1.15   Schematic representation of methods for stable-isotope protein labeling for quantitative proteomics.
A) Proteins are labeled metabolically by culturing cells in media that are isotopically enriched (for example, containing 15N 
salts, or 13C-labeled amino acids or isotopically depleted. B) Proteins are labeled at specific sites with isotopically encoded 
reagents. The reagents can also contain affinity tags, allowing for the selective isolation of the labeled peptides after protein 
digestion. The use of chemistries of different specificity enables selective tagging of classes of proteins containing specific 
functional groups. C) Proteins are isotopically tagged by means of enzyme-catalyzed incorporation of 18O from 18O water dur-
ing proteolysis. Each peptide generated by the enzymatic reaction carried out in heavy water is labeled at the C-terminus. In 
each case, labeled proteins or peptides are combined, separated and analyzed by mass spectrometry and/or tandem mass 
spectrometry for the purpose of identifying the proteins contained in the sample and determining their relative abundance. 
The patterns of isotopic mass differences generated by each method are indicated schematically. The mass difference of 
peptide pairs generated by metabolic labeling is dependent on the amino acid composition of the peptide and is therefore 
variable. The mass difference generated by enzymatic 18O incorporation is either 4 Da or 2 Da, making quantitation difficult. 
The mass difference generated by chemical tagging is one or multiple times the mass difference encoded in the reagent 
used.
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protein complexes were compared such as RNA polymerase II pre-initiation complex (PIC) and 
a control sample or the protein composition of different subtypes of 20S proteasome subunits 
were	determined	(Ranish	et	al.,	2003;	Schmidt	et	al.,	2006).	And	protein	secretion	and	body	fluids	
were	analyzed	quantifying	proteins	from	the	urinary	of	mice	deficient	in	factor	H	or	comparing	
human	cerebrospinal	fluid	(CSF)	from	aged	vs.	young	individuals	and	from	patients	with	AD	vs.	
healthy individuals (Braun et al., 2006; Zhang et al., 2005a; Zhang et al., 2005b). The method 
is suitable for large-scale analysis of complex samples including whole proteomes and allows 
quantitative analysis of proteins. The ICAT approach is based on two principles. First, a short 
sequence of contiguous amino acids from a protein (e.g. trypsinized peptides of 5–25 residues) 
contains	sufficient	information	to	identify	that	unique	protein.	Second,	pairs	of	peptides	tagged	
with the light and heavy ICAT reagents, respectively, are chemically identical and therefore 
serve	as	ideal	mutual	internal	standards	for	accurate	quantification.	In	MS,	the	ratios	between	
the peaks intensities of the lower and upper mass of the pairs provide an accurate measure of 
the relative abundance of the peptides (and hence the proteins) in the original sample pools. 
This is because the MS intensity response to a given peptide is independent of the isotopic 
composition	 of	 the	 ICAT	 reagents.	 The	 data	 of	 this	 report	 provide	 the	 first	 comprehensive	
proteomic	profiling	of	a	transgenic	mouse	line	using	the	ICAT	technology.
 
Figure 1.16      The ICAT strategy for identifying and quantifying differential protein expression.
Two protein mixtures representing two different samples are treated with the isotopically light and heavy ICAT reagents, 
respectively; an ICAT reagent is covalently attached to each cysteinyl residue in every protein. Proteins from sample 1 
are shown in green, and proteins from sample 2 are shown in blue. The protein mixtures are combined and proteolyzed 
with trypsin to peptides, and ICAT-labeled peptides are isolated utilizing the biotin tag. These peptides are separated by 
microcapillary high-performance liquid chromatography. A pair of ICAT-labeled peptides is chemically identical and is easily 
visualized because they essentially co-elute. There is a 9 Da mass difference measured in a scanning mass spectrometer 
(4.5 mass-to-charge (m/z) units difference for a doubly charged ion). The ratios of the original amounts of proteins from the 
two samples are strictly maintained in the peptide fragments. The relative quantification is determined by the ratio of the 
peptide pairs. Every other scan is devoted to fragmenting and then recording sequence information about an eluting peptide 
(tandem mass spectrum). Computer searching of the recorded sequence information against large protein databases identi-
fies the protein.
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2. Aim of this work
The focus of the group where this work was performed is to characterize the function of 
neurotrypsin proteolytic and non-proteolytic activity in the brain and the NMJ. In a screen for 
trypsin-like serine peptidases, neurotrypsin mainly was found in the nervous system. Spatial and 
temporal distribution suggested a role for neurotrypsin in processes such as synaptic plasticity 
that is generally accepted to be involved in learning and memory. As mentioned earlier agrin 
is a substrate for neurotrypsin but the functional role of the cleavage and the molecular fate of 
the resulting fragments are as yet unknown. Consequently, no generic downstream signaling 
pathway could be assigned to the agrin cleavage. Furthermore, despite of the conspicuous 
non-catalytic domains neither additional substrates nor other proteolytic-independent binding 
partners of neurotrypsin could be found.
This study was performed to shed light on the molecular function of neurotrypsin proteolytic 
and non-proteolytic activity using a quantitative proteomic analysis. To this end transgenic 
mice	overexpressing	neurotrypsin	under	the	control	of	the	brain	specific	promotor	Thy-1.2	were	
generated and synaptosomes as well as hippocampal subcellular fractions of transgenic mice 
were	compared	with	their	wild-type	litter	mates.	For	the	proteomic	profiling	two	complementary	
approaches were chosen. Firstly, peptides of the two states were labeled with either light or 
heavy	 isotope-coded	 affinity	 tags	 (ICAT)	 followed	 by	 fractionation	 and	 affinity	 purification	
and subsequent measurement by LC-ESI-MS. The acquired CID spectra were cross-correlated 
with	theoretical	spectra	to	identify	peptide	sequences,	which	in	turn	were	assigned	to	specific	
proteins.	Relative	quantification	of	each	protein	(ICAT	light	wild-type	versus	ICAT-heavy	transgenic	
samples) was calculated using Automated Statistical Analysis on Protein Ratio (ASAP Ratio) and 
XPRESS software that both reconstructed ion chromatograms for the peptide ions measured. 
Secondly, proteins were fractionated and then separated by two-dimensional polyacrylamide 
gel electrophoresis (2DE). Spot intensities from wild-type and transgenic mice were compared 
using	Proteomweaver	and	differentially	regulated	spots	were	excised	and	identified	by	MALDI	
TOF-TOF mass spectrometry. 
Computer based analysis and manual inspection of the high throughput data put forth a set of 
proteins	with	changed	abundance	ratios.	Finally,	candidate	proteins	whose	expression	profile	
has been changed due to either direct or indirect interaction with neurotrypsin were validated 
by	Western	blot	or	immunohistochemical	analysis.
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3. Results
3.1 Neurotrypsin in the mouse brain
3.1.1	 Neurotrypsin	is	expressed	in	synaptosomes	and	the	hippocampus
The expression of neurotrypsin in human brain was found in presynaptic nerve endings of cortical 
synapses	 (Molinari	 et	 al.,	 2002).	 Immunogold	 localization	 at	 synapses	 with	 affinity-purified	
antibodies raised against the proteolytic domain of neurotrypsin showed exclusive labeling 
of presynaptic terminals in the region lining the synaptic cleft, the active zone. In addition, 
due to the signal peptide for secretion and multiple non-catalytic domains, well known from 
other secreted peptidases, neurotrypsin is possibly released into the synaptic cleft and remains 
associated with membrane bound pre- or postsynaptic components or the ECM within the 
cleft.
3.1.1.1 Isolation of synaptosomes
To investigate the expression level of neurotrypsin and to search for changes in protein 
expression	in	neurotrypsin-overexpressing	mice	by	isotope-coded	affinity	tag	(ICAT)	technology,	
synaptosomes were isolated from whole brain homogenate of P20 and P40 mice (Fig. 3.1a). 
Synaptosomes are isolated synapses produced by subcellular fractionation of brain tissue. 
They are formed during mild disruption. Shearing forces cause the nerve endings to break off 
and by subsequent resealing of the membranes, synaptosomes are generated (Turner AJ, 
1997). They contain the complete presynaptic terminal, including the synaptic cleft, synaptic 
vesicles, mitochondria and the attached postsynaptic density (PSD). Synaptosomes retain 
the morphological features and chemical composition of the synaptic boutons (Fig. 3.1b). 
Apart from the fact that synaptosomes represent a highly specialized subcellular fraction, 
they also include impurities, e.g. cell debris, intracellular organelles such as nuclei, Golgi, ER or 
lysosomes, and more pronounced, components of astroglial origin. However, synaptosomes 
are preferentially isolated from whole brain homogenate of adolescent and adult mice while 
endogenous neurotrypsin expression in the developing CNS. E.g. the diencephalon and the 
cerebellum are largely devoid of staining (Wolfer	et	al.,	2001).	Depending	on	the	neuronal	tissue,	
the expression is strongest in late embryonic stages and stays high until postnatal day 15 (P15) 
after birth and seems to decline during adolescence. Therefore, we decided also to analyze 
a	more	defined	area	of	the	brain,	the	hippocampus,	which	is	known	to	express	high	levels	of	
neurotrypsin starting from P4 to P10.
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3.1.1.2 Subcellular fractionation of the hippocampus
Hippocampi of P10 mice were dissected and subjected to subcellular fractionation (Fig 3.1c). 
Cell debris and nuclei were removed by two repetitive centrifugation steps at 1’000x g. The 
resulting supernatant S1’ was further subdivided with a 34’000x g centrifugation step into a 
pelletous fraction P2 and a soluble fraction S2. In order to characterize the hippocampal fractions, 
marker proteins were immunoblotted (Fig. 3.1d). Striking evidence suggests that P2 very much 
resembles the synaptosomes. Presynaptic synaptophysin and postsynaptic markers glutamate 
receptors 2 and 3 (GluR2/3) as well as postsynaptic density protein-95 (PSD-95) were heavily 
enriched in P2 as opposed to S2. Obviously, also cytosolic proteins like microtubule-associated 
protein	2	 (MAP2),	neurofilament-160	 (NF-160),	and	 the	ER-marker	Grp-78	were	present	 in	P2,	
indicating that P2 was contaminated with extra synaptic molecules. S2 was virtually devoid of 
GluR 2/3, PSD-95, and synaptophysin, whereas MAP2 and the Golgi-marker β-COP were strongly, 
and NF-160 was slightly enriched. Grp-78 was evenly distributed when comparing P2 and S2. 
Altogether, conspicuous data demonstrate that S2 mainly consists of soluble cytosolic proteins, 
whereas P2 includes more membranous or membrane associated molecules. Importantly, all 
forthcoming studies in this report, comparing wild-type with transgenic animals, were either 
performed with synaptosomes of P20 and P40 mice or with hippocampal subcellular fractions 
S2 and P2 of P10 mice. 
3.1.1.3	 Detection	of	neurotrypsin	in	wild-type	and	overexpressing	mouse	lines
Until now, neurotrypsin protein has not been detected in mouse CNS. In order to detect 
neurotrypsin we used, two polyclonal antibodies G87 and G93 raised against the protease domain 
(PD)	of	human	neurotrypsin	(hNT)	and	against	the	full-length	(fl)	protein	of	mouse	neurotrypsin	
(mNT), respectively. Synaptosomes were isolated from a pool of whole brains of P12 – P15 wild-
Figure 3.1     Isolation of synaptosomes and 
subcellular fractionation of the hippocam-
pus.
(A) Schematic diagram of the preparation of syn-
aptosomes. Synaptosomes are obtained after 
homogenization and subcellular fractionation of 
brain tissue. The fractionation involves differential 
and density-gradient centrifugation to separate 
synaptosomes from nuclei (P1), cell debris (S2), 
and mitochondria (M). (B) Representative elec-
tron micrograph of isolated synaptosomes. Pre- 
and postsynaptic components, mitochondria, as 
well as impurities are present in the sample. SV, 
synaptic vesicle; SJ, synaptic junction; M, mito-
chondira (Schrimpf et al., 2005). (C) Subcellular 
fractionation of the hippocampus using three 
centrifugation steps results in a pelletous (P2) 
and a soluble fraction (S2). (D) Marker protein 
analysis of the hippocampus fractions. Pre- and 
postsynaptic markers synaptophysin, glutamate 
receptors 2 and 3 (GluR-2/3), and postsynaptic 
density protein-95 (PSD-95) are enriched in P2 
as opposed to S2. Dendritic microtubule-associ-
ated protein-2 (MAP-2) and Golgi specific β-COP 
are accumulated in S1’ and S2. Neurofilament-
NF-160 and ER protein Grp-78 are distributed 
likewise in S1’, P2, and S2. Hp: hippocampus 
homogenate.
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type and human neurotrypsin-overexpressing transgenic mice (M491S). Brain homogenates, 
supernatant S2, and synaptosomes were loaded onto a SDS-PAGE and immunodetected with 
G93 antibody. Endogenous mNT with a calculated molecular mass of 84.1 kDa was found in 
equal amounts in wild-type and transgenic mice and evenly distributed among the fractions 
(Fig.	3.2a,	arrowhead).	This	is	a	contradictory	finding	to	the	immunogold	labeling	for	neurotrypsin	
previously performed in our laboratory, which showed an accumulation of gold particles in the 
presynaptic active zone (Molinari et al., 2002). Yet the signal was absent in the brain homogenate 
of the neurotrypsin knock-out (KO) mice. The human transgene though with a Mr: 97.0 kDa, was 
enriched in the transgenic samples (3.2a, asterisk), indicating an overexpression of hNT. The 
background signal in the wild-type samples running exactly at the same size was also seen 
in	the	KO,	suggesting	that	an	unspecific	band	was	recognized	by	G87.	PSD-95	was	used	as	a	
loading control and to show an enrichment of synaptic components in the synaptosomes.
In addition, neurotrypsin expression was also probed by immunoblot assay in the hippocampal 
fractions comparing wild-type and transgenic M494 mice, using G87. Here, endogenous full-
length protein was enriched in pelletous fraction P1, and particularly in P2 (Fig. 3.2b, arrowhead). 
The transgenic full-length hNT was also strongest in P2 and basically absent in S2 (Fig. 3.2b, 
asterisk).	Interestingly,	the	antibody	also	recognized	the	unspecific	band	in	the	hippocampus,	
but to a lesser extent as opposed to the synaptosomes. On the one side, native PD was 
highly abundant in P1 and in P2 of wild-type samples (Fig. 3.2b, PD). On the other hand, an 
accumulation of exogenous PD in P1 of transgenic samples was not observed. Anyhow, there is 
strong evidence for an induction of human neurotrypsin expression in the hippocampus, since 
in all other fractions, although weakly, an increased signal for full-length protein and PD was 
found in transgene samples. Taken together, these data suggest a moderate overexpression 
of hNT in the transgenic mouse lines M491S and M494. Furthermore, a generic accumulation 
of endogenous neurotrypsin in synaptosomes was not found. Instead, full-length endogenous 
neurotrypsin was enriched in P2 fractions of the hippocampus, whereas the PD was enriched 
in P1.
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Figure 3.2     Neurotrypsin expression in synaptosomes and the hippocampus of wild-type and transgenic mice.
(A) Detection of neurotrypsin in brain homogenate (H), supernatant 2 (S2), and synaptosomes (Ss) of P12 - P15 wild-
type (wt) and M491S transgenic (tg) mice with G93 antibody raised against full-length mouse neurotrypsin. The double 
band represents the human neurotrypsin overexpressed in transgenic samples (asterisk). The lower band is endogenous 
mouse neurotrypsin, which is absent in the neurotrypsin knock-out (KO) mouse (arrowhead). PSD-95 immunoblot confirms 
the enrichment of postsynaptic elements in synaptosomes (the picture was kindly provided by A. Stephan). (B) Both the 
endogenous mouse (arrowhead) and the overexpressed human (asterisk) full-length (fl) form of neurotrypsin are enriched 
in the pelletous fractions P1 and P2 of the hippocampus. Similarly, the protease domain (PD) is more abundant in P1 and 
P2, compared to the soluble fractions S1’ and S2. The signals for exogenous full-length protein and PD are enriched in 
transgenic samples (M494).
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3.2 Neurotrypsin cleaves agrin in cell culture and in the CNS
3.2.1 Agrin processing by neurotrypsin in synaptosomes and in the 
hippocampus
In the CNS the type II transmembrane form of agrin-y4z-/+ is predominant (Neumann et al., 2001). 
To test whether agrin is enriched in synaptosomes, protein extracts of whole brain homogenate 
(H), supernatant S2, and synaptosomes (Ss) from M491S were loaded on a 4 – 12% NuPAGE 
gel in equal amounts and immunoblotted with R132 antibody raised against the 90-kDa agrin 
fragment and R139 antibody against the LG3 domain (Fig. 3.4a). In contrast to the smeary full-
length agrin signal from the cell culture assay, agrin full-length protein was resolved in three 
distinct bands above 250 kDa. It might well be that they represent different glycosylation forms of 
agrin. Compared to transgenic samples the uppermost band was strongest mainly in wild-type 
synaptosomes. Interestingly, it was this particular form of agrin that disappeared in the transgenic 
samples. Here again, the most outstanding change was observed in synaptosomes, suggesting 
a preferential cleavage of the fully glycosylated form of full-length agrin. Furthermore, the 90-
kDa cleavage product was accumulated in wild-type S2 as compared to wild-type H and wild-
type	Ss,	indicating	a	release	into	the	ECM	of	the	fragment	after	cleavage.	Without	controversy,	
the fragment was enriched in every transgenic sample, implying an increased cleavage by 
neurotrypsin. Similar observations were made for the LG3 domain, which was strongest in the S2 
fraction  when comparing wild-type samples. (Fig. 3.4a).
Western	blotting	of	hippocampal	subcellular	fractions	homogenates	revealed	a	similar	picture	
of the agrin fragment distribution using R132 and R139 antibodies (Fig. 3.3b and 3.4b – d). In 
wild-type samples three distinct agrin full-length bands were detected all of which appeared 
above 250 kDa. In M494 transgenic mice, the intensity of the lowest band of the three was 
similar to wild-type, while the upper two were seemingly reduced. Surprisingly, exactly these 
two upper bands of agrin were by far the most abundant ones in the KO samples, whereas the 
lowest band was weaker (Fig. 3.3b). Consequently, neurotrypsin might preferentially cleave the 
upper full-length agrin forms also in the hippocampus. Comparing the various fractions of wild-
type hippocampal fractions, a different distribution of agrin full-length variants was observed. 
While	 in	 the	 pelletous	 fraction	 P1,	 which	mainly	 consists	 of	 nuclei	 and	 heavy	membranous	
compartments like ER, the putatively immature forms of agrin were strongly represented, the 
situation had completely changed in supernatant S1 and pelletous fraction P2. Mainly in P2, 
the potentially fully glycosylated form of agrin was enriched, whereas in soluble fraction S2, 
composed of cytosolic molecules and light membranous structures like Golgi, all agrin full-
length	forms	were	more	or	less	evenly	distributed.	These	findings	indicate	that	during	secretion,	
agrin might run through a maturation process that ends with a fully glycosylated form that 
is most susceptible to neurotrypsin cleavage. In wild-type, both the 112-kDa and the 90-kDa 
intermediate agrin fragments were produced in equal amounts, whereas in the transgenes the 
production of the 90-kDa fragment was increased due to excessive proteolytic activity at the α- 
and β-cleavage sites. In the KO however, no cleavage product was found at all (Fig. 3.4b and 
c). The same observations were made for the immunodetection of the LG3 domain. Stronger 
signals were detected in the hippocampus of neurotrypsin-overexpressing mice as compared 
to wild-type littermates. No LG3 domain was found in the neurotrypsin KO (Fig. 3.4b and c). 
In the control line S/A 785, overexpressing an inactive variant of neurotrypsin, no differences 
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were found comparing wild-type and transgene (Fig. 3.4d). Moreover, a comparison of the 104 
and 90-kDa fragments as well as the LG3 domain among the subcellular fractions, showed an 
enrichment of the signals in S2 wild-type, suggesting a release of the cleavage products from 
heavy membranous structures such as the synaptic plasma membrane (Fig. 3.4b – d). These data 
provide	evidence	supporting	the	hypothesis	that	agrin	is	specifically	cleaved	by	neurotrypsin	in 
vivo. In neurotrypsin-overexpressing mice an accumulation of the agrin cleavage products and 
a decline of the potentially fully glycosylated mature full-length agrin form was demonstrated. 
In	addition,	due	to	the	lack	of	neurotrypsin	activity	in	the	KO,	there	is	first	of	all	no	production	of	
any cleavage product, and second of all an accumulation of the uncleaved full-length agrin 
forms. Noticeable the most susceptible agrin variant to neurotrypsin cleavage is enriched in P2. 
Nevertheless, the fate of the cleavage products remains to be shown.
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Figure 3.3     Agrin processing by neurotrypsin in synaptosomes and in the hippocampus.
(A) Immunoblot with R132 antibody against the 90-kDa fragment of whole mouse brain homogenate (H), supernatant 2 
(S2), and synaptosomes (Ss) detects three major agrin full-length bands. Comparing wild-type (wt) and transgenic (tg) 
samples the uppermost band is strongest in wt Ss and S2. The 90-kDa fragment of agrin is enriched in the tg samples 
(upper panel). Consequently, when R139 antibody, directed against the laminin globular domain 3 (LG3) is used the signal 
is also enriched in tg (lower panel). The Western blot was kindly provided by A. Stephan. (B) An immunoblot of M494 hip-
pocampus homogenate (Hp) and its subcellular fractions using R132 antibody detects three full-length agrin bands (upper 
panel). In the supernatant 1 (S1), and pelletous fraction 2 (P2), the upper band is most prominent and is processed most 
intensively, when comparing wt and tg. Otherwise, the three bands in pellet 1 (P1) and soluble fraction 2 (S2) are evenly 
distributed. In wt, the strongest enrichment of the 90-kDa agrin fragment is seen in S2 (middle panel). An increase in the 
cleavage product is clearly observed in tg samples. Strong evidence for an increased cleavage of agrin in tg is the fact 
that the LG3 domain (lower panel) is also increased. The fragment can hardly be detected in wt P1 and P2, whereas it is 
enriched in S2. (C) In the neurotrypsin knock-out mouse (KO) the distribution of agrin full-length protein is similar to (B), 
but as expected, a decline of the upper band is not observed (upper panel). In addition, absolutely no signal is seen for the 
90-kDa (middle panel) and the LG3domain (lower panel). (D) An immunoblot of agrin from control mice overexpressing a 
proteolytic inactive form of neurotrypsin (S/A) shows no increase of agrin cleavage products, when comparing wt and tg. 
The distribution of agrin full-length bands is as described above.
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3.3	 Proteomic	 profiling	 of	 synaptosomes	 and	 the	 hippocampus	
comparing wild-type and transgenic mice
In	the	search	for	neurotrypsin-dependent	differences	in	protein	regulation,	proteomic	profiling	
using	isotope-coded	affinity	tags	(ICAT)	and	mass	spectrometry	was	performed.	Samples	from	
wild-type mice were compared with samples from transgenic mice overexpressing neurotrypsin 
under the control of the Thy-1.2 promotor. The mouse lines used in this study was M491S and 
M494. Synaptosomes from wild-type and transgenic P20 and P40 mice as well as hippocampus 
fractions S2 and P2 of P10 mice have been processed.
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Figure 3.4     Sample preparation for quantitative proteome analysis using isotope-coded affinity tags (ICAT).
(A) Before ICAT labeling protocol was conducted, the samples were separated on a gel and stained with silver. Equal 
amounts of wild-type (wt) and transgenic (tg) synaptosomes (Ss) isolated from P20 and P40 whole mouse brain were 
loaded on an SDS-PAGE (left panels), and hippocampal supernatant 2 (S2) and pellet 2 (P2) fractions of P10 mice were 
loaded on a 4 - 12% NuPAGE gel (right panel). Differences, comparing S2 and P2, are highlighted with red asterisks. 
(B) Schematic diagram of the ICAT labeling protocol. Protein extracts derived from wt mice were isotopically labeled with 
ICAT light while ICAT heavy was used for tg samples. The two samples were combined and trypsin digested. Thereafter 
the complex peptide mixture was fractionated with a strong cation exchange-column (SCX) followed by avidin-affinity 
purification of each individual fraction. Subsequent measurement of the ICAT labeled, cysteine-containing peptides was 
performed, with reversed-phase liquid-chromatography electrospray ionization tandem mass spectrometry (RP-LC-ESI-
MS/MS). Peptide sequences were determined and protein assignment was performed by database searching using SE-
QUEST and Mascot search engines. Relative quantification was computed with Automated Statistical Analysis on Protein 
Ratio (ASAPRatio) and XPRESS software. Finally, data mining was carried out. (C) SCX elution profiles of Ss P20 and 
P40 and S2and P2 from P10 are depicted. Fractions (fr.) shaded in blue were discarded, fractions in green were pooled, 
and those in orange were collected individually for avidin-affinity purification.
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3.3.1	 Sample	validation	for	the	proteomic	profiling
After the proteins had been isolated, they were loaded on a gel and stained with silver to estimate 
the quality of the sample. Equal amounts of synaptosomes from wild-type and transgenic 
P20 mice were loaded on a reducing 12% SDS-PAGE and stained with silver. Synaptosomes 
from P40 mice were loaded equally on a reducing 10% SDS-PAGE (Fig. 3.5a, left and middle). 
Both showed a typical ladder-like separation of proteins from low to high molecular masses. 
Comparable staining intensity was observed comparing wild-type with transgenic samples. For 
the hippocampal fractions a 4 – 12% NuPAGE gel was used to separate the proteins from S2 and 
P2. Equal amounts of proteins from wild-type and transgenic samples were stained (Fig. 3.5a, 
right). The band pattern of wild-type and transgenic S2 and P2 were the same. Differences were 
only found when lanes from S2 were compared with lanes from P2, pointing out different protein 
compositions of the two (asterisk).
3.3.2	 Isotope-coded	 affinity	 tag	 (ICAT)	 labeling	 and	multidimensional	 peptide	
separation
The ICAT method involved the following sequential steps (Fig. 3.5b): (1) The side chains of 
cysteinyl residues in a reduced protein sample representing one state, here wild-type, were 
derivatized with the isotopically light form of the cleavable ICAT reagent. The equivalent groups 
in a sample representing a second state, here transgenic, were derivatized with the isotopically 
heavy reagent (mass difference between light and heavy is 9 Da). (2) The two samples were 
combined and enzymatically cleaved by trypsin to generate peptide fragments, some of which 
are tagged with ICAT. (3) The complex peptide mixture was fractionated using strong cation 
exchange	(SCX)	chromatography	(Fig.	3.5c).	Highly	similar	elution	profiles	were	observed	for	all	
samples processed. The difference in the elution chromatogram of P40 synaptosomes might 
be due to the fact that originally less amount of protein was used as compared to the other 
approaches.	 (4)	 The	 tagged	 (cysteine-containing)	 peptides	 were	 isolated	 by	 avidin-affinity	
chromatography. (5) Finally, the isolated peptides were separated and analyzed by reversed-
phase microcapillary liquid chromatography electrospray ionization tandem mass spectrometry 
(RP-μLC-ESI-MS/MS). In this last step automated multistage MS determined both the quantity 
and sequence identity of the proteins from which the tagged peptides originated. This was 
achieved by measuring the signal intensities of peptides eluting from the RP-column in the MS 
mode to determine the relative quantities for pairs of peptide ions of identical sequence tagged 
with the isotopically light or heavy form. They differ in mass by the mass differential encoded by 
the ICAT reagent (9 Da).  Peptide sequence information was generated by selecting peptide 
ions of a particular mass-to-charge (m/z) ratio for CID in the mass spectrometer, operating in 
the MS/MS mode (Gygi et al., 1999a; Gygi et al., 1999c; Link et al., 1997). Using sophisticated 
computer search algorithms SEQUEST and Mascot search engines (Eng et al., 1994; Perkins et 
al., 1999), the resulting CID spectra were automatically correlated with sequence databases to 
identify the protein from which the peptide originated. Combination of the results generated by 
MS and MS/MS analyses of ICAT-labeled peptides therefore determined the relative quantities 
as well as the sequence identities of the components of the protein mixture.
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3.3.3 Quantitative proteome analysis of synaptosomes from P20 and P40 mice 
using the ICAT method
Synaptosomes from whole mouse brain of P20 and P40 wild-type and transgenic mice 
overexpressing neurotrypsin were isolated. Equal amounts of synaptosomal proteins (for P20 
M491S mouse line 0.65 mg protein for each wild-type and transgene, and for P40 M494 mouse 
line 1 mg protein for each was used) from wild-type (light) and transgene (heavy) were labeled 
with	cleavable	ICAT	and	prepared	for	the	analysis	by	RP-µLC-ESI-MS/MS.	In	total,	36	avidin-affinity	
purified	SCX	fractions	for	P20	and	46	fractions	for	P40	mice	were	measured	by	a	classical	ion	trap	
mass spectrometer, LCQ Deca XP. The mass spectrometer operated in a dual mode in which it 
alternated between one survey scan and three MS/MS scans. In the survey scan mode relative 
quantities of precursor ions were measured and in the MS/MS scans sequential information was 
collected. Typical base peak chromatogram of SCX fractions showed ICAT-labeled peptides 
eluting from the RP column by increasing concentration of acetonitrile. An expanded view of 
an ICAT pair was monitored from a survey scan at the retention time indicated with a red line 
(Fig. 3.6a and b). The monoisotopic peak of the light variant of the precursor ion with a m/z ratio 
of 1084.83 was more abundant than the monoisotopic peak of the heavy labeled peptide. Co-
elution and a detected mass difference of 4.5 U implied that the two ions represent a pair of 
doubly charged ICAT-labeled peptides of identical sequence (a mass difference of 9 Da with a 
charge state of two). By the reconstruction of the single ion chromatograms (SIC) for doubly and 
triply charged ions the relative quantities of the precursor ions were determined. The contour 
of the respective peaks was integrated using Automated Statistical Analysis of Protein Ratio 
(ASAPRatio) (Li et al., 2003). The ASAPRatio program computes the peptide ratio in two substeps: 
(1) Abundance ratios of the peptides with corresponding precursor masses in different charge 
states	(2+:	1.618;	3+:	1.63)	were	first	grouped	together	to	calculate	an	abundance	ratio	(1.627	±	
0.257) (Fig. 3.6c). (2) Abundance ratios of the peaks in different RP-chromatographic fractions 
(1.527	 ±	 0.258	 and	 3.503	 ±	 0.314)	were	 then	merged	 to	 calculate	 the	 unique	peptide	 ratio	
(1.537	±	0.142)	(Fig.	3.6d).	However,	the	main	function	of	the	ASAPRatio	program	is	to	evaluate	
an	abundance	ratio	for	each	protein	identification	in	an	LC-ESI-MS/MS	experiment.	If	a	single	
peptide	was	identified	for	a	protein,	the	corresponding	unique	peptide	ratio	and	its	associated	
error were passed on as the protein abundance ratio and its error. Frequently however, more 
than	one	unique	peptide	was	identified	for	the	same	protein.	In	this	case,	statistical	methods	for	
weighted samples were applied to calculate the protein abundance ratio and its associated 
standard deviation from all of its corresponding unique peptide ratios. Thus, the unique peptide 
ratios	 (3.003	 ±	 2.224	and	 1.537	 ±	 0.142)	were	weighted	by	 their	 errors.	 The	 result	 of	 this	 step	
was	a	protein	abundance	ratio	of	1.55	±	0.224	for	the	identified	protein,	of	which	two	different	
peptides	 have	been	 identified	and	quantified	 (Fig.	 3.6c).	 The	CID	 spectrum	derived	by	 the	
fragmentation of the precursor ion with m/z 1084.83 provides enough information to deduce 
the amino acids sequence of the peptide (Fig. 3.6e). Fragment ions in the spectrum represent 
mainly single-event cleavage of peptide bonds resulting in sequence information recorded 
from both the N and C termini simultaneously. The one-letter code for encountered amino acids 
is	LTDFGFCAGITPEQSKR.	Database	searching	with	this	spectrum	identified	a	peptide	allocated	
to p21-activated kinase (PAK1).
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Figure 3.5     Mass spectrometry with synaptosomes using isotope-coded affinity tagging (ICAT).
(A) A representative elution chromatogram of a strong cation exchange (SCX) fraction from P20 synaptosomes after avi-
din-affinity purification measured with 3D ion trap mass spectrometer LCQ Deca. The acetonitrile (ACN) gradient, eluting 
the peptides from the reversed-phase column is indicated in blue. The red line marks the retention time (RT) of the ICAT-
pair depicted in (B). (B) A zoom into a survey scan showing a pair of ICAT-labeled peptides of identical sequence with a 
monoisotopic mass-to-charge (m/z) ratio of 1084.83 for the light and for the heavy variant of 1089.38. The difference in m/z 
of 4.55 U reveals that doubly charged precursor ions are depicted here. The peak with m/z 1084.83 was captured in the ion 
trap for collision-induced dissociation (CID) resulting in a MS/MS spectrum. (C) A reconstructed single-ion chromatogram 
(SIC) computed with Automated Statistical Analysis of Protein Ratio (ASAPRatio) for the precursor ions measured in (B). 
The elution profiles in the upper panel are derived from doubly charged light and heavy labeled peptide. The areas used 
for calculating the abundance ratio of 1 : 1.618 are in green. The lower panel depicts the SIC from triply charged ICAT-pair 
with a calculated abundance ratio of 1.63. The ratios of the doubly and triply charged peptides are averaged and weighted 
by the corresponding spectrum intensities to obtain the peptide light:heavy ratio and its error of 1.627 ± 0.257. The red ar-
row points at the precursor ion selected for MS/MS, the red line is the raw signal, blue is the Savitzky-Golay smoothened 
signal, and the magenta line is the background noise subtracted from the spectrum. On the right are the start and end 
scan numbers, the background intensities, and the retention time of the light and heavy peptides, the acceptance, the 
abundance ratios, and the weight of the charge state. (D) Screen shot of accepted protein ratio (1.550 ± 0.224) calculated 
by ASAPRatio. Abundance ratios of peaks from the same peptide in different chromatographic fractions, e.g. 1.527 ± 
0.258 and 3.503 ± 0.314, were grouped to calculate the unique peptide ratio of 1.537 ± 0.142. The unique peptide ratios 
were weighted by their errors, resulting in the protein abundance ratio of 1.55 ± 0.224. (E) SEQUEST program searched 
the acquired CID spectra against the database. This tandem mass spectrum was assigned to the peptide with amino acid 
sequence LTDFGFCAGITPEQSKR. The highlighted ‘C’ indicates a fragment ion with an ICAT-modification attached to the 
cysteinyl residue. This peptide in turn is allocated to Ser/Thr-protein kinase PAK 1.
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3.3.3.1	 Data	filtering	with	Peptide-	and	ProteinProphet	(I)
PeptideProphet was used to assess the validity of peptide assignments (Keller et al., 2002). 
Sensitivity	 and	 error	 rates	 for	 peptide	 identifications	 in	 the	 experiments	 with	 P20	 and	 P40	
synaptosomes were computed with PeptideProphet. For both an error rate of 5% was chosen, 
from which a minimal probability threshold of 0.58 for P20 and 0.63 for P40 arose. From a 
total of 8500 peptides in P20 and 5018 in P40, 7687 (sensitivity of 90.4%) and 4021 (sensitivity 
of	83.7%)	correctly	estimated	peptides	passed	 the	filter	 (Fig.	3.7).	Proteins	were	filtered	using	
ProteinProphet, a statistical model for computing probabilities for a protein being present in 
a sample (Nesvizhskii et al., 2003). Only proteins with a probability ≥ 0.95 were allowed to pass 
the	filter.	Totally,	690	proteins	from	P20	animals	and	462	proteins	from	P40	animals	were	present.	
Sensitivities	and	error	rates	of	protein	identifications	as	a	function	of	minimum	protein	probability	
were	computed.	False	positive	identifications	in	both	P20	and	P40	were	estimated	at	2	proteins	
per sample (Fig. 3.7).
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Figure 3.6     PeptideProphet and ProteinProphet analysis for synaptosomes of P20 and P40 mice.
Sensitivity and error plots from PeptideProphet. In P20 mice an estimated number of 8500 peptides were correctly identified. 
With an error rate of 5% the number of correctly identified peptides is reduced to 7687 with a minimal probability threshold 
(MPT) of 0.58. In P40 mice merely 5018 correctly identified peptides were found in the whole dataset. Filtering with an error 
rate of 5% resulted in an estimated number of correctly identified peptides of 4201 with a MPT of 0.63. ProteinProphet pre-
dicted a total number of correct protein entries of 846 for P20 and of 585 for P40. An MPT of 0.95 was set. For P20 mice, 690 
proteins passed the filter with an error rate of 0.3%. 462 proteins with an error rate of 0.5% passed the filter in P40 mice.
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3.3.4	 Quantitative	proteomic	profiling	of	the	hippocampus	from	P10	mice	using	
ICAT
Hippocampi dissected from P10 wild-type and transgenic M494 mice were homogenized and 
centrifuged to produce soluble fraction S2 and pelletous fraction P2. For the labeling with the 
cleavable ICAT reagent 2 mg of proteins were used from wild-type and transgene S2 and 
P2.	 In	 total	33	SCX	 fractions	 for	S2	and	30	SCX	 fractions	 for	P2	were	collected,	avidin-affinity	
purified	and	subsequently	 loaded	on	a	C18	column	 for	 reversed-phase	microcapillary	 liquid	
chromatography (RP-μLC). An increasing concentration of acetonitrile eluted the peptides from 
the column. Electrospray ionization generated gas phase ions that were conveyed to linear ion 
trap	 (IT)	 –	 Fourier	 Transform	 Ion	Cyclotron	 Resonance	Mass	 Spectrometer.	Whilst	 performing	
this measurement in the ICR cell, fragment data can be performed in the IT simultaneously. 
Full	MS	scans	were	measured	over	the	entire	mass	range	(m/z	300	-	2,000).	In	the	first	step,	the	
IT	accumulated	ions.	A	defined	number	of	ions	was	then	transferred	to	the	ICR	cell,	where	the	
accurate mass determination took place and a full FT was performed to give a high resolution 
MS spectrum. Simultaneously, three MS/MS experiments were performed in the IT. The resulting 
fragments were measured with two detector plates in the IT (NOTE: not high accuracy). Typical 
base peak chromatograms of SCX fractions and an expanded view of a survey scan over the 
mass range of m/z 300 – 1100 showed ICAT-labeled peptides of identical sequence eluting from 
the RP column (Fig. 3.8a). Blown-up extracts of survey scans demonstrate the high resolution 
and mass accuracy of the LTQ FT-ICR mass analyzer (Fig 3.8b, c). The isotopic distribution of 
doubly and triply charged precursor ions was resolved and the m/z ratio of each isotope was 
determined with high accuracy, resulting in peak intervals of 0.5 units for doubly (Fig. 3.8b) and 
0.33 units for triply (Fig. 3.8c) charged ions. In addition, the survey scan (Fig. 3.8d (middle)), 
showing two doubly charged ICAT-pairs of different relative abundance (NOTE: the intensity of 
one pair is enhanced two-fold) point out the usefulness of atomole sensitivity and high resolution 
capacity of FT-ICR mass spectrometer for the analysis of complex peptide mixtures with MS. A 
mass spectrometer with less analytical power would not have resolved the two ICAT-pairs with the 
corresponding isotopic distribution and would probably not have selected the peak m/z 738.40 
for CID as it was done for this particular precursor ion. However, for the purpose of identifying 
the sequence of the tagged peptide, the peak marked with an asterisk was selected for CID. 
Database	searching	with	the	CID	spectrum	identified	the	amino	acid	sequence:	CIEEAIDKLSK,	
which in turn was unambiguously allocated to glutamine synthetase (Fig. 3.8d).
As	opposed	to	the	ICAT	experiment	with	synaptosomes,	the	XPRESS	quantification	tool	was	used	
to	compute	the	relative	quantification	of	abundance	ratios	for	proteins	from	the	hippocampus	
(Han et al., 2001) (Fig. 3.8e). Although the ASAPRatio software tool has several advantages 
over XPRESS, the XPRESS tool has one decisive advantage when analyzing complex peptide 
mixtures with a highly sensitive, accurate, and high-resolution mass spectrometer. That is, when 
the	light	and	heavy	elution	profiles	are	computed	with	XPRESS,	a	user	defined	value	for	the	mass	
tolerance	can	be	set.	Consequently,	by	setting	a	mass	tolerance	of	±	0.5	units,	simultaneously	
eluting precursor ions with highly similar m/z values  but of different amino acid composition can 
largely be discriminated. Thus, the signals from the ‘contaminating’ ions are excluded from the 
SIC. Only signals from the ICAT-pair of interest are taken into account for the computation of 
the abundance ratio. The ASAPRatio program on the other hand, would reconstruct a SIC by 
summing up all signals within the range of m/z values	covering	the	first	three	theoretical	isotopic	
peaks	of	an	ion.	For	a	doubly	charged	ion	this	would	correpsond	to	a	tolerance	of	±	1.5	m/z	
units.
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Figure 3.7     ICAT labeled hippocam-
pal S2 fraction analyzed by mass spec-
trometry using FT-ICR MS.
(A) A representative elution chromatogram 
of a strong cation exchange (SCX) frac-
tion after avidin-affinity purification with 
relative intensities of eluted precursor ions 
measured with LTQ Fourier Transform 
Ion Cyclotron Resonance (FT-ICR) mass 
spectrometer (above). The acetonitrile 
(ACN) gradient, eluting the peptides from 
the reversed-phase column is shown in 
blue. The red line refers to the retention 
time (RT) of the survey scan at RT: 51.27 
(below), showing multiple ICAT-pairs. (B) 
A zoom into a survey scan of a doubly 
charged ICAT-pair with identical intensities 
of monoisotopic mass-to-charge (m/z) ra-
tios. (C) A survey scan of a triply charged 
ICAT-pair coming off the reversed-phase 
column with identical monoisotopic peak 
intensities. For both B) and C), the isotopic 
distribution was resolved thanks to the 
high-resolution capacity of the FT-ICR. (D) 
An elution profile of a SCX fraction (above). 
The high-resolution survey scan at RT: 
50.13 shows two doubly charged ICAT-
pairs (middle). One pair is represented by 
monoisotopic m/z: 738.40 (light) and m/z: 
742.91 (heavy). The intensity is blown-up 
2x. The other pair comprises monoisotopic 
peaks 740.40 and 744.92. The precursor 
ion marked with an asterisk was selected 
for CID. The resulting spectrum (below) 
was correlated with sequence database 
using SEQUEST. The peptide assigned to 
the spectrum is: CIEEAIDKLSK, which in 
turn is unique to glutamine synthetase. (E) 
The peptide ratio of the reconstructed sin-
gle-ion chromatograms (SIC) for ICAT light 
and heavy labeled precursor ions meas-
ured in (D) was computed with XPRESS 
quantification tool. Generally, the mass 
tolerance was set to ± 0.5 units for doubly 
charged ions and for triply charged ± 0.33 
units were chosen. The light : heavy ratio 
is 1 : 1.55.
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3.3.4.1	 Data	filtering	with	Peptide-	and	ProteinProphet	(II)
Equally	as	with	the	ICAT	experiment	with	synaptosomes,	the	peptides	and	proteins	were	filtered	
automatically using Peptide- and ProteinProphet statistical analysis programs (Fig. 3.9). Peptides 
were	filtered	using	PeptideProphet	with	an	error	rate	of	5%.	In	S2	the	total	estimated	number	of	
correctly	identified	peptides	was	14076,	12336	of	which	passed	the	filter.	The	minimal	probability	
threshold (MPT) was computed at 0.58 with a sensitivity of 87.6%. The MPT for ProteinProphet was 
set	to	0.95,	resulting	in	the	identification	of	a	total	of	1376	correctly	and	6	incorrectly	assigned	
proteins.	Similarly,	the	6523	peptide	assignments	from	P2	were	filtered	with	an	error	rate	of	5%,	
ending	up	with	an	estimated	number	of	correctly	identified	peptides	of	6027	with	an	MPT	of	0.53	
and a sensitivity of 92.4%. Subsequently, the peptides were allocated to proteins, which were 
filtered	again,	applying	an	MPT	of	0.95	to	ProteinProphet,	resulting	in	the	correct	identification	
of	 883	 proteins	 with	 an	 error	 rate	 of	 0.4%.	 Sensitivities	 and	 false	 positive	 identification	 error	
rates	of	protein	identifications	as	a	function	of	minimum	computed	protein	probability	for	the	
experiments with S2 and P2 were listed (Fig. 3.9).
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Figure 3.8     PeptideProphet and ProteinProphet analysis for hippocampus S2 and P2.
Sensitivity and error plots from PeptideProphet. In S2 an estimated number of 14076 peptides were correctly assigned. 
Within an error rate of 5% the number of correctly identified peptides is reduced to 12336 peptide assignments with a mini-
mal probability threshold (MPT) of 0.58. In P2, totally 6523 correctly identified peptides were estimated. Filtering with an 
error rate of 5% resulted in an estimated number of correctly identified peptides of 6027 with a MPT of 0.53. ProteinProphet 
predicted a total number of correct protein entries of 1656 for S2 and 1046 for P2. When a MPT of 0.95 was set, 1382 
proteins passed the filter with an error rate of 0.4% for S2 and 883 proteins with an error rate of 0.4% in P2.
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3.3.4.2 Visual inspection and comparison of data sets obtained from repeated MS runs
Images obtained from high-throughput MS contain information that remains hidden when 
looking	at	a	 single	elution	profile	at	a	 time.	A	 software	 tool,	MSight,	was	applied	 for	 the	2D	
representation of liquid chromatography mass spectrometry (LC-MS) runs of hippocampus S2 
fractions (Palagi et al., 2005). Four consecutive early SCX fractions (fractions 3 – 6) and two 
later fractions (fraction 19/20) were analyzed by MSight side-by-side for quality control of the 
LC-MS performance (Fig 3.10a). The signals represent eluting precursor ions from the RP column 
detected in the ICR cell. Contaminating compounds were scarcely detected in the sample. 
On the x-axis the m/z ratio and on the y-axis the time (t) is displayed. Due to comparable 
patterning	 among	 the	 fractions	 the	 analysis	 of	 the	 reconstructed	 elution	 profiles	 indicated	
that the four early consecutive fractions (fr. 3 - 6) had highly similar peptide composition. In 
other words, peptides of identical sequence and thus with the same chemical composition 
were separated in multiple fractions during SCX and behaved similarly during HPLC using a 
RP column. Consistently, due to discriminative sample composition the 2D images of the two 
latter	fractions	(fr.	19,	20)	looked	completely	different	as	compared	to	the	profiles	of	fractions	
3 – 6, but are very similar themselves. A zoom into the four early SCX fractions showed paired 
signals	that	represent	co-eluting	ICAT-pairs.	With	increasing	fraction	number	the	pairs	appeared	
(red circles) and disappeared (blue circles) indicating that during SCX they were separated 
according to their ionic strength, and upon elution from the RP column the ICAT peptide of 
the same sequence behaved the same (Fig. 3.10b). Thus, peptides of identical amino acid 
composition were fractionated over multiple fractions, depending on their capacity to bind 
to the SCX column with increasing salt concentration. Furthermore, with increasing fraction 
number the 2D reconstruction showed an augmented overall ion intensity particularly among 
the early fractions pointing to the fact that more and more peptides eluted from the RP column. 
This	is	due	to	the	fact,	that	the	elution	profile	of	S2	peptides	during	SCX	HPLC	showed	increased	
signal intensities with increasing fraction number implying more peptides to be present in later 
fractions (compare mAU in fractions 3 – 6 of SCX in Fig. 3.5c).
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Figure 3.9     Visualization of liquid chromatography mass spectrometry using MSight.
(A) A comparison of 2D representations of datasets from six liquid chromatography mass spectrometry (LC-MS) runs of hip-
pocampus S2 fractions fracionated by strong cation exchange (SCX). MS-runs of four consecutive early (fr.03 - fr.06) and two 
consecutive late (fr.19, fr.20) SCX fractions are shown. Elution chromatograms have a high degree of overlap in fr.03 -06 and 
fr.19/20. Convincingly, the overlapping signals are virtually absent comparing e.g. fr.06 with fr.19. (B) A zoom into LC-MS runs 
of fr.03 - fr.06 shows signals that emerge (red circles) and signals that disappear (blue circles). The paired signals represent 
eluting ICAT-pairs and their isotopic distribution that were fractionated by SCX. X-axis: m/z, Y-axis retention time (t).
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3.3.4.3	 Computational	analysis	of	peptide	identifications
To	assess	whether	our	approach	resulted	in	reliable	and	accurate	identifications	the	data	of	S2	
were further analyzed. Delta mass analysis showed a similar distribution for both the observed 
masses (m/z) and the calculated masses (Da) of the precursor ions. Generally, the delta masses 
were below 0.04 Da, which corresponds approximately to the mass accuracy of the FT-ICR. There 
was	a	significant	correlation	between	the	observed	or	calculated	masses	and	the	delta	masses.	
With	increasing	observed	m/z	value	of	the	precursor	ion	a	larger	deflection	to	the	calculated	
mass (delta mass) can be expected (Fig. 3.11a). And with increasing calculated masses the 
delta masses also increased linearly (Fig. 3.11b), indicting that with the FT-ICR MS the highest 
mass accuracy can be achieved for ions between m/z 400 – 1200, and for peptides between 
1000 – 2500 Da. In nearly 98% of all peptides no missed cleavage site from the trypsin digestion 
was found (Fig. 3.11c), and only 2.5% of the precursor ions were singly charged (Fig. 3.11d). 
The majority of the ions were doubly charged (74.5%) or triply charged (23%). The frequency 
of average peptide length showed two Gaussian distribution with one maximum at 13 and the 
other at 16 amino acids. Surprisingly, there was a third maximum at 23 amino acids (Fig. 3.11e). 
Finally, the percentage of amino acid frequency was determined (Fig. 3.11f). In nature, the 
correlation	between	observed	and	expected	frequencies	of	amino	acids	is	highly	significant	(r	
= 0.89) excluding the outlier arginine. Only the frequency of arginine seems to be a product of 
natural selection acting on one or more of the arginine codons. Instead of particular amino acids 
being optimal at a certain position in any given protein, the most important thing determining 
the frequency of an amino acid is simply the number of codons coding for it. Therefore, S, L, 
G,	A,	K,	V,	T,	D,	and	E	are	the	most	frequent	amino	acids,	which	was	nicely	reflected	by	the	
histogram.	Also	the	low	abundant	amino	acids	in	vertebrates,	H,	M,	W,	and	Y,	were	rare	in	our	
approach. Although in nature, with an observed frequency of 3.3%, cysteine is a relatively rare 
amino acid, in the ICAT approach it was among the most abundant amino acids (7.3%). This is in 
nice	agreement	with	the	expectation	that	every	peptide	identification	should	bear	at	least	one	
cysteine.	In	summary,	the	computational	analysis	of	the	peptide	identifications	from	S2	revealed	
that the data obtained were in excellent agreement with what was being expected. 
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3.3.5	 Categorization	of	total	protein	identifications	from	synaptosomes	and	the	
hippocampus
As	mentioned	earlier	hundreds	and	thousands	of	proteins	were	identified	from	synaptosomes	
and the hippocampus proteome. To get a general idea of what kind of molecules have really 
been analyzed the complete data sets of P20 synaptosomes and the hippocampus fractions S2 
and P2 were subjected to the Gene Ontology (GO) tool GoMiner (Zeeberg et al., 2003). GoMiner 
is a program package that organizes lists of interesting genes and proteins derived from high-
throughput microarray or proteomic experiments for biological interpretation in the context 
of	GO	terms.	In	this	report,	GoMiner	was	used	to	classify	protein	identifications	into	‘molecular	
functions’	and	‘cellular	compartments’	(NOTE:	one	protein	can	be	classified	into	multiple	GO	
terms,	and	not	every	protein	was	classified	due	to	lacking	information).	690	proteins	from	P20	
Figure 3.10     MS-data analysis of peptide identifications in S2.
(A) Distribution of observed peptide masses mass-over-charge (m/z) ratio and calculated peptide masses (Da) (B) versus 
delta mass (Da) measured by the mass spectrometer. (C) Histogram of percentage of all peptides with missed trypsin 
cleavage sites and with singly, doubly, or triply charged state (D). (E) Histogram of the frequency of peptide length and 
amino acid (AA) appearance in the dataset (F).
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mice, 1382 from S2 and 883 proteins from P2 were annotated (Fig. 3.12). The synaptosomal 
proteins were most prominent in ‘membrane’ 33%, ‘mitochondria’ 29%, and ‘protein complex’ 
26%.	Other	highly	abundant	proteins	were	 those	classified	 to	 ‘ECM’	19%	and	 ‘cytoskeleton’	
19%, whereas ‘cytosol’ 10%, ‘ribosome’ 3%, ‘Golgi’ 6% and ‘ER’ 7% proteins were rather seldom. 
Furthermore, proteins involved in ‘transporter activity’ constituted 12% of the synaptosomal 
proteins, ‘structural molecules’ and ‘signal transduction’ proteins constituted 5% each. Together, 
these three categories represent by far the most important molecular functions in synaptosomes. 
On the other hand, proteins from ‘transcription regulator’ 0%, ‘translation regulator’ 1%, ‘enzyme 
regulator’ 2% and ‘motor activity’ 2% are poorly represented in synaptosomes. A high percentage 
of membrane bound and membrane associated proteins and protein complexes involved in 
signal transduction and transporter activities are well expected. Moreover, mitochondrial as 
well as cytoskeletal and other structural constituents such as scaffolding proteins from the 
postsynaptic density, are important elements of the synapse, while proteins from the protein 
synthesis machinery, ER and Golgi are less abundant. Altogether this describes very well the 
composition and function of synaptosomes. Interestingly, a similar distribution was found for 
P2.	45%	of	all	annotated	proteins	were	classified	 to	 ‘membrane’.	Still	36%	were	allocated	 to	
‘mitochondria’. Prominent terms for P2 also were ‘ECM’ 19%, ‘cytoskeleton’ 18%, and ‘protein 
complex’ 21%. Components of the ‘cytosol’ 8%, ‘ribosome’ 11%, ‘Golgi’ 9%, and ‘ER’ 9% were 
sparsely	identified	in	P2.	In	contrast	to	the	synaptosomes,	the	‘nucleus’	16%	was	more	represented.	
Comparing the isolation protocol for synaptosomes and P2, contaminating nuclei, which were 
not	pelleted	during	the	first	centrifugation	step	ended	up	in	P2	and	not	in	synaptosomes.	Unlike	
the synaptosomes,	P2 emerges from S1’ and was not further treated and directly analyzed by 
mass spectrometry. In the isolation protocol for synaptosomes more nuclei were lost when S1’ 
was further centrifuged to get P2’, which was subjected to density-gradient centrifugation where 
finally	most	of	the	remaining	nuclei	were	lost.	Regarding	the	‘molecular	functions’,	synaptosomes	
and P2 also had a lot in common: proteins of the same categories were enriched in P2, such 
as	‘transporter	activity’	16%,	‘structural	constituent’	11%,	and	‘signal	transduction’	9%.	Whereas	
‘transcriptional’ 1% and ‘translational regulator’ 2% as well as ‘enzyme regulator’ 2% and ‘motor 
activity’	3%	were	categories	with	only	a	few	identifications.	Striking	differences	were	found	in	S2.	
For instance with 24%, the category ‘membrane’ contained the fewest proteins in S2 among 
all subcellular fractions analyzed. There was nevertheless a considerable amount of membrane 
protein because light vesicular membrane structures and membrane-associated proteins were 
annotated to this category as well. ‘ECM’ with 13% and ‘mitochondrion’ with 20% however, 
were underrepresented in S2 as compared to P2 and synaptosomes, whereas molecules from 
the ‘cytosol’ 17% were enriched. Surprisingly, ‘nucleus’ with 33% contained the most proteins 
in S2. However, a lot of nuclear proteins are known to translocate between the nucleus and 
the	cytoplasm	and	consequently	an	accumulation	thereof	is	plausible.	Altogether,	the	findings	
speak in favor of the fact that S2 is mainly composed of soluble cytosolic proteins. Consistently, 
‘transporter activity’ 7% and ‘signal transduction’ 5% were markedly reduced in S2 as compared 
to P2 and synaptosomes. ‘Structural constituents’ were, with 7% quite abundant and proteins 
from ‘transcription regulator’ 2%, ‘translation regulator’ 3% and ‘enzyme regulator’ 5% were 
more frequent in S2 than in synaptosomes and P2. In all fractions, 1 – 2 % of the proteins were 
classified	as	 ‘unknown’.	 In	 summary,	 the	distribution	of	proteins	 into	 ‘cellular	compartments’	
and ‘molecular function’ revealed that synaptosomes and P2 were highly similar, consisting of 
a lot of molecules that are involved in signal transduction and vesicular transport associated to 
membranes whereas S2 had a different composition, mainly being constituents of intracellular 
proteins complexes.
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3.4 Differentially regulated proteins in synaptosomes and the 
hippocampus
MS/MS peak lists from the raw data of S2 and P2 were converted both to Mascot generic 
format	(MGF)	for	data	files	submitted	to	Mascot	and	to	mzXML	files	for	SEQUEST	searches.	The	
MS/MS data from the synaptosomes were database searched with SEQUEST only. All SEQUEST 
search	results	were	filtered	with	Peptide-	and	ProteinProphet	and	quantified	using	ASAPRatio	
and XPRESS software, respectively. Proteins were considered as differentially regulated when 
their abundance ratio exceeded 20% up- or down regulation in transgenic neurotrypsin-
overexpressing mice. Using the ICAT technology 66 proteins from P20 and 81 proteins from P40 
synaptosomes were differentially expressed. In the hippocampus 106 proteins from S2 and 67 
proteins in P2 were changed.
3.4.1 Neurotrypsin-dependent changes of protein abundance in synaptosomes 
and the hippocampus proteome
The molecular entities may be perturbed and cellular pathways activated or inhibited due to 
the neurotrypsin overexpression. In the following sections, selected proteins are presented in the 
context of their functional categorization (Tables 1 – 7).
Figure 3.11  Protein identifications from synaptosomes and the hippocampus are annotated to Gene Ontology 
(GO) terms ‘cellular compartment’ and ‘molecular function’.
(A) Protein datasets from synaptosomes of P20 (orange) and pelletous fraction P2 (green) as well as soluble fraction S2 
(blue) from the hippocampus were categorized into GO terms. For all three datasets the distribution of correct protein iden-
tifications into ‘cellular compartments’ and ‘molecular functions’ are shown in % of the total, e.g. the ‘membrane fraction’ 
represents 34% in synaptosomes, 45% in P2, and only 24% in S2, whereas the ‘cytosol’ is most prominent in S2 (17%). 
The ‘mitochondria’ are highly enriched in synaptosomes and P2. Proteins localized to the nucleus are frequently found in 
S2. (B) For the ‘molecular function’, molecules involved in ‘transporter activity’ are enriched in synaptosomes (12%) and to 
a higher extent in P2 (16%). The ‘structural constituents’ are mainly present in P2 (11%) and S2 (7%), and ‘signal transduc-
tion’ molecules are most abundant in P2 (9%). ‘Translational regulators’ (3%) and ‘enzyme regulators’ (2%) are rare but still 
enriched in S2. Note that one single protein can be annotated to multiple terms.
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SS P20 SS P40
Accession 
Numbera Protein
Mw 
(kDa)b
protein ra-
tio ± s.d.c
No.d protein ra-
tio ± s.d.c
No.d
Cytoskeleton, cell adhesion
P60766 Cdc 42 21.3 1.13 ± 0.18 5 1.59 ± 0.24 2
Q99PT1 Rho GDI alpha 23.4 0.57 ± 0.08 1
O88643 p21-activated kinase (PAK 1) 60.7 1.55 ± 0.22 2
O89053 Coronin-1A 51.0 1.48 ± 0.25 6 1.54 ± 0.25 1
P12960 Contactin 1 113.4 1.55 ± 0.16 5
Synaptic transmission, neurotransmitter uptake, neuroendocrine
Q9Z2W9 Glutamate receptor 3 100.4 1.77 ± 0.19 4
P62835 Rap-1A 66.3 1.88 ± 0.17 10
P43006 EAAT2/GLT1 62.0 1.51 ± 0.36 3
P15105 Glutamine synthetase 42.0 0.73 ± 0.04 37
P63318 PKC-ε 83.6 0.60 ± 0.06 2
Q9Z140 Copine VI (neuronal) 61.8 1.85 ± 0.45 3
P60202 Myelin proteolipid protein 30.1 1.55 ± 0.13 3 1.29 ± 0.12 3
P16014 Chromogranin B 78.0 1.32 ± 0.38 1 1.83 ± 0.18 1
Transport, exocytosis, endocytosis
P28738 Kinesin heavy chain, neuron specific 109.2 1.64 ± 0.58 2 1.74 ± 0.30 1
P62823 Rab3C 25.8 1.05 ± 0.10 2 1.99 ± 0.55 2
O08539 Amphiphysin 2 64.5 1.38 ± 0.33 3 1.52 ± 0.27 4
P17426 Adaptor protein complex AP-2, α1 107.7 1.61 ±0.15 10
Cell proliferation/differentiation
P63085 MAPK 1 41.3 1.37 ± 0.29 1 1.66 ± 0.30 1
Glucose metabolism, tricarboxylic acid cycle, fatty acid metabolism 
P17710 Hexokinase-1 108.3 1.80 ± 0.30 2
Q9JK42 Pyruvate deyhdrogenase kinase isoform 2 46.1 0.54 ± 0.06 2
Q9D6R2 Isocitrate deyhdrogenase [NAD] subunit α 39.6 1.65 ± 0.16 5
P14152 Malate dehydrogenase, cyt. 36.3 1.03 ± 0.07 3 1.55 ± 0.13 5
P06151 L-lactate dehydrogenase A chain 36.5 1.02 ± 0.14 4 1.54 ± 0.52 3
Q05816 Fatty acid-binding protein, epidermal 15.0 1.59 ± 0.55 4 1.19 ± 0.11 3
Varia
P55264 Adenosine kinase 40.1 0.47 ± 0.04 1 0.10 ± 0.02 1
P35762 CD81 25.8 2.58 ± 0.41 1 2.27 ± 0.33 1
P13861 cAMP-dependent protein kinase type II-α 45.5 1.50 ± 0.22 2 1.22 ± 0.47 2
Q9Z268 RasGAP-activating-like protein 1 89.4 0.56 ±0.08 2
Q60864 Stress-induced-phosphoprotein 1 62.9 1.55 ± 0.12 3 1.67 ± 0.41 2
Table 1        Regulated proteins in synaptosomes
aPrimary UniProt accession number. bMolecular mass. cAverage abundance ratio (wt = 1) followed by the standard deviation com-
puted with ASAP Ratio algorithm. dNumber of different cystein-containing peptides.
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Accession 
Numbera Protein
Mw 
(kDa)b
protein ratioc
No.d
Synaptic vesicle, endocytosis
P39053 Dynamin 1 97.8 S2: 0.75 S2: 3
Q9WVE8 PACSIN 2 55.8 S2: 0.77 S2: 2
O70439 Syntaxin 7 29.7 P2: 1.23 P2: 1
Synaptic vesicle, exocytosis
P62823 Rab3C 25.9 S2: 1.20 S2: 1
Q80UJ7 Rab3-GAP 130.0 S2: 0.82 S2: 4
Synaptic vesicle, vesicular trafficking
Q9D0M5 Dynein light chain 10.4 S2: 0.76 S2: 3
P28740 Kinesin-like protein KIF2A 81.0 S2: 1.25 S2: 4
Q8BGN8 Synaptoporin 29.2 S2: 0.72 S2: 2
Neurotransmission, synaptic plasticity
P54920 α-SNAP 33.2 S2: 0.70 S2: 1
P28663 ß-SNAP 33.2 S2: 0.63 S2: 5
P46460 Vesicle-fusing protein NSF 82.6 S2: 0.60P2: 1.17
S2: 5
P2: 8
O08599 Syntaxin-binding protein 1 (Munc18-1) 67.6 S2: 0.84 P2:1.13
S2: 3
P2: 3
P63040 Complexin 1 15.0 S2: 0.71 S2: 1
Q9Z2Q6 Septin 5 42.8 S2: 0.67 S2: 2
P11798 CaMK II α 54.3 S2: 0.85P2: 0.70
S2: 3
P2: 3
Q9Y2H0 Disks large-associated protein 4 (SAPAP4) 80.5 P2: 1.29 P2: 2
P70175 Disks large homolog 3 (SAP102) 93.5 S2: 1.33 S2: 1
Q9Z140 N-copine 61.8 S2: 0.71P2: 0.83
S2: 5
P2: 6
Neuroendocrine, synapse remodelling 
P16014 Chromogranin B 78.0 S2: 0.70 S2: 1
Q62443 Neuronal pentraxin 1 47.1 S2: 0.71 S2: 2
P43006 EAAT2/GLT1 62.0 P2: 0.75 P2: 2
Table 2            Regulated proteins in the hippocampus involved in vesicular trafficking, neuro-
transmitter release, and synaptic plasticity
aPrimary UniProt accession number. bMolecular mass. cAverage abundance ratio (wt =1) computed with XPRESS software. dNum-
ber of different cystein-containing peptides.
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Accession 
Numbera Protein
Mw 
(kDa)b
protein ratioc
No.d
Cell adhesion
P11627 Neural cell adhesion molecule L1 141.0 S2: 0.79P2: 1.30
S2: 6
P2: 8
Q810U4 NrCAM 138.5 S2: 0.78 S2: 5
Q60625 ICAM-5 86.9 S2: 0.67 S2: 4
Q99N28 Nectin-like protein 1 42.9 S2: 0.73 S2: 1
Q3TYL3 Opoid-binding cell adhesion molecule (OBCAM) 37.2 S2: 0.56 S2: 3
P12960 Contactin 1  113.3 S2: 0.66 S2: 2
Neuron migration and differentiation of the nervous system
Q61361 Brevican 96.0 S2: 0.75 S2: 3
O88809 Doublecortin 40.6 S2: 1.27 S2: 2
O08919 Numb-like protein 64.2 S2: 0.82P2: 1.32
S2: 2
P2: 1
Q80YX1 Tenascin-C 231.8 S2: 0.75P2: 1.53
S2: 19
P2: 7
Cell proliferation
P34884 Macrophage migration inhibitory factor 12.4 S2: 1.25P2: 1.42
S2: 2
P2: 2
Q9DCT8 Cysteine-rich protein 2 22.7 S2: 1.30P2: 1.55
S2: 2
P2: 2
P63085 MAPK 1 41.1 P2: 1.39S2: 1.20
P2: 1
S2: 3
P20444 PKC-α 76.7 P2: 0.64 P2: 3
P46527 Cyclin-dependent kinase inhibitor 1B 22.2 S2: 0.56 S2: 1
Table 3             Regulated proteins in the hippocampus involved in cell adhesion, cell migration
 and cell proliferation 
aPrimary UniProt accession number. bMolecular mass. cAverage abundance ratio (wt =1) computed with XPRESS software. dNum-
ber of different cystein-containing peptides.
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Accession 
Numbera Protein
Mw 
(kDa)b
protein ratioc
No.d
Microtubule cytoskeleton
P14873 Microtubule-associated protein 1B (MAP 1B) 270.4 P2: 1.29 P2: 8
O88643 p21-activated kinase (PAK 1) 60.7 S2: 1.27 S2: 1
Q8R5C5 Actin-related protein 1B 42.3 P2: 1.30 P2: 1
Q9ERD7 Tubulin ß-3 50.4 P2: 1.35 P2: 3
Q9D6F9 Tubulin ß-4 49.6 P2: 1.40 P2: 6
Actin cytoskeleton
Q9QXS6 Drebrin 77.2 S2: 1.04P2: 1.46
S2: 9
P2: 6
P63001 Rac1 21.5 S2: 0.92P2: 1.20
S2: 5
P2: 4
P60766 Cdc42 21.3 S2: 1.38 S2: 2
Q99JY9 Actin-like protein 3 47.2 P2: 1.27 P2: 3
P47754 F-actin caping protein α-2 32.8 S2: 0.83 S2: 3
Q61792 LIM and SH3 domain protein 1 30.0 S2: 1.33P2: 2.95
S2: 2
P2: 2
Q9CVB6 Actin-related protein 2/3 complex, subunit 2 34.4 S2: 1.31 S2: 1
Q8R5H6 WASP-family protein member 1 61.5 P2: 2.20 P2: 1
O89053 Coronin-1A 50.9 P2: 1.26 P2: 1
Type III intermediate filament
P20152 Vimentin 53.6 P2: 0.82 P2: 1
Table 4             Regulated proteins in the hippocampus involved in cytoskeletal rearrangements
aPrimary UniProt accession number. bMolecular mass. cAverage abundance ratio (wt =1) computed with XPRESS software. dNum-
ber of different cystein-containing peptides.
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Accession 
Numbera Protein
Mw 
(kDa)b
protein 
ratioc No.
d
Glycolysis
P17710 Hexokinase 1 102.4 S2: 0.73 S2: 5
P17182 α-enolase 47.0 S2: 1.25P2: 1.26
S2: 7
P2: 4
P17183 γ-enolase 47.2 S2: 1.56P2: 1.32
S2: 2
P2: 1
Pyruvate dehydrogenase complex
Q8BKZ9 Pyruvate dehydrogenase protein X component, mitochondrial 54.0 S2: 0.73 S2: 1
P35486 Pyruvate dehydrogenase E1 component α-subunit,mitochondrial 43.2
S2: 0.80
P2: 1.23
S2: 4
P2: 5
Q9D051 Pyruvate dehydrogenase E1 component ß-subunit,mitochondrial 38.9 P2: 1.38 P2: 1
Tricarboxylic acid cycle
Q9CZU6 Citrate synthase, mitochondrial 51.7 P2: 1.26 P2: 4
Q99KI0 Aconitate hydratase, mitochondrial 85.5 S2: 0.90P2: 1.21
S2: 4
P2: 3
O88844 Isocitrate dehydrogenase [NADP] cytoplasmic 46.7 P2: 1.34 P2: 2
P54071 Isocitrate dehydrogenase [NADP], mitochondrial 58.8 S2: 1.24P2: 1.26
S2: 4
P2: 2
Glucose metabolism
Q8CAA7 Phosphoglucomutase-2-like 1 70.3 P2: 1.43 P2: 1
Q05816 Fatty acid-binding protein, epidermal 15.0 S2: 0.77 S2: 3
P47856 Glucosamine-fructose-6-phosphate aminotransferase 1 78.7 S2: 0.77 S2: 2
Lipid metabolism
O35678 Monoglyceride lipase 37.5 S2: 0.69 S2: 1
P02772 Alpha-fetoprotein 67.3 S2: 1.52 S2: 3
Q61425 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 34.5 P2: 1.31 P2: 1
Q61207 Prosaposin 58.1 S2: 1.44P2: 1.30
S2: 6
P2: 6
Q9R0Q7 Prostaglandin E synthase 3 18.7 S2: 1.20P2: 1.33
S2: 3
P2: 3
Table 5 Proteins regulated in the hippocampus involved in glycose metabolism and tri-
 carboxylic acid cycle, and lipid metabolism
aPrimary UniProt accession number. bMolecular mass. cAverage abundance ratio (wt =1) computed with XPRESS software. dNum-
ber of different cystein-containing peptides.
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Accession 
Numbera Protein
Mw 
(kDa)b
protein ratioc
No.d
Glutamate turnover, detoxification of ammonia
P26443 Glutamate dehydrogenase 1, mitochondrial 61.2 S2: 0.66P2: 1.37
S2: 2
P2: 4
P15105 Glutamine synthetase 42.0 S2: 1.40P2: 0.85
S2: 6
P2: 4
Apotposis
P21796 VDAC 1 30.8 P2: 0.70 P2: 2
Sodium/potassium transport
Q6PIC6 α3 Na+/K+-ATPase 111.7 S2: 0.73P2: 0.83
S2: 8
P2: 12
P14094 β1 Na+/K+-ATPase 35.2 S2: 0.71 S2: 2
P14231 β2 Na+/K+-ATPase 33.3 S2: 0.60 S2: 1
Ubl conjugation pathway, protein folding, transcriptional regulator, splicing
activity
Q7TPH6 Myc-binding protein 2 51.8 S2: 0.78P2: 1.66
S2: 2
P2: 1
P63038 Heat shock protein 60 61.0 P2: 1.40 P2: 5
Q6ZQ38 Cullin-associated NEDD8-dissociated protein 1 136.3 S2: 1.25 S2: 3
Q6PDM2 Splicing factor arginine/serine rich 1 27.6 S2: 0.58P2: 2.32
S2: 3
P2: 1
Protease inhibitor
O08677 Kiniogen-1 73.1 S2: 1.48 S2: 2
Table 6             Proteins regulated in the hippocampus involved in various molecular functions
aPrimary UniProt accession number. bMolecular mass. cAverage abundance ratio (wt =1) computed with XPRESS software. dNum-
ber of different cystein-containing peptides.
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S2 P2
Accession 
Numbera Protein
Mw 
(kDa)b
protein
ratio
protein
ratio 
Vesicular trafficking
P50396 Rab GDI 1 51.1 0.58 0
Q9DBG3 AP-2 complex subunit β-1 105.4 0.49
Q01853 Translational ER ATPase 90.0 0.53
Q6P8X1 Sorting nexin 6 46.9 0.15
Q9Z140 N-copine 62.6 1.58
Neurite extension, cell proliferation
Q76MZ3 PP2A, subunit A, 65 kDa regulatory subunit 65.3 0.59
P58389 PP2A, regulatory subunit B’ 37.0 1.62
O08553 Dihydropyrimidinase-related protein 2 (DRP 2) 62.5 0.63 1.56
Q62188 Dihydropyrimidinase-related protein 3 (DRP 3) 62.3 0.56 1.59
P53810 Phsophatidylinositol transfer protein-α 31.9 0.66
Q9R0P9 Ubiquitin cyrboxyl-terminal hydrolase isoenzyme L1 24.8 0.56
O54983 Mu-crystallin homolog 33.5 0.61 0.59
Cytoskeleon
Q61166 Microtubule-associated protein RP/EB familiy member 1 30.0 1.75 0.56
P03995 GFAP 49.9 0.64
P20153 Vimentin 53.6 0.42
Glucose metabolism, glycolsis, cell cycle
Q9DBJ1 Phosphoglycerate mutase 1 28.8 0.20
P17182 α-enolase 47.3 0.58
Q8CAA7 Phosphoglucomutase 2-like 1 70.3 1.50
P34022 Ran-specific GAP 23.6 0.48
Q921Q5 Rap1 GDI 1 66.4 1.70
Varia
P55264 Adenosine kinase 40.5 1.60
Q3TCW4 Neurochondrin 79.0 2.23
Table 7        Proteins regulated in the hippocampus revealed by 2D gel electrophoresis
aPrimary UniProt accession number. bMolecular mass. cAverage abundance ratio (wt=1).
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3.4.2	 Quantitative	proteomic	profiling	using	2D	gel	electrophoresis
Despite	an	increase	in	overall	protein	identifications,	the	four	data	sets	obtained	from	the	ICAT	
analysis	 showed	a	 very	 substantial	 overlap,	 indicating	 that	 increasing	 sample	diversification	
alone	will	 not	 be	 sufficient	 to	 overcome	 the	 inherent	 redundancy	 of	 a	 shotgun	 approach.	
Therefore,	a	different	strategy	was	needed	that	is	capable	of	adding	new	protein	identifications,	
especially those which are differentially regulated. To target another set of proteins in the 
CNS of neurotrypsin-overexpressing mice and thereby assess their expression levels a 2D gel 
electrophoresis proteomics approach in combination with mass spectrometry (2DE-MS) was 
chosen. Protein extraction from wild-type and transgenic hippocampus S2 and P2 was followed 
by	 2DE.	 Spots	 on	 the	 gels	 were	 analyzed	 with	 ProteomWeaver	 a	 platform	 for	 quantitative	
analysis of 2D gels. For both fractions, 2D gels of three wild-type and three transgenic 
samples were matched and spot intensities were measured. In each case, two protein-spots 
were compared pairwise on a matrix of 3 x 3 gels and average abundance changes were 
calculated. In total 626 spots were detected from S2, among which 33 were up regulated 
and 56 spots were down regulated in transgenic samples. As for P2 in total 343 spots were 
distinguished. 8 of them were up- and 11 were down regulated (Fig. 3.13). Spots of different 
average	intensities	were	excised,	in-gel	digested	and	protein	identifications	were	determined	
by	matrix-assisted	laser	desorption/ionization	tandem	time	of	flight	(MALDI-TOF/TOF)	(Fig.	3.14).	
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Figure 3.12     Experimental set-up for 2D gel electrophoresis (2DE) to compare differential protein expression in 
the hippocampus.
(A) Three gels from wild-type (wt) and transgenic (tg) hippocampus P2, and (B) three gels from wt and tg hippocampus S2 
were prepared and analyzed. For each sample 18 x 24 cm, 10% polyacrylamide 2D gels with linear pH-gradients of 4 - 7 
were generated and spot intensities were measured using Proteomweaver. 2D gels were analyzed by pairwise comparison 
of average spot intensities from wt and tg samples.
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3.4.3 Regulatory changes of molecular functions
3.4.3.1 Cytoskeleton reorganization, cell proliferation/differentiation
Cdc42 belongs to the Rho family of Ras like GTPases and was up regulated in the hippocampus 
S2 and in synaptosomes of young and adult transgenic mice (Table 1 and 4). Interestingly, 
Rho dissociation inhibitor (GDI) alpha, an inhibitor of Rho family GTPases, was down regulated 
in synaptosomes. Cdc42 is an important regulator of the actin cytoskeleton. For instance, 
activated	Cdc42	can	interact	with	Wiskott-Aldrich	syndrome	protein	(WASP)	that	itself	activates	
Arp2/3, which is a nucleation protein complex for F-actin polymers (Yamaguchi et al., 2005). 
Furthermore,	WASP-family	protein	WAVE	plays	a	critical	 role	downstream	of	Rac	 in	regulating	
the	actin	cytoskeleton	required	for	membrane	ruffling	(Miki	et	al.,	1998).	Both	WASP1	and	Rac1	
expression were induced in transgenic P2 (Table 4). Together with PKCε (down regulated in 
P40 synaptosomes) and δ, Cdc42 induces neurite outgrowth (Troller and Larsson, 2006). 
Cdc42 is also involved in axon guidance via PAK1 (Robles et al., 2005) (up regulated in P20 
Figure 3.13     Upregulated spots in the hippocampus of neurotrypsin overexpressing mice.
(A) A zoom into 2D gels from wild-type (wt) and transgenic (tg) mice of soluble fraction S2. Arrowheads point to 4 spots 
with higher intensities in tg as compared to wt. (B) A magnification of two color-coded spots from (A) showing higher 
intensities in the tg samples. The protein identities were revealed by excision and in-gel trypsin digestion of the spots, 
followed by Matrix-Assisted Laser Desorption/Ionization -Time Of Flight (MALDI-TOF) tandem mass spectrometry. Neu-
rochondrin was upregulated in tg by 2.23x and Rap1, GTP-GDP dissociation stimulator 1 (Rap1 GDI 1) was increased 
in tg by a factor of 1.70.
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synaptosomes and S2 (Tables 1 and 4)). PAK proteins are critical effectors that link RhoGTPase 
to cytoskeleton reorganization and regulate a number of processes such as cell proliferation 
and motility. Recently it was found that PAK 1 has three nuclear localization signals (NLS) that 
associate with chromatin and thus modulates transcription (Singh et al., 2005). Furthermore, 
adhesion stimulates direct association of PAK1 with Mitogen-activated protein kinase 1 (MAPK1) 
and leads to MAPK-dependent PAK1 Thr212 phosphorylation (Sundberg-Smith et al., 2005). MAP 
kinases, also known as extracellular signal-regulated kinases (ERKs), act as integration points 
for multiple biochemical signals, and are involved in a wide variety of cellular processes such 
as proliferation, differentiation, transcription regulation and development. The activation of 
this kinase requires its phosphorylation by upstream kinases. Upon activation, it translocates to 
the nucleus of stimulated cells, where it phosphorylates nuclear targets, which in turn initiate 
transcription. MAPK1 was more abundant in transgenic mice overexpressing neurotrypsin in 
both synaptosomes and the hippocampus (Tables 1 and 3).	Drebrin is a cytoplasmic actin-
binding protein thought to play a role in the process of neuronal outgrowth. A decrease in 
drebrin expression in the brain has been implicated as a possible contributing factor in the 
pathogenesis of AD. Drebrin was up regulated in transgenic hippocampus P2 (Table 4).
3.4.3.2 Cell adhesion
Contactin 1 is a member of the immunoglobulin superfamily. It is a GPI-anchored neuronal 
membrane protein that functions as a heterophilic cell adhesion molecule, binding to NrCAM 
and neurofascin. It may play a role in the formation of axon connections in the developing 
nervous system. Contactin 1 expression was induced in adult transgenic animals by 1.55 but was 
reduced in S2 by a factor of 0.66 (Tables 1 and 3).
Neural cell adhesion molecule L1 is an axonal glycoprotein that belongs to the immunoglobulin 
supergene family. The ectodomain consists of several immunoglobulin-like domains and 
fibronectin-like	 repeats.	 It	 is	 linked	 via	 a	 single	 transmembrane	 sequence	 to	 a	 cytoplasmic	
domain. L1 plays an important role in nervous system development, including neuronal 
migration and differentiation. Mice that do not express L1 have defects in axon guidance of 
the corticospinal tract (Cohen et al., 1998). L1 expression was decreased in S2 but induced in 
P2 in P10 mice (Table 3).
Neuronal cell adhesion molecule (NrCAM) contains multiple immunoglobulin-like C2-type 
domains	and	fibronectin	type-III	domains.	It	is	involved	in	neuron-neuron	adhesion	and	promotes	
directional signaling during axonal outgrowth. Allelic variants of the gene have been associated 
with autism and addiction. Complex homo- and heterophilic binding and several extracellular 
ligands of NrCAM have been described, but less is known about intracellular interaction partners. 
Binding partner to the cytoplasmic terminus of NrCAM is ankyrin G and SAP102 (see later in the 
text) (Davey et al., 2005). Furthermore, the cytoplasmic C-terminus of NrCAM contains a typical 
sequence	motif	for	binding	to	PDZ	domains.	Specific	interactions	of	the	intracellular	domain	of	
NrCAM with class I PDZ domains of PSD-95 and SAP97 were demonstrated (Dirks et al., 2006). 
Intercellular adhesion molecule-5 (ICAM-5) is a dendritically polarized membrane glycoprotein 
in telencephalic neurons. ICAM-5 displays two types of adhesion activity, homophilic binding 
between neurons and heterophilic binding between neurons and leukocytes (Tian et al., 2000). 
Both immunoglobulin superfamily members NrCAM and ICAM-5, were down regulated in 
transgenic S2 (Table 3).
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3.4.3.3 Synaptic transmission and synaptic plasticity
Glutamate receptors are the predominant excitatory neurotransmitter receptors in the 
mammalian brain and are activated in a variety of neurophysiologic processes. These receptors 
are heteromeric protein complexes with multiple subunits, each possessing transmembrane 
region, and all arranged to form a ligand-gated ion channel. The ionotrophic glutamate 
receptor 3 (GluR3) belongs to a family of AMPAR and was up regulated in P20 synaptosomes 
(Table 1). Alternative splicing results in several different isoforms, which may vary in their signal 
transduction	properties.	Knockout	mice	deficient	 in	 the	expression	of	both	GluR2	and	GluR3	
are severely impaired in the basal synaptic transmission. However, these mutant mice are 
competent in establishing several forms of long-lasting synaptic changes in the CA1 of the 
hippocampus, including LTD and LTP (Meng et al., 2003). 
Small GTPase Rap1 plays an important role in the induction of mGluR5-dependent LTD by direct 
coupling	to	receptor	trafficking	machineries	to	facilitate	the	loss	of	synaptic	AMPAR	(Huang	et	
al., 2004). Negative effects of Rap1 are observed in NMDAR-mediated synaptic transmission in 
hippocampal pyramidal neurons. This implies a possible role for Rap1 in glutamatergic synaptic 
transmission. In the context of neurotrypsin overexpression, Rap1 was up regulated by 1.88 in the 
synaptosomes of P40 transgenic mice (Table 1) as well as Rap1 GDI1 that was also up regulated 
in S2 by 1.7 as found in 2DE analysis (Table 7).
Protein	kinase	C	(PKC)	is	a	family	of	serine-	and	threonine-specific	protein	kinases	that	can	be	
activated by Ca2+ and second messenger DAG. PKC family members phosphorylate a wide 
variety of protein targets and are known to be involved in diverse cellular signaling pathways. 
Each	member	of	the	PKC	family	has	a	specific	expression	profile	and	is	believed	to	play	distinct	
roles in cells. PKCε, down regulated in synaptosomes by 40% (Table 1) has been shown to be 
involved in many different cellular functions, such as neuron channel activation, apoptosis, 
cardioprotection from ischemia, heat shock response, as well as insulin exocytosis. Knockout 
studies in mice suggest that PKCε is important for lipopolysaccharide (LPS)-mediated signaling 
in activated macrophages and may also play a role in controlling anxiety-like behavior. PKCα, 
also down regulated in P2 by 35% (Table 3) has been reported to play roles in many different 
cellular processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell 
volume control.
N-copine contains two copies of C2-domain. The mRNA expression was detected only in brain 
and was up regulated by stimulation evoking CA3-CA1 LTP. Thus, N-copine may have a role in 
synaptic plasticity (Nakayama et al., 1998). In situ hybridization analysis showed that N-copine 
mRNA was expressed exclusively in neurons of the hippocampus and in the main and accessory 
olfactory bulb. In immunohistochemical analyses, N-copine was mainly detected in the cell 
bodies and dendrites of neurons. In fractionation experiments of brain homogenate, N-copine 
was associated with the membrane fraction in the presence of Ca2+ but not in its absence. 
Therefore, N-copine may have a role as a Ca2+ sensor in postsynaptic events (Nakayama et 
al., 1999). There is evidence that copines may represent members of universal transduction 
pathways for Ca2+ signaling because it was found that copines are capable of interacting with 
a wide variety of “target” proteins including MAP/ERK kinase 1 (MEK1), protein phosphatase 
5, and the Cdc42-binding kinase. The interaction with copines may result in the recruitment 
of target proteins to membrane surfaces and regulation of the enzymatic activities of target 
proteins (Tomsig et al., 2003). N-copine was up regulated in synaptosomes of P20 transgenic 
animals by 1.85 and down regulated in the hippocampus of P10 transgenic mice (S2: 0.71; P2: 
0.83).
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The ‘SNARE hypothesis’ is a model explaining the process of docking and fusion of vesicles to their 
target membranes. According to this model, membrane proteins from the vesicle (v-SNAREs) 
and	proteins	from	the	target	membrane	(t-SNAREs)	govern	the	specificity	of	vesicle	targeting	
and docking through mutual recognition. Once the 2 classes of SNAREs bind to each other, 
they form a complex that recruits the general elements of the fusion apparatus, namely NSF 
(N-ethylmaleimide-sensitive factor) and SNAPs (soluble NSF-attachment proteins). Stimulation of 
NSF ATPase activity by alpha-SNAP is required for SNARE complex disassembly and exocytosis 
(Barnard	et	al.,	1997).	A	specific	interaction	of	the	GluR2	C-terminal	peptide	with	ATPase	NSF	
and alpha- and beta- SNAPs was found (Osten et al., 1998). The direct interaction suggests a 
rapid	NSF-dependent	modulation	of	AMPAR	trafficking	and	stabilization.	Alpha-	and	gamma-
SNAPs are found in a wide range of tissues and act synergistically in intra-Golgi transport. The 
third	 SNAP,	beta,	 is	 brain-specific.	 Thus,	NSF	and	 SNAPs	play	 key	 roles	 in	 vesicular	 trafficking	
through the secretory pathway and appear to be general components of the intracellular 
membrane	fusion	apparatus	(Whiteheart	et	al.,	1993).	Both	alpha-SNAP	and	beta-SNAP	were	
down regulated in transgenic S2. NSF protein was also less expressed in S2 by 40% (Table 2). 
Proteins	 that	 bind	 to	 cytoplasmic	 tails	 of	 AMPARs	 control	 receptor	 trafficking	 and	 thus	 the	
strength of postsynaptic responses. Adaptor protein complex 2 (AP-2) associates with a region 
of	GluR2	that	overlaps	with	the	NSF	binding	site.	AP-2	is	involved	specifically	in	NMDA	receptor-
induced internalization of AMPAR, and is essential for hippocampal LTD (see ‘endocytosis’). NSF 
function, on the other hand, is needed to maintain synaptic AMPAR responses, but is not directly 
required for NMDA receptor-mediated internalization and LTD (Lee et al., 2002). Interestingly, 
NSF is up regulated in P2 by 1.17 (Table 2) and AP-2 alpha 1 subunit is also up regulated in P40 
synaptosomes (Table 1 and 3). The AP-2 complex is a heterotetramer consisting of two large 
adaptins (alpha or beta), a medium adaptin (mu), and a small adaptin (sigma). The complex 
is part of the protein coat on the cytoplasmic face of coated vesicles, which links clathrin to 
receptors in vesicles. It was shown to interact with amphiphysin 2 (McMahon et al., 1997). AP-
2 complex subunit alpha 1 was found in synaptosomes of adult mice and was up regulated 
whereas beta 1 subunit was down regulated in S2 demonstrated by 2DE (Tables 1 and 7).
Syntaxin binding protein (Munc18-1) is required for neurotransmitter release and inhibits binding 
of synaptobrevin and SNAP-25 to syntaxin 1A to modulate SNARE complex formation. During 
synaptic vesicle exocytosis, Munc18-1 is known to bind tightly to syntaxin-1, but only when 
syntaxin-1 is in a closed conformation that is incompatible with SNARE complex formation. 
Munc18-1 also binds tightly to assembled SNARE complexes containing syntaxin-1, suggesting 
that binding of Munc18-1 to closed syntaxin-1 is a specialization that evolved to meet the strict 
regulatory requirements of neuronal exocytosis, whereas binding of Munc18-1 to assembled 
SNARE	 complexes	 reflects	 a	 general	 function	 of	 proteins	 involved	 in	 executing	 membrane	
fusion (Dulubova et al., 2007). Deletion of Munc18-1 in mice leads to a complete loss of 
neurotransmitter secretion from synaptic vesicles throughout development. However, this does 
not	prevent	normal	brain	assembly,	including	formation	of	layered	structures,	fiber	pathways,	
and	morphologically	defined	synapses	(Verhage	et	al.,	2000).	However,	Munc18-1	was	down	
regulated in S2 by 0.84 and up regulated in P2 by 1.14 (Table 2).
Ca2+/calmodulin-dependent protein kinase II (CaMK II) belongs to the Ser/Thr protein kinase 
family, and to the Ca2+/calmodulin-dependent protein kinase subfamily. This enzyme is composed 
of four different chains: alpha, beta, gamma, and delta. The alpha chain is required for 
hippocampal LTP and spatial learning. In addition to its calcium-calmodulin (CaM)-dependent 
activity, this protein can undergo autophosphorylation, resulting in CaM-independent activity. 
LTP and LTD of synaptic function often requires Ca2+-influx	 via	NMDARs	and	changes	 in	 the	
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autophosphorylation of CaMK II at Thr286. Autophosphorylated CaMK II binds directly to NMDAR 
subunits, co-localizes with NMDARs in the PSD, and phosphorylates NR2B subunits. Calcium entry 
through postsynaptic NMDARs and subsequent activation of CaMK II triggers synaptic plasticity 
in many brain regions. Switching synaptic NMDAR containing NR2B subunits that bind CaMK II 
with	high	affinity	with	those	containing	NR2A,	a	subunit	with	low	affinity	for	CaMK	II,	dramatically	
reduces LTP. Thus association between active CaMK II and NR2B is required for different forms 
of synaptic enhancement (Barria and Malinow, 2005). In particular, although NR2A and NR2B 
subunits are highly homologous, the sites of their interaction with CaMK II as well as the regulation 
of this binding differ. It is the CaMK II-dependent phosphorylation of the PDZ1 domain of PSD-95 
regulating the signaling transduction pathway downstream of NMDA receptors (Gardoni et al., 
2006). CaMK II expression was reduced both in S2 and P2 by 15 and 30%, respectively (Table 2).
NMDARs are targeted to dendrites and anchored at the PSD through interactions with PDZ 
proteins. However, little is known about how these receptors are sorted from the ER and Golgi 
apparatus to the synapse. It was found that synapse-associated protein 102 (SAP102) interacts 
with the PDZ-binding domain of Sec8, a member of the exocyst complex. Interactions between 
SAP102 and Sec8 are involved in the delivery of NMDARs to the cell surface in neurons. It was 
suggested that an exocyst-SAP102-NMDAR complex is an important component of NMDAR 
trafficking	(Sans	et	al.,	2003).	Humans	with	mutations	in	SAP102	show	mental	retardation.	Using	
SAP102	KO	mice,	specific	impairments	in	synaptic	plasticity	were	found.	This	was	paralleled	by	
inflexibility	and	impairment	in	spatial	learning	(Cuthbert	et	al.,	2007).	Interestingly,	SAP102	was	
up regulated in transgenic S2 by 1.33 (Table 2).
SAPAP 4 is a membrane-associated guanylate kinase found at the PSD in neuronal cells. It is a 
signaling molecule that can interact with potassium channels and receptors, as well as other 
signaling molecules. It can interact with PSD-95 and may be involved in clustering PSD-95 in the 
postsynaptic density region. It may play a role in PSD structure and synaptic function (Takeuchi 
et al., 1997). SAPAP 4 was up regulated in P2 by 30% (Table 2).
3.4.3.4	 Exocytosis
The Ca2+-triggered release of neurotransmitters is mediated by fusion of synaptic vesicles with 
the plasma membrane. Complexins are two highly conserved cytosolic proteins that modulate 
neurotransmitter release. In vitro, they bind in a 1:1 stoichiometry to the assembled synaptic 
SNARE complex and modulate neuroexocytosis (Pabst et al., 2002). Besides synaptotagmin 
1, fast Ca2+-triggered exocytosis requires complexins. Complexin binding activates SNARE 
complexes into a metastable state and Ca2+-binding to synaptotagmin 1 triggers fast exocytosis 
by displacing complexin from metastable SNARE complexes (Tang et al., 2006). Complexins 
compete with alpha-SNAP for SNARE complex binding. They are enriched in neurons where they 
co-localize with syntaxin and SNAP-25 (McMahon et al., 1995). Complexin 1 is down regulated 
in the soluble fraction of the hippocampus by 0.71 (Table 2).
Septin 5, which is predominantly expressed in the nervous system, was associated with membrane 
fractions, and co-precipitated with synaptic vesicles. It is linked to syntaxin by direct binding via 
the SNARE interaction domain. This interaction was occluded by the binding of alpha-SNAP, 
suggesting that septin 5 may regulate the availability of SNARE proteins through its interaction 
with syntaxin (Beites et al., 2005). Transfection of cells with wild-type septin 5 inhibited secretion, 
whereas GTPase dominant-negative mutants enhanced secretion. Thus, septins may regulate 
vesicle dynamics through interactions with syntaxin (Beites et al., 1999). Septin 5 overexpression 
exerted dopamine-dependent neurotoxicity (Dong et al., 2003). Homozygotic septin 5 null mice 
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appeared normal with respect to synaptic properties and hippocampal neuron outgrowth, 
suggesting that septin 5 is not essential for neuronal development or function. Changes in 
expression of other septins may account for its functional redundancy (Peng et al., 2002). In S2 
of neurotrypsin-overexpressing mice septin 5 was down regulated by 0.67 (Table 2).
Rab3C plays a role in intracellular vesicle-mediated transport. It may be involved in Ca2+-
dependent	 exocytosis	 and	 neurotransmitter	 release.	 Rab3-induced	modifications	 to	 primed	
vesicles	causes	a	 transient	 increase	 in	 the	transduction	efficacy	of	 synaptic	action	potential	
(Schluter et al., 2006). Rab3C expression was induced both in P40 synaptosomes of transgenic 
mice by 1.99 and in S2 of the hippocampus by 1.20 (Table 1 and 2). GDP GDI are proteins 
that regulate the GDP-GTP exchange reaction of members of the Rab family. GDIs slow down 
the rate of dissociation of GDP from Rab proteins. Rab GDI 1 is expressed primarily in neural 
and	sensory	tissues.	Mutations	 in	Rab	GDI	1	have	been	 linked	to	X-linked	nonspecific	mental	
retardation. Interestingly, 2DE revealed that Rab GDI 1 was down regulated in S2 by 0.58 (Table 
7). The cycling between the GDP-bound and GTP-bound forms of Rab small GTPases is also 
regulated by the action of a GTPase activating proteins (GAPs). Rab3-GAP 1 is a heterodimeric 
complex consisting of a 130 kDa catalytic subunit and a 150 kDa noncatalytic subunit. It is 
specifically	active	on	the	Rab3	subfamily	members	(Rab3A,	-B,	 -C,	and	-D).	 In	hippocampus	
S2	overexpressing	neurotrypsin,	the	Rab3-specific	Rab-GAP	1	catalytic	subunit	was	reduced	by	
0.82. (Table 2).
3.4.3.5 Endocytosis
Amphiphysin	2	(BIN1)	is	a	putative	tumor	suppressor	that	was	identified	through	its	interaction	with	
the Myc oncoprotein. Two isoforms are produced by alternative splicing, one of which is mainly 
expressed in the nerve terminals. Amphiphysin, through its SH3 domain, acts as an adaptor for 
a	series	of	proteins	important	for	the	clathrin-mediated	endocytosis,	such	as	dynamin	(Wigge	
and McMahon, 1998). Amphiphysin 2 is not only a regulator of the early steps of endocytosis. It 
could also play a role at the surface of endocytic vesicles that have just been formed and of 
the	future	endosomes,	in	order	to	regulate	intracellular	trafficking.	It	was	up	regulated	both	in	
synaptosomes of young (1.38) and adult (1.52) transgenic mice (Table 1).
Dynamin	 1	 is	 involved	 in	 clathrin-mediated	 endocytosis	 and	 other	 vesicular	 trafficking	
processes (Koenig and Ikeda, 1989; Roux et al., 2006). Actin and other cytoskeletal proteins 
act as binding partners for dynamin 1, which can also self-assemble leading to stimulation of 
GTPase	activity.	A	 long	proline-rich	 stretch	present	 in	dynamin	1	 specifically	 recognizes	and	
binds the SH3 domain-containing neuronal protein amphiphysin 2 (Grabs et al., 1997). PACSIN 
2	is	a	ubiquitously	expressed	isoform	of	the	brain-specific	PACSIN	1.	PACSIN	2	binds	dynamin	I,	
synaptojanin,	synapsin	I,	and	N-WASP,	a	stimulator	of	Arp2/3	induced	actin	filament	nucleation.	
In neuroendocrine cells PACSIN 2 co-localizes with dynamin consistent with a role for PACSIN 
in dynamin-mediated endocytic processes. Furthermore, PACSINs localize to sites of high actin 
turnover,	such	as	filopodia	tips	and	lamellipodia	(Qualmann	and	Kelly,	2000).	It	strongly	suggests	
that PACSINs link endocytosis and actin dynamics. Both proteins dynamin 1 and PACSIN 2 were 
down regulated in S2 transgenic sample by 0.75 and 0.77, respectively (Table 2).
Syntaxin 7 is a component of the SNARE complex crucial for vesicle docking and fusion events 
with	membranes.	It	mediates	the	endocytic	trafficking	from	early	endosomes	to	late	endosomes	
and lysosomes. The crystal structure of an endosomal SNARE core complex contained four 
SNAREs: syntaxin 7, syntaxin 8, vti1b and endobrevin/VAMP-8 were resolved (Antonin et al., 
2002). Syntaxin 7 showed an upregulation of 1.23 in transgenic P2 (Table 2).
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3.4.3.6 Neuroendocrine, synapse remodeling, and neurotransmitter clearance
Chromogranin B is a tyrosine-sulfated secretory protein found in a wide variety of peptidergic 
endocrine cells. It functions as a neuroendocrine secretory granule protein, which may be the 
precursor for other biologically active peptides. It was up regulated in synaptosomes of P20 by 
1.32 as well as of P40 mice by 1.83 (Table 1) but down regulated in the hippocampal S2 of P10 
transgenic mice by 0.70 (Table 2).
Neuronal pentraxin 1 (NP1) is a protein involved in excitatory synapse remodeling that has recently 
been shown to mediate neuronal death induced by reduction in neuronal activity in mature 
neurons (DeGregorio-Rocasolano et al., 2001). Treatment of cortical neurons in culture with Aβ 
produces a marked increase in NP1 protein that precedes apoptotic neurotoxicity. Silencing 
NP1 gene expression by RNA interference prevents the loss of synapses, the reduction in neurite 
outgrowth, and apoptosis evoked by Aβ. Transgenic overexpression of NP1 reproduced the 
neurotoxic effects of Aβ. Moreover, it was found that NP1 was increased in dystrophic neurites 
of brains from patients with sporadic late-onset AD. Thus, NP1 is a key factor for the synapse loss, 
neurite damage, and the apoptotic neuronal death evoked by Aβ (Abad et al., 2006). It was 
down regulated in S2 by 0.71 (Table 2).
Excitatory	amino	acid	transporter	2	(EAAT2)	 is	specific	to	astrocytes	under	normal	conditions.	
Functional studies suggest that up to 95% of all glutamate is cleared from the synaptic cleft 
by EAAT2 (Zhou and Sutherland, 2004). Loss of EAAT2 has been reported in amyotrophic lateral 
sclerosis (ALS) and Alzheimer's disease (Masliah et al., 1996; Rothstein et al., 1995). Interestingly, 
numerous abnormally spliced EAAT2	 mRNAs	 have	 been	 identified	 from	 the	 affected	 areas	
of ALS patients and the expression of these abnormally spliced RNA species correlated with 
the loss of EAAT2 protein in ALS (Lin et al., 1998). The loss of functional EAAT2 could lead to 
the accumulation of extracellular glutamate, resulting in cell death known as excitotoxicity. 
Furthermore, increased expression of EAAT2 was found in the prefrontal cortex of schizophrenics 
(Matute et al., 2005). These examples illustrate that under normal conditions, expression and 
splicing of EAAT2 must be tightly controlled otherwise the clearance of glutamate from the 
synaptic cleft is disturbed, which has fatal consequences. In the synaptosomes of adult mice 
overexpressing neurotrypsin, EAAT2 was up regulated (Table 1). In the hippocampus EAAT2 was 
found in P2. Its expression was down regulated by 0.75 in the transgenic samples (Table 2).
Glutamine is the main source of energy and is involved in cell proliferation, inhibition of apoptosis, 
and cell signaling (Haberle et al., 2005). Glutamine synthetase (GS) is expressed throughout 
the body and plays an important role in controlling body pH and in removing ammonia 
from the circulation. In the CNS, GS is almost exclusively expressed by the glial cells and 
astrocytes (Grossman et al., 1994). GS serves to convert L-glutamate, the primary amino acid 
neurotransmitter in the CNS. L-glutamate is converted to glutamine under the consumption of 
ATP and ammonia. Glutamine diffuses from the astrocytes to the neurons, where it is converted 
back to L-glutamate by glutaminase, thus re-entering the neurotransmitter pool. If the synthesis 
of glutamine is blocked, neither uptake nor de novo	synthesis	 is	sufficient	to	maintain	proper	
neurotransmission (Laake et al., 1995). The main mechanism for ammonia elimination in the brain 
is its reaction with glutamate to form glutamine. Acute intoxication with large doses of ammonia 
leads to rapid death. GS activity and glutamine content in brain are modulated by NMDA 
receptors and nitric oxide (Kosenko et al., 2003). High extracellular glutamate concentrations 
have	been	 identified	as	a	 likely	 trigger	of	epileptic	 seizures	 in	mesial	 temporal	 lobe	epilepsy	
(MTLE). Loss of GS was particularly pronounced in areas of the MTLE hippocampus with astroglial 
proliferation.	 Quantitative	 immunoblotting	 showed	 no	 significant	 change	 in	 the	 amount	 of	
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EAAT2.	Therefore,	a	deficiency	in	GS	in	astrocytes	is	a	possible	molecular	basis	for	extracellular	
glutamate accumulation and seizure generation in MTLE (Eid et al., 2004). In the ICAT screen GS 
was down regulated in the synaptosomes of transgenic mice by 0.73. The expression was also 
reduced in transgene P2 of the hippocampus by 0.85, but was up regulated in the S2 fraction 
of neurotrypsin-overexpressing mice by 1.40 (Table 1 and 6).
3.4.3.7 Metabolic processes
Aerobic glycolysis of glucose to pyruvate requires two equivalents of ATP to activate the 
process, with the subsequent production of four equivalents of ATP and two equivalents of 
NADH. Thus, conversion of one mole of glucose to two moles of pyruvate is accompanied by 
the net production of two moles each of ATP and NADH.
Glucose + 2 ADP + 2 NAD+ + 2 Pi --------> 2 Pyruvate + 2 ATP + 2 NADH + 2 H+
Hexokinase	1	is	the	enzyme	involved	in	the	first	reaction	of	the	glycolysis.	It	catalyzes	the	ATP-
dependent phosphorylation of glucose that activates the biochemically inert glucose into a 
labile form capable of being further metabolized. Hexokinase 1 is up regulated in synaptosomes 
by 1.80 but down regulated in S2 by 0.73 (Tables 1 and 5). Before pyruvate kinase catalyzes the 
final	step	of	the	glycolysis	by	conserving	the	high-energy	phosphate	of	phosphoenolpyruvate	
(PEP) as ATP and thereby producing pyruvate, phosphoglycerate mutase and enolase convert 
the relatively low energy phosphoacyl-ester of 3-phosphoglycerate in two catalyzed reactions 
to	PEP.	While	the	expression	of	phosphoglycerate	mutase	1	and	α-enolase was down regulated 
in the 2DE experiment (Table 7), two isoforms of enolase, alpha and gamma, were up regulated 
both in S2 and P2 in ICAT (Table 5).
The bulk of ATP used by many cells to maintain homeostasis is produced by the oxidation of 
pyruvate in the tricarboxylic acid (TCA) cycle. The fate of pyruvate depends on the cell energy 
charge. In cells or tissues with a high-energy charge pyruvate is directed toward gluconeogenesis, 
but when the energy charge is low pyruvate is preferentially oxidized to CO2 and H2O in the 
TCA	cycle,	with	generation	of	15	equivalents	of	ATP	per	pyruvate.	When	transported	into	the	
mitochondrion, pyruvate encounters two principal metabolizing enzymes: pyruvate carboxylase 
and	pyruvate	dehydrogenase	(PDH),	the	first	enzyme	of	the	PDH	complex.	When	the	energy	
charge is low coenzyme A (CoA) is not acylated, pyruvate carboxylase is inactive, and pyruvate 
is preferentially metabolized via the PDH complex and the enzymes of the TCA cycle. Reduced 
NADH and FADH2 generated during the oxidative reactions can then be used to drive ATP 
synthesis via oxidative phosphorylation. The PDH complex is comprised of multiple copies of 3 
separate enzymes: pyruvate dehydrogenase (20-30 copies), dihydrolipoyl transacetylase (60 
copies) and dihydrolipoyl dehydrogenase (6 copies) and 5 different coenzymes. The net result 
of the reactions of the PDH complex is:
Pyruvate + CoA + NAD+ ------> CO2 + acetyl-CoA + NADH + H+
The reactions of the PDH complex serves to interconnect the metabolic pathways of glycolysis, 
gluconeogenesis and fatty acid synthesis to the TCA cycle. As a consequence, the activity 
of the PDH complex is highly regulated by a variety of allosteric effectors and by covalent 
modification.	PDH	activity	is	regulated	by	its	state	of	phosphorylation,	being	most	active	in	the	
dephosphorylated	 state.	 Phosphorylation	of	 PDH	 is	 catalyzed	by	a	 specific	 PDH	 kinase.	 The	
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activity	of	the	kinase	is	enhanced	when	cellular	energy	charge	is	high	which	is	reflected	by	an	
increase in the level of ATP, NADH and acetyl-CoA. Conversely, an increase in pyruvate strongly 
inhibits PDH kinase. In the synaptosomes of transgenic mice the PDH kinase isoform 2 is down 
regulated by 0.54 and components of the PDH complex are down regulated in S2 and up 
regulated in P2 (Tables 1 and 5).
The	first	reaction	of	the	TCA	cycle	is	the	condensation	of	the	methyl	carbon	of	acetyl-CoA	with	
the	keto	carbon	of	oxaloacetate	(OAA).	When	the	cellular	energy	charge	increases	the	rate	
of	flux	through	the	cycle	will	decline	leading	to	a	build-up	of	citrate.	Excess	citrate	is	used	to	
transport acetyl-CoA carbons from the mitochondrion to the cytoplasm where they can be 
used for fatty acid and cholesterol biosynthesis. Additionally, the increased levels of citrate 
in the cytoplasm activate the key regulatory enzyme of fatty acid biosynthesis, acetyl-CoA 
carboxylase. Citrate synthase was up regulated in the hippocampus P2 fraction (Table 5). The 
isomerization of citrate to isocitrate is catalyzed by aconitase and is the second step in the TCA 
cycle. Its expression was up regulated in P2 hippocampus fraction (Table 5).
In the third step, isocitrate is oxidatively decarboxylated to α-ketoglutarate by isocitrate 
dehydrogenase, (IDH). There are two different IDH enzymes. The IDH of the TCA cycle uses 
NAD+ as a cofactor, whereas the other IDH uses NADP+ as a cofactor. Unlike the NAD+-requiring 
enzyme, which is located only in the mitochondrial matrix, the NADP+-requiring enzyme is found 
in both the mitochondrial matrix and the cytosol. IDH catalyzes the rate-limiting step, as well as 
the	first	NADH-yielding	reaction	of	the	TCA	cycle.	All	IDH	isoforms	found	in	the	ICAT	screen	were	
up regulated (Table 1 and 5).
L-malate	 is	 the	 specific	 substrate	 for	malate	dehydrogenase	 (MDH),	 the	final	enzyme	of	 the	
TCA cycle. The forward reaction of the cycle, the oxidation of malate yields OAA. MDH was up 
regulated at least in synaptosomes of P40 animals (Table 1). 
In addition, lactate dehydrogenase (LDH) catalyzes the interconversion of pyruvate and lactate 
with concomitant oxidation of NADH. The lactate produced during anaerobic glycolysis diffuses 
from the tissues and is transported to highly aerobic tissues such as cardiac muscle liver or brain. 
The lactate is then oxidized to pyruvate in these cells by LDH and the pyruvate is further oxidized 
in the TCA cycle. If the energy level in these cells is high the carbons of pyruvate will be diverted 
back to glucose via the gluconeogenesis pathway. Mammalian cells contain two distinct 
types of LDH subunits, termed M and H. Combinations of these different subunits generates 
LDH isozymes with different characteristics. The H type subunit predominates in aerobic tissues 
while the M subunit predominates in anaerobic tissues. The H-type LDH is utilized for oxidizing 
lactate to pyruvate and the M-type the reverse. In synaptosomes of P40 transgenic mice 
LDH-M is up regulated (Table 1). Finally, after glycogen phosphorylase has broken off a single 
glucose molecule from the greater glycogen structure the free glucose has a phosphate group 
on its 1-carbon. This glucose-1-phosphate isomer cannot be metabolized easily. The enzyme 
phosphoglucomutase phosphorylates the 6-carbon, while subsequently dephosphorylating the 
1-carbon. The result is glucose-6-phosphate, which can now travel down the glycolysis pathway. 
Phosphoglucomutase also acts in the opposite fashion when a large concentration of glucose-
6-phosphate is present. Phosphoglucomutase 2-like 1 expression was increased in S2 of 2DE and 
P2 of ICAT by 1.5 and 1.43, respectively (Tables 5 and 7).
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3.4.3.8 Neuron migration and differentiation of the nervous system
Brevican is the most abundant chondroitin sulfate proteoglycan in the ECM of the adult rat 
brain. Brevican expression is up regulated coincident with glial cell proliferation and/or motility 
and during early CNS development and in invasive glioma. An understanding of the molecular 
interactions that mediate Brevican function is still in its infancy because of the existence of 
several isoforms, each of which may mediate different functions (Viapiano et al., 2003). It was 
demonstrated that MMP-1, -2, -3, -7, -8, -10, and -13 and aggrecanase-1 digest brevican in a 
similar pattern to aggrecan and suggest that they may be responsible for the physiological 
turnover and pathological degradation of brevican (Nakamura et al., 2000). Expression of 
brevican was reduced in hippocampal S2 by 0.75 (Table 3).
In the developing cortex, cortical neurons must migrate over long distances to reach the site of 
their	final	differentiation.	Doublecortin	appears	to	direct	neuronal	migration	by	regulating	the	
organization and stability of microtubules (Gleeson et al., 1999). It contains two doublecortin 
domains, which bind microtubules. A certain proportion of doublecortin interacts with AP-1 
and/or AP-2 complex in vivo and are consistent with a potential involvement of doublecortin 
in	 protein	 sorting	or	 vesicular	 trafficking	 (Friocourt	 et	 al.,	 2001).	 Doublecortin	 expression	was	
induced in S2 by 1.27 (Table 3).
3.4.3.9 Apoptosis
Mitochondrial outer membrane permeability is conferred by a family of voltage-dependent 
anion channels (VDACs), also known as mitochondrial porins. VDACs conduct small molecules 
and constitute one component of the permeability transition pore that opens in response to 
apoptotic	 signals	 (Shimizu	et	al.,	 1999).	Mitochondrial	 porins	 have	 significant	 roles	 in	diverse	
cellular	processes	including	regulation	of	mitochondrial	ATP	and	calcium	flux.	Furthermore,	fear	
conditioning	and	spatial	 learning	are	disrupted	 in	VDAC-deficient	mice.	Electrophysiological	
recordings	of	VDAC-deficient	hippocampal	slices	reveal	deficits	in	long	and	short-term	synaptic	
plasticity	 (Weeber	et	al.,	 2002).	VDACs	may	also	 serve	as	binding	 sites	 for	 kinases,	 including	
hexokinase.	 Mitochondria-bound	 hexokinase	 activity	 was	 significantly	 reduced	 in	 oxidative	
muscles (heart and soleus) in vdac1(-/-) mice. Mice lacking both VDAC1 and VDAC3 have 
reduced exercise capacity together with impaired glucose tolerance. Therefore, there is a 
link between VDAC1 mediated mitochondria-bound hexokinase activity and the capacity for 
glucose	clearance	(Anflous-Pharayra	et	al.,	2007).	VDAC1	was	reduced	in	transgenic	P2	by	30%	
(Table 6).
3.4.3.10 Varia
Adenosine kinase (AK) is an abundant enzyme in mammalian tissues, which was strongly down-
regulated in both P20 and P40 transgenic animals. The enzyme catalyzes the transfer of the 
gamma-phosphate from ATP to adenosine, thereby serving as a regulator of concentrations 
of both extracellular adenosine and intracellular adenine nucleotides. Immunohistochemical 
analysis of brain sections of mice revealed intense staining for adenosine kinase, mainly in 
astrocytes, which were more or less evenly distributed throughout the brain, as well as in some 
neurons, particularly in olfactory bulb, striatum, and brainstem. Adenosine has widespread 
effects on the cardiovascular, nervous, respiratory, and immune systems and inhibitors of the 
enzyme could play an important pharmacological role in increasing intravascular adenosine 
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concentrations	and	acting	as	anti-inflammatory	agents.	Endogenous	adenosine	 in	 the	brain	
is thought to prevent the development and spread of seizures via a tonic anticonvulsant 
effect (Gouder et al., 2004). Brain levels of adenosine are primarily regulated by the activity 
of adenosine kinase. Thus, transient down regulation of AK after acute brain injury protects the 
brain from seizures and cell death. Conversely, chronic overexpression of AK causes seizures in 
epilepsy and promotes cell death in epilepsy and stroke (Boison, 2006). AK was down regulated 
in synaptosomes of transgenic young (0.47) and adult (0.1), whereas 2DE revealed that AK was 
up regulated in S2 by 60% (Tables 1 and 7)
The Na+/K+-ATPase (NKA) belongs to the family of P-type cation transport ATPases. NKA is an 
integral membrane protein responsible for establishing and maintaining the electrochemical 
gradients of Na+ and K+ ions across the plasma membrane. These gradients are essential for 
osmoregulation, for sodium-coupled transport of a variety of organic and inorganic molecules, 
and for electrical excitability of nerve and muscle. This enzyme is composed of two subunits, 
a large catalytic subunit (alpha) and a smaller glycoprotein subunit (beta). Multiple genes 
encode the catalytic subunit of NKA. Today three alpha subunits are known in the brain: 
alpha 1 isoform is found in many cell types, the alpha 2 isoform is predominantly expressed 
in astrocytes, and the alpha 3 isoform is exclusively expressed in neurons (Shull et al., 1986). 
Several disorders have been associated with mutations in NKA alpha isoforms (rapid-onset 
dystonia parkinsonism, familial hemiplegic migraine type-2), as well as reduction in NKA content 
(depression	and	Alzheimer’s	disease),	thereby	raising	the	issue	of	whether	haploinsufficiency	or	
altered enzymatic function contribute to disease etiology. Mice heterozygous for the alpha3 
isoform	displayed	spatial	learning	and	memory	deficits,	increased	locomotor	activity,	and	a	40%	
reduction in hippocampal NMDA receptor expression (Moseley et al., 2007). There is biochemical 
evidence that agrin binds to the alpha3 subunit of the NKA in CNS neurons. Co-localization with 
agrin binding sites at synapses supports the hypothesis that the alpha3NKA is a neuronal agrin 
receptor. A 20 kDa C-terminal agrin fragment that acts as a competitive antagonist depresses 
action potential frequency, showing that endogenous agrin regulates native alpha3NKA 
function. Therefore it was hypothesized that agrin regulates activity-dependent processes in 
neurons (Hilgenberg et al., 2006). α3, β1, and β2 subunits were all down regulated in transgenic 
S2 and P2 by around 30% (Table 6).
3.4.4	 GO	annotation	of	differentially	expressed	proteins
Because only small differences in protein abundance ratios were found we thought that 
modulatory changes of neurotrypsin-dependent cellular processes and molecular functions 
were better to disclose. The question arose whether the regulatory changes were more distinct 
when the changed proteins were grouped into functional categories. Therefore, the regulated 
proteins irrespective of their up- or down regulation were brought together and grouped into 
GO	 terms.	 Pie	 diagrams	 of	 ‘biological	 process’	 in	 general	 and	more	 specific	 of	 ‘transport’	
and ‘metabolic process’ highlighted the affected categories (Fig. 3.15). NOTE: not every GO 
term that changed proteins could possibly be annotated to, was taken into account. Some 
rare	GO	 terms	were	 ignored.	 Furthermore,	one	 term	does	not	necessarily	 reflect	100%	of	all	
regulated proteins. And due to manifold functions proteins were allowed being allocated to 
multiple categories. In the hippocampus changed proteins that are involved in neuronal signal 
transduction mechanisms such as ‘synaptic transmission’, ‘signal transduction’, and ‘synaptic 
plasticity’ accounted for 36%. 45% of the differentially regulated proteins were involved in 
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morphological or functional rearrangements of neuronal cells like ‘neurite development’, ‘cell 
proliferation and motility’, ‘axon/neuron guidance’ and ‘differentiation’, while ‘adhesion’ 
was composed of 19%. In synapses much more regulated proteins were involved in signal 
transduction (54%). Less affected were proteins involved in proliferation and differentiation 
(30%). A comparable amount of candidates played a role in ‘adhesion’ (16%).
As for the ‘metabolic process’, 26% were involved in fatty acid/lipid metabolism, whereas in 
the synaptosomes it was 56%. In the hippocampus the tricarboxylic acid (TCA) cycle was well 
represented by 35% and in the synaptosomes it was mere 4%. 39% in the hippocampus and 40% 
in the synaptosomes, were involved in ‘glycolysis’ and ‘glucose and glutamate metabolism’. 
Comparing the diagrams ‘transport’ from the hippocampus and the synaptosomes a lot of 
similarities were found. Together ‘endocytosis’ and ‘exocytosis’ represented 44% (hippocampus) 
and 38% (synaptosomes) of the differentially regulated proteins. 56% and 62% were annotated 
to vesicle transport mechanisms like ‘antero- and retrograde ER-Golgi transport’, ‘secretory 
pathway’ and ‘vesicle mediated transport’. However, the major difference here was the total 
amount	of	proteins	classified	into	the	GO	term	‘transport’;	whereas	only	18	hippocampal	proteins	
fell into this category from the synaptosomes 29 different proteins were involved in ‘transport’. 
hippocampus
synaptosomes
transportbiological process metabolic process
Total: 76
Total: 83
Total: 23
Total: 25
Total: 18
Total: 29
Figure 3.14    Differentially expressed proteins from synaptosomes and the hippocampus are annotated according 
to Gene Ontology (GO) terms.
Categorization of changed proteins from the hippocampus (S2 and P2 together) and the synaptosomes into GO terms ir-
respective of up- or downregulation. Highly represented categories imply perturbance of the particular process or function. 
Relatively a lot of proteins were allocated to ‘biological processes’ such as signal transduction (in synaptosomes), ‘cell 
adhesion’, ‘synaptic plasticity and transmission’, as well as ‘cell proliferation’ and ‘differentiation’, ‘neurite development’ 
and ‘axon/neuron guidance’. Many proteins were found involved in ‘metabolic process’ as diverse as ‘fatty acid/lipid me-
tabolism’, ‘tricarboxylic acid cycle’ (hippocampus), ‘glycolysis’ (hippocampus), and ‘energy reserve metabolism’. Finally, 
proteins assigned to ‘transport’ such as ‘endo- and exocytosis’ and ‘vesicle mediated transport’ are also remarkably often 
changed.
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3.5	 Verification	of	candidate	proteins
3.5.1	 	Verification	of	three	candidates	found	in	synaptosomes
Adenosine is a potent modulator of excitatory neurotransmission, especially in seizure-prone 
regions such as the hippocampal formation. Chronic overexpression of AK causes seizures and 
promotes	 cell	 death	 in	 epilepsy	 and	 stroke.	Whereas	 transient	 down	 regulation	 of	 AK	 after	
acute	brain	injury	protects	the	brain	from	seizures	and	cell	death.	The	finding	that	AK	is	reduced	
in the synaptosomal preparations of transgenic mice suggested a compensatory mechanism 
to potentially evoked seizure by neurotrypsin overexpression.
A	specific	 role	of	TM-agrin	 in	shaping	the	cytoskeleton	of	neurites	 in	 the	developing	nervous	
system (Annies et al., 2006) and the knowledge that PAK1 protein is an important regulator of 
cytoskeletal dynamics lead to the hypothesis that increased cleavage of agrin by overexpressed 
neurotrypsin might elicit a signaling pathway implicating PAK1 as a molecular switch. It was 
further shown that the intracellular level of activated Cdc42 and Rac1 (Parrini et al., 2002) 
regulates its dimerization. Moreover, PAK1 is believed to act directly on the JNK1 MAP kinase 
pathway.
Finally, the MAPK/ERK pathway is a signal transduction cascade that couples intracellular 
responses to the binding of growth factors to cell surface receptors. The pathway has a 
hierarchical structure starting with the extracellular stimuli activating MAP kinase kinase kinase 
(MAPKKK), MAP kinas kinase (MAPKK) and MAP kinase (MAPK) that transduces further signals to 
the	nucleus,	which	then	promotes	transcription	of	specific	genes.	The	MAPK	signaling	pathway	
is usually activated by growth factors, which might be provided by the excessive production of 
the C-terminal agrin LG3 domain by neurotrypsin.
In	 order	 to	 confirm	 the	 regulatory	 changes	 in	 protein	 expression	 of	 AK,	 PAK1,	 and	MAPK1,	
quantitative	 Western	 blotting	 was	 performed.	 The	 abundance	 ratios	 of	 the	 proteins	 were	
assessed by spot densitometry of at least three immunoblots of three independent preparations. 
PSD-95	was	used	for	normalization.	As	opposed	to	the	findings	from	the	ICAT	proteomic	profiling,	
AK tested in different mouse lines (M494, M491S and S/A785) was either not regulated in P20 
synaptosomes or up regulated in synaptosomes of P40 neurotrypsin overexpression mice (Fig. 
3.16a and b).
Synaptosomes of P20 M494 mice showed an increased abundance ratio in PAK1 expression in 
transgenic samples. The outcome with a regulation factor of 1.5 was consistent with the ICAT 
(Table 1). However, a ratio of 1: 1 was found for PAK1 in synaptosomes of the same age from the 
other neurotrypsin-overexpressing mouse line M491S (Fig. 3.17a and b).
MAPK 1 showed a ratio of 1.20, 1.37, and 1.66 in the ICAT screen (Tables 1 and 3). Consistently, 
an increased expression level of 1.22 and 1.25 was also found in P20 synaptosomes of M494 and 
M491S	mice,	and	yet	an	abundance	ratio	of	1.49	was	demonstrated	in	M494	P40.	The	Western	
blotting of synaptosomes from the control line f494 with a silent transgene revealed a ratio of 
0.79 and 1.15 for P20 and P40, respectively (Fig. 3.17c and d).
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Although the quantitative changes of AK found in the ICAT approach revealed a down regulation 
in	the	transgenic	samples	could	not	be	confirmed	by	immunoblotting,	further	efforts	have	been	
taken to investigate the expression level in more detail. Because the synaptosomes originated 
from a pool of whole mouse brains, it was hypothesized that the differential regulation of AK 
was	restricted	to	well-defined	specialized	areas	of	the	brain	such	as	the	hippocampus,	where	
exogenous neurotrypsin was abundant. Moreover, the 2DE analysis suggested that AK might 
indeed be up regulated in S2. Therefore, immunohistochemical staining of coronal sections from 
mouse brains comparing wild-type and transgene were prepared. A punctated somatic, AK-
Figure 3.16     Verification of p21-activated kinase (PAK 1) and mitogen-activated protein kinase 1 (MAPK 1) expres-
sion in synaptosomes.
(A) To confirm the MS-data, suggesting an upregulation of PAK 1 in synaptosomes of neurotrypsin overexpressing mice (P20: 
1.59, P40: 1.04), equal amounts of protein extracts were loaded on a SDS-PAGE. PAK 1 was immunoblotted and quantified 
in wild-type (wt) and transgenic (tg) mice (N=3). PSD-95 was used as a reference protein for normalization. (B) A histogram 
confirming an increase in the tg samples of P20 M494 and a tremendous decrease in P40 M494 mice. Changes are not 
detectable in P20 M491S. In tg mice f494 no change for PAK 1 expression was found in P40 and slightly reduced levels were 
found in P20 animals. (C) MAPK 1 showed an upregulation by a factor of 1.66 in the ICAT with P40 synaptosomes, a 1.39 
upregulation in P2, and 1.22 upregulation in S2. The protein was immunoblotted and relative quantities were calculated. (D) 
In both, M494 and M491S of P20 synaptosomes, MAPK 1 was slightly stronger in tg samples. In P40 the increase was even 
stronger, confirming the findings of ICAT. In the control line f494 MAPK 1 expression is at 0.8 in P20 and at 1.18 in P40.
Figure 3.15     Verification of adenosine kinase expression in synaptosomes.
(A) To confirm the MS-data, suggesting a downregulation of adenosine kinase (AK) in synaptosomes of neurotrypsin overex-
pressing mice (P20: 0.47, P40: 0.10), equal amounts of synaptosomal protein extracts from wild-type (wt) and transgenic (tg) 
mice were loaded on a SDS-PAGE, immunoblotted with anti-AK antibody and quantified (N=3). PSD-95 was used as a refer-
ence protein for normalization. (B) A histogram showing slightly increased expression of AK in the tg samples of P40 mice for 
M494 and M491S. For the S/A 785 mouse line no regulation was found in P40. In P20 mice, AK was equally expressed in both 
wt and tg. (C) Immunohistochemical staining of AK in the neocortex of wt and tg P40 mice. The AK-positive cells in the dashed 
squares were counted and wt was plotted against tg. In both the deeper and the higher cortical layers more AK-positive cells 
in tg than in wt were found. Cortical layers I - VI are indicated. Layer VI is shortened in tg animals.
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positive staining was evenly distributed throughout the different layers of the cortex. Interestingly, 
cortical layer VI was shortened in the transgenic P40 M494 mice as compared to wild-type litter 
mates. In addition, the number of AK-positive cells was increased in transgenic samples by 25% 
in layers III and V (Fig. 3.16c). At this point it was unclear whether the staining is glial or neuronal. 
From the literature it was described that AK is primarily expressed in astrocytes (Gouder et al., 
2004). The question, whether the neurotrypsin induced, newly expressing cells were of neuronal 
or	of	astroglial	origin	arose.	Therefore,	fluorescent	immunohistochemistry	with	double	labeling	
of AK and neuronal or astroglial marker proteins were performed. Double staining of cortical 
layers	I	–	III	with	AK	and	neuronal	marker	NeuN	antibodies	confirmed	the	increased	number	of	
AK-positive	cells.	But	firstly,	the	AK	signal	did	not	co-localize	with	NeuN	staining	and		secondly	
the number of neuronal cells was equal comparing wild-type and transgene (Fig. 3.18a). A 
comparable situation was found in layers V and VI where more AK-positive cells were found, 
but neither an increase in neuronal cells nor co-localization was found (Fig. 3.18b). In contrast, 
co-localization	studies	with	glial	fibrillary	acidic	protein	(GFAP)	and	AK	demonstrated	that	in	the	
hippocampus and particularly in the dentate gyrus there was a substantial overlap between 
the two (Fig. 3.19a, b). In the dentate gyrus the protrusions stained with GFAP antibody reaching 
out of the cell bodies originated by up to 100% from AK-positive cells. Furthermore, there was an 
increase in both AK- and GFAP-positive staining in the dentate gyrus. However, the AK-positive 
cells outside of the dentate gyrus rarely co-localized with GFAP. There, neither the number of 
GFAP-positive nor the number of AK-positive cells seemed to be changed, indicating that the 
newly AK-positive cells in the dentate gyrus are of astroglial origin (Fig. 3.19a).
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Figure 3.17     Adenosine kinase expression in the cortex.
(A) In cortical layers I - III the adenosine kinase (AK)-positive cells are enriched in the transgenic mice (1 vs. 4), whereas 
the number of neurons, detected with neuron-specific marker NeuN is unchanged (2 vs. 5). Absolutely no co-localization 
of the two proteins could be observed (3 and 6). (B) There are also more AK-positive cells in cortical layers V and VI (1, 4), 
and the number of neurons is similar as well (2 vs. 5). Co-localization was not found either (3 and 6).
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Figure 3.18     Adenosine kinase expression in the hippocampus.
(A) Comparing the hippocampus of wild-type (wt) and transgenic (tg) mice, the number of adenosine kinase (AK)-positive 
cells as well as glial fibrillary acidic protein (GFAP) positive cells are increased, first of all in the dentate gyrus (arrow-
heads). Co-localization mainly was found in the dentate gyrus ((3 and 6) (B) The number of AK-positive cells is increased 
in the detnate gyrus of tg mice (1 and 4). The staining for GFAP is stronger in tg dentate gyrus (B2, B5). Co-localization of 
AK-positive cells with GFAP staining was found mainly within the dentate gyrus. Somatic staining for AK with GFAP-posi-
tive protrusions extending from the cell bodies suggests astroglial expression of AK (arrows in 3 and 6).
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3.6	 Verification	of	regulated	proteins	found	in	the	hippocampus
Firstly,	 in	order	 to	ascertain	 the	accurate	protein	 identification	and	quantification	of	 several	
candidates by quantitative MS, the tandem mass spectra and SICs were examined. Secondly, 
the	protein	 of	 interest	was	 immunoblotted	and	quantified.	 Three	 independent	 preparations	
were analyzed each.
3.6.1	 Copine	VI	(N-copine)	is	a	Ca2+ sensor in postsynaptic events
N-copine is a molecule from the CNS whose function is poorly understood. It is regulated in an 
activity dependent manner and may target proteins to membrane surfaces where they can 
exert their function. Moreover N-copine probably serves as a postsynaptic Ca2+ sensor capable 
to elicit signaling pathways. 
SEQUEST	identified	three	out	of	a	total	of	four	identified	peptides	from	N-copine.	All	four	peptides	
were	identified	by	Mascot	search	engine.	A	representative	CID	spectrum	derived	from	Mascot	
showed	a	high	coverage	of	fragmentation	peak	 identification	(Fig.	3.20a).	The	difference	of	
relative intensities between the light and heavy form of the precursor ions became apparent 
when a zoom in a survey scan was made in such a way that the isotopic distribution was resolved 
(Fig.	3.20b,	left).	The	relative	peak	intensities	for	the	light	isotopes	were	significantly	higher	than	
those	for	the	heavy-labeled	precursor	ions.	Because	this	particular	peptide	was	only	identified	
by Mascot no XPRESS ratio was calculated. Instead, the raw data were used to estimate the 
peptide	abundance	ratio.	Therefore	with	MSight	the	elution	profiles	of	the	respective	ions	were	
reconstructed and displayed in a 3D diagram (Fig. 3.20b, right). Therein, time was taken into 
account	 as	 an	 additional	 parameter,	 showing	 precise	 co-elution	 and	 confirming	 reduced	
signal	 intensities	for	the	heavy	form.	The	protein	 identification	as	well	as	the	quantification	of	
N-copine by MS was convincing, at least for peptides of the C-terminal side (see below). Four 
peptides	were	 identified	with	high	discriminant	scores	and	a	peptide	ratio	of	at	 least	0.74	or	
less (Fig. 3.20c). The accepted protein abundance ratio for N-copine in S2 was 0.71 and in P2 
it was 0.83. The primary structure of N-copine is composed of 557 amino acids. In silico trypsin 
digestion resulted in 12 theoretical Cys-containing peptides of which 5 are located to the C-
terminal half of the protein and 7 to the N-terminal half. Assuming that peptides longer than 25 
amino	acids	are	hardly	identified	by	MS,	four	out	of	five	potential	peptides	from	the	C-terminal	
half of the protein were detected, while none out of four from the N-terminal half remained 
undetected.	A	sequence	alignment	of	the	four	identified	peptides	with	the	eight	members	of	
the	copine	 family	ensured	 the	univocal	 identification	of	peptides	 from	N-copine	by	MS	 (Fig.	
3.20d). Even the highly homologous very N-terminal peptide starting at amino acid 521 could 
unambiguously be assigned to N-copine because of the monoisotopic mass difference of the 
two is 27 Da (CVLAEVPR vs. CVLAEVPK). This mass difference can easily be discriminated by FT-
ICR MS. Taken together the convincing MS-data and the fact that N-copine may be involved in 
synaptic plasticity led us to the decision to further investigate the expression level. Consequently 
Western	blot	analysis	was	performed	to	verify	the	regulatory	changes	in	N-copine	expression	
(Fig. 3.21, c). The same quantities of protein extracts from wild-type and transgene S2 and P2 
were	immunoblotted	with	antibodies	against	N-terminal	half	of	N-copine,	neurofilament	160	(NF	
160) and β-actin. Both NF160 and β-actin are regarded as housekeeping proteins in neuronal 
tissue and are unlikely to be affected by neurotrypsin overexpression. Therefore, they were used 
as loading controls for normalization. No change was detected for S2 whereas for P2 a down 
regulation	of	10%	was	verified.	The	regulatory	changes	were	significant	with	the	normalization	
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to both NF160 and β-actin (Fig. 3.21b, d).
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Figure 3.19     Protein identification and relative quantification of N-copine (copine VI) in the hippocampus by 
mass spectrometry.
(A) Mascot search result of the CID spectrum from a doubly charged parent ion with mass-to-charge (m/z) ratio of 
1169.15 found in soluble fraction S2. The CID series of the y-type ions is nearly complete. Furthermore, all of the y-type 
ions ending with a proline (y(5), y(10), y(17)) are highly abundant, while the corresponding b-ions (b(3), b(10), b(15)) 
are completely absent. Notably, the abundance of y(10) is low. This is due to the fact that N-terminal of the proline is a 
glycine, whose fragmentation on the C-terminal side is often reduced. Thus, even though the bond N-terminal to proline 
is particularly labile to CID, the cleavage N-terminal to glycine was favored, resulting in a high abundance of y(11). (B) 
Full MS scan at RT: 65.58 of the ICAT-pair of which the parent ion was selected for tandem MS denotes the ICAT light 
labeled form. A typical isotopic distribution of a doubly charged ion with m/z  > 1000 whose second peak, bearing one 
isotope is most abundant. The peak intensity for the light form is significantly higher than the one for the heavy form (left). 
The three dimensional single-ion chromatogram (SIC) displays the higher abundance of the light form. Precise co-elution 
of the light and heavy variant of an ICAT-pair is shown (right). (C) Summary table for all four identified peptides allocated 
to N-copine. The first column of the table shows the amino acid sequence of identified peptides. In the second and third 
column the frequency of identification with either Mascot or SEQUEST search engines is listed. The fourth and fifth col-
umn indicate the peptide abundance ratio calculated either by XPRESS software or deduced from SICs of the raw data. 
The last column reflects the amino acid positions of the petpide identification in the N-copine primary sequence. The last 
row in the table is the summary for N-copine identification and quantification. The abundance ratio of each peptide is 
graphically shown in a histogram (below). Wild-type (wt) is set to 1. The peptides are all downregulated in transgenic by 
at least a factor of 1.35. (D) Sequence alignment of the peptides allocated to N-copine with homologous peptides from 
other members of the copine family make a unique identification of copine VI clear. Indeed, all of the identified peptides 
unambiguously affiliate to N-copine. Their amino acid composition varies in such a way that the mass differences can be 
distinguished in mass spectrometry. Astonishingly, the peptides all lay on the C-terminal halft of the N-copine.
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3.6.2 Glutamine synthetase is responsible for the conversion of L-glutamate
Despite GS being almost exclusively expressed by glial cells and astrocytes it represents an 
interesting candidate for a downstream effector of neurotrypsin overexpression in synaptosomes 
and the hippocampus. It’s important function in converting the primary excitatory neurotransmitter 
L-glutamate to glutamine as well as the possible role of GS in hippocampal epilepsy brings it 
under the spotlight.
In	S2	GS	was	identified	by	6	different	peptides	all	with	high	reliability.	With	Mascot	search	engine	
five	different	peptides	were	identified	and	with	SEQUEST	only	three	were	(Fig.	3.22c).	Most	CID	
spectra	 showed	a	 very	 high	coverage	of	 fragmentation	peak	 identification	with	an	almost	
complete series of y-type ions (Fig. 3.22a). Typically, the y-type ion ending with a proline is 
most intensive because the N-terminal peptide bond of proline is particularly labile to CID. The 
extended survey scan of the corresponding ICAT-pair of which the heavy variant was selected 
for MS/MS (Fig. 3.22a) indicated that the heavy labeled peptide has a higher peak intensity as 
compared to the light variant (Fig. 3.22b, left). To estimate the abundance ratio of this ICAT-pair 
the SIC was reconstructed by MSight. It clearly demonstrates that the heavy peptide was more 
abundant	than	the	light	peptide	by	a	factor	of	1.53	(Fig.	3.22b,	right).	This	finding	was	consistent	
among all peptides allocated to GS, since peptide abundance ratios lay between 1.17 and 
1.54 (Fig. 3.22c, d). Thus, the protein abundance ratio in S2 was 1.40. In P2, where GS was also 
detected	the	ratio	was	reversed,	namely	0.85.	Verification	by	immunoblot	analysis	of	the	data	
from the ICAT screen revealed only minor aberration in GS expression comparing transgenic 
with wild-type (Fig. 3.22e). In M494 neurotrypsin-overexpressing mouse line no change of GS 
expression was found in P2 whereas in S2 a 10% down regulation was found. This is directly 
opposite to what was predicted by the ICAT. On the other hand, testing M491S a down regulation 
of	0.83	in	P2	was	verified	while	the	regulation	in	S2	was	still	not	reproducible.	In	the	control	mouse	
line S/A785 no change was detected in P2 but in S2 the diminution of 10% was similar to M494.
Figure 3.20     Verification of N-copine expression in the hippocampus.
(A) N-copine was immunoblotted and quantified (N=3). Equal amounts of protein extracts from S2 were loaded. Two reference 
proteins (neurofilament NF 160 and β-actin) were used for normalization. (B) No significant downregulation was found in S2. 
(C) Equal amounts of protein extracts from P2 were loaded. The two reference proteins NF 160 and β-actin were used for 
normalization. (D) In P2 a significant downregulation by 10% was found (asterisk) with two-tailed p-value < 0.0001.
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Figure 3.21    Protein identification and relative quantification of glutamine synthetase in the hippocampus by 
mass spectrometry.
(A) The Mascot search result of the CID spectrum from hippocampus soluble fraction S2 of doubly charged parent ion with 
mass-to-charge (m/z) ratio: 1054.52. The fragmentation of N-terminal peptide bonds, resulting in a nearly complete series 
of y-type ions. The y-type ion ending with proline (y(6)) has the most intensive peak while the corresponding b-ion (b(11)) 
is completely absent. (B) Full MS scan of the ICAT-pair, of which the parent ion selected for tandem MS denotes the ICAT 
heavy labeled form. A typical isotopic distribution of a doubly charged ion with m/z  > 1000, where the second peak bear-
ing one isotope is most abundant. The peak intensity for the heavy form is significantly higher than the one for the light 
form (left). The 3D single-ion chromatogram (SIC) confirms a higher abundance for the heavy form. Precise co-elution of 
the light and heavy variant of the parent ions is shown (right). (C) Summary table of all six peptides allocated to glutamine 
synthetase (GS). The first column of the table shows the amino acid sequence of peptide identifications. In the second 
and third columns the frequency of peptide identifications with either Mascot or SEQUEST search engines is listed. The 
fourth and fifth columns indicate the peptide abundance ratio either calculated with XPRESS software or deduced from 
SICs of the raw data. The last column reflects the positions of the amino acids for each peptide of GS. Considering the fact 
that the primary structure of GS is composed of 373 amino acids it is evident that the identified peptides cover fragments 
evenly disrtibuted over the complete amino acid sequence. The last row in the table is a summary for GS identification 
and quantification. Totally 6 different peptides were allocated, 5 of them were identified by Mascot and 3 by SEQUEST. 
Using XPRESS software a computed protein abundance ratio of 1 : 1.39 was calculated. The ratio in P2 was 1 : 0.85. (D) 
The peptide abundance ratios in S2 shown in a histogram. Wild-type (wt) is set to 1. All peptides are equally upregulated 
in transgenic by at least a factor of 1.17. (E) Statistical analysis from Western blot analysis of S2 and P2 fractions from 
different mouse lines. Antibodies against GS and β-actin were used to quantify the regulatory changes. In P2 no significant 
change was confirmed, whereas in M491S mice a downregulation of 0.83 is shown. In S2 no change is detected.
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3.6.3	 Neuron	specific	alpha3	Na+/K+-ATPase	is	essential	for	the	excitability	of	
nerve cells
The alpha 3NKA isoform is exclusively expressed in neurons. Mutations in NKA alpha isoforms 
have been associated with multiple disorders involving rapid-onset of dystonia, Parkinsonism, 
and familial hemiplegic migraine type-2. A reduction in NKA content leads to depression and 
AD. Moreover, mice heterozygous for the alpha3NKA displayed spatial learning and memory 
deficits	as	well	as	a	40%	reduction	in	hippocampal	NMDA	receptor	expression.	Most	interestingly,	
alpha3NKA	potentially	constitutes	a	neuronal	receptor	for	agrin.	Alpha3NKA	was	identified	in	S2	
as well as in P2 by mass spectrometry. The CID spectra of the peptides allocated to alpha3NKA 
had	high	discriminant	score	values,	reflected	with	almost	complete	coverage	of	fragment	peak	
identification	(Fig.	3.23a).	SICs	of	the	peptides	identified	by	Mascot	were	reconstructed	with	raw	
data	(Fig.	3.23b)	and	SICs	identified	by	SEQUEST	were	computed	with	XPRESS.	Peptide	ratios	from	
S2 (Fig. 3.23c1) and from P2 (Fig. 3.23c2) were taken together and displayed in bar diagrams. In 
S2	alpha3NKA	was	identified	by	eight	different	peptides,	two	of	which	showed	a	ratio	of	nearly	
one. All others had a reduced abundance ratio of at least 1: 0.75. In P2 even twelve peptides 
were allocated to alpha3NKA. Here, only one is an outlier, which of all things has one missed 
cleavage site. Astonishingly, almost every Cys-containing peptide from the N-terminal side of 
alpha3NKA	was	found	(Fig.	3.23d).	Only	two	unidentified	Cys-containing	peptides	(red)	were	
located N-terminally of the middle of the protein, whereas at least four were missing from the C-
terminal	half	(NOTE:	many	unidentified	peptides	are	composed	of	more	than	20	amino	acids).	
On	the	other	hand	only	two	identified	peptides	were	localized	C-terminally.	The	two	peptides	
highlighted	in	blue	were	identified	and	quantified	in	S2	as	well	as	in	P2,	but	unexpectedly	they	
only appeared changed in P2. The peptide further downstream (LIICEQCQR) (green) was down 
regulated again. Despite this discrepancy it seemed that alpha3NKA was down regulated in 
transgenic samples and alpha1NKA was not (data not shown). Therefore the two proteins were 
examined	further	by	Western	blot	quantification.
First, it was shown that the alpha3NKA was detectable in all but the S2 fraction of the 
hippocampus (Fig. 3.24a). Thus, the following experiments were performed with the P2 fraction. 
Second, quantitative immunoblot assays for alpha3- and alpha1NKA from different mouse 
lines were performed (Fig. 3.24b). Three independent preparations of wild-type and transgenic 
samples	were	tested.	None	of	them	showed	a	significant	change	in	NKA	expression	neither	in	
neurotrypsin-overexpressing animals nor in KO. This is in contradiction to the MS-data, suggesting 
a down regulation of more than 25% in transgenic S2 and 20% in P2.
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Figure 3.22     Protein identification and relative quantification of α3 Na+/K+-ATPase in the hippocampus by mass 
spectrometry.
(A) The Mascot search results of CID spectra from doubly charged parent ions with mass-to-charge (m/z) ratios of 915.47 
in soluble fraction S2 and in pelletous fraction P2 of 861.41. In both instances the heavy labeled peptide was selected for 
MS/MS. The fragmentation at the N-terminal peptide bonds, resulting in y-type ions, is in both samples nearly complete. 
Prolines are either absent in the sequence (A1), or so close to the N-terminus that fragmentation is rare (y(12)). The y(5) 
ion ending with a proline is clearly present (A2). The corresponding b-type ion (b(9)) is not detected. (B) Single-ion chro-
matograms (SIC) of the parent ions identified in (A) showing precise co-elution of light and heavy labeled peptides. The 
maximum peak intensity in S2 for light is 7 x 105 and for the heavy peptide it is 4.5 x 105 (B1). The ICAT-pair identified 
in P2 has a SIC with maximal peak intensity of 1.2 x 107 for light and of 9 x 106 for heavy (B2), resulting in a decreased 
abundance ratio for the transgenic samples. In fact the ratio of KYNTDCVQGLTHSK is 1 : 0.63 and the ratio of SPDCTHD-
NPLETR is 1 : 0.79. (C) The abundance ratios of all peptides allocated to α3Na+/K+-ATPase (α3NKA) are displayed in his-
tograms for S2 (C1) and P2 (C2). Strikingly, in S2 most of the ratios are between 0.5 and 0.75 except for the two peptides 
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CIELSSGSVK and CATILLQGK, which have a ratio of nearly 1 : 1. The average ratio though, is 0.73 (C1). In P2, totally twelve 
different peptides were allocated to α3NKA with an average ratio of 0.83. Three peptides have one missed cleavage (*), among 
which one is an outlier (°) showing a peptide ratio of nearly 0.5. (D) Allocation of peptide identifications from S2 and P2 to the 
amino acid sequence of α3NKA (green). Peptides in magenta were found in P2 only. The two peptides with a ratio of 1 : 1 in 
S2 lie in the middle of the sequence (blue). Notably, there are primarily peptides from the N-terminal half of the protein that 
were found in the proteomic profiling. The missing Cys-containing peptides (red) from the C-terminus are often very long (> 20 
amino acids) and therefore, not very likely being identified by mass spectrometry.
Figure 3.23     Verification of α3 Na+/K+-ATPase expression in different mouse lines.
(A) Immunoblotting of α3 Na+/K+-ATPase (α3NKA), showing an equal distribution in all hippocampus fractions apart from solu-
ble fraction S2, where it is absent (upper panel). β-actin is shown as a loading control (lower panel). (B) To confirm the data from 
ICAT-MS, suggesting a downregulation of α3NKA by 20% but no change in the expression of α1 Na+/K+-ATPase (α1NKA) in 
the pelletous fraction P2 of transgenic mice, α3NKA and α1NKA were immunoblotted and quantified. Equal amounts of protein 
extract from wild-type (wt) and neurotrypsin overexpressing mice M494 (tg), as well as S/A 785 (tg) were tested. β-actin was 
used for normalization. Signal intensities were measured by spot densitometry and relative expression levels were calculated. 
(C) Histogram showing the expression levels of α1NKA and α3NKA from M494, M491S, S/A 785 and neurotrypsin knock-out 
(NTKO) mice. None of them showed significant changes either in α3NKA or α1NKA expression. Wt was set to 100.
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3.6.4	 Differential	protein	expression	of	various	other	proteins
The	 list	 of	 protein	 identifications	with	 deviating	 abundance	 ratios	 comparing	wild-type	 and	
transgenic samples is by all means manifold and revealing. Therefore, other proteins were tested 
in	order	to	verify	the	findings	by	the	ICAT	method	(Fig.	3.25).	One	verification	was	achieved	with	
EAAT2.	In	the	ICAT	P2	it	was	down	regulated	by	25%.	Similarly	it	was	reduced	by	Western	blot	
quantification.	Furthermore,	EAAT2	was	slightly	up	regulated	in	NTKO	and	not	regulated	at	all	in	
S/A785.	For	VDAC1	as	well,	the	data	from	ICAT	were	confirmed	by	Western	blot.	A	decreased	
expression of 10% was found by immunoblot assay in M494 and M491S, while the expression 
was not changed either in NTKO or S/A 785. Likewise the decreased expression of α-CaMK 
II	by	15	–	30%	found	with	 ICAT	was	confirmed	in	the	hippocampus	of	M494	transgenic	mice,	
although the reduction was only 5%. Interestingly, the autophosphorylated form, phospho-α-
CaMK II was enriched by 10% in transgenic P2 fraction. This analysis provides more evidence 
that in the neurotrypsin-overexpressing mice differentially expressed proteins were present but 
the aberrations were little and versatile and thus challenging to prove.
Figure 3.24     Differential protein expression in the hippocampus of neurotrypsin overexpressing mice.
Various proteins with differential regulation found in the ICAT experiments were tested by immunoblot analysis. The immuno-
blots were carried out for pelletous fractions P2 comparing wild-type (wt) and transgenic (tg) samples. ICAT-MS suggested a 
downregulation of excitatory amino acid transporter 2 (EAAT2) in P2 of transgenic mice and an upregulation in the synapto-
somes of adult transgenic mice. By immunoblot quantification the reduction was confirmed in P2 of M494 .In NTKO, EAAT2 
was slightly increased. In the control line S/A785 the transporter protein is basically not regulated. RhoGDP-dissociation 
inhibitor 1 (Rho GDI 1) was downregulated in the ICAT of synaptosomes from P20 mice, but was slightly increased in P2 of 
both, M494 and NTKO by immunoblot assay. The ratio for voltage-dependent anion-selective channel protein 1 (VDAC 1) in 
ICAT-MS was 0.70 in P2 and was also reduced by immunoblot quantification in M494 and M491S, whereas in the NTKO and 
S/A785 its expression was not changed. Calcium/calmodulin-dependent protein kinase II alpha (α-CaMK II), downregulated in 
ICAT P2 by 0.70, is slightly reduced in M494. The autophosphorylated form (Thr-286), p-CaMK II α, is upregulated in M494.
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4. Discussion
The	results	of	this	report	support	the	idea	that	neurotrypsin	is	a	brain-specific	serine	peptidase.	
In synaptosomes and the hippocampus neurotrypsin intrinsically recognizes the proteoglycan 
agrin and mediates cleavage at two positions. The catalytic activity on agrin was elevated in 
neurotrypsin-overexpressing mice and completely diminished in neurotrypsin KO mice. Both the 
22-kDa C-terminal LG3 domain and the 90-kDa agrin intermediate fragments were enriched in 
the S2 fractions of hippocampal and synaptosomal preparations. However, the fate of the agrin 
cleavage products is still vague. In transgenic mice, changes in protein expression of molecules 
interacting either directly or indirectly with neurotrypsin are subtle. In fact, alterations in protein 
abundance	of	more	than	1.5-fold	were	scarcely	identified.	The	proteomic	profiling	implies	that	in	
the transgenic mice cellular processes, such as synaptic plasticity, cytoskeleton reorganization, 
and exo- and endocytosis are affected, since the majority of the changed proteins are allocated 
to	 these	 functional	units.	 Taken	 together	our	 findings	 suggest	 that	neurotrypsin	 is	 involved	 in	
synaptic transmission and can regulate synapse structure and activity.
4.1 Neurotrypsin – Agrin interaction in synaptosomes and in the 
hippocampus
Synaptosomes are isolated synapses produced by subcellular fractionation of brain tissue. 
Morphologically they consist of the complete presynaptic terminal, including mitochondria, 
synaptic vesicles and portions of the postsynaptic density. Recent proteomic analysis showed 
that on the molecular level synaptosomes are enriched in proteins associated with synaptic 
function, including synaptic vesicle exocytosis for neurotransmitter release, vesicle endocytosis 
for recycling, as well as postsynaptic receptors and scaffolding proteins from the PSD. Moreover, 
a large number of soluble and membrane-bound molecules serving functions in synaptic signal 
transduction	 and	metabolism	were	detected	 (Schrimpf	 et	 al.,	 2005;	Witzmann	et	 al.,	 2005).	
Western	blot	analysis	of	synaptosomes	indicated	that	neurotrypsin	is	not	particularly	enriched	in	
synapses.	The	neurotrypsin	specific	substrate	agrin	however,	at	least	the	most	susceptible	form	to	
neurotrypsin cleavage, was clearly accumulated in wild-type synaptosomes. On the other hand, 
the agrin cleavage products were almost undetectable in wild-type synaptosomes indicating 
that they are released from the synaptic cleft. They might either diffuse out of the synaptic 
junction or be internalized, be it by the pre- or postsynapse, where they might elicit cellular 
signaling. Furthermore, in transgenic synaptosomes the cleavage products are well detectable. 
This speaks in favor of the idea that due to the extensive production of agrin fragments, they 
aggregate in the synaptic cleft and can therefore not be appropriately removed from there. 
Thus, to shed light on the proteomic changes in neurotrypsin-overexpressing mice, performing 
a large-scale proteomic approach was tempting. Endogenous neurotrypsin expression as well 
as the activity of the Thy-1.2 expression cassette decline to baseline after postnatal day 15 
(P15).	Therefore	quantitative	proteomic	profiling	of	synaptosomes	from	P20	and	P40	mice	was	
undertaken in order to identify long-term proteomic changes in transgenic animals. Regarding 
the	accurately	defined	spatial	distribution	of	neurotrypsin	expression	(Wolfer	et	al.,	2001)	and	the	
fact that synaptosomes are usually isolated from whole mouse brains or at least from large brain 
regions	such	as	the	cortex,	provoked	us	to	additionally	target	a	specific	area	of	the	brain	that	
is involved in processes such as storage of memory and learning. Moreover, we wanted to seek 
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changes	that	are	temporally	and	spatially	related	to	endogenous	neurotrypsin	function.	With	
samples from younger animals we intended to track down short-term effects of overexpressed 
neurotrypsin on differential protein expression. Therefore in a second approach, hippocampi of 
P10 mice were dissected and subjected to subcellular fractionation and subsequent proteomic 
analysis. The hippocampus was homogenized and fractionated to reduce the complexity of 
the samples. To classify the two fractions, S2 and P2, which were generated as a result of the 
differential centrifugation, were grouped according to their composition of marker proteins. 
Accordingly, S2 is regarded as the ‘soluble’ fraction, consisting mainly of cytosolic proteins 
including dendritic marker MAP2, NF-160, Golgi-marker β-COP and Grp78. P2 on the other hand 
is particularly delineated by ‘membranous’ or ‘synaptosome-like’ fraction. It mainly contains 
postsynaptic integral membrane protein GluR 2/3, scaffolding and membrane-associated 
PSD-95, and presynaptic vesicle glycoprotein synaptophysin. P2 also comprises ER vesicles 
demonstrated by the presence of Grp78. β-COP and MAP2 were nearly absent, implying that 
light Golgi vesicles and proteins from dendrites were exclusively present in S2. Moreover, full-length 
neurotrypsin and the protease domain were heavily enriched in P2. Similar to the synaptosomes 
the most amenable agrin full-length form to neurotrypsin cleavage was strongest in wild-type 
P2. Both cleavage products were more pronounced in S2. For all these reasons, we postulate 
that agrin processing by neurotrypsin also occurs in the hippocampus. Consequently, in order to 
identify neurotrypsin-dependent changes four different ICAT screens were performed: two with 
synaptosomes (P20 and P40) and two with P10 hippocampal fractions, S2 and P2. The samples 
were treated similarly. The major differences were imposed during mass spectrometry and 
relative	quantification.	While	for	the	synaptosomes	a	classical	3D	ion	trap	mass	spectrometer	
was used and the computation of the abundance ratios was performed with ASAPRatio, for 
the hippocampal fractions a highly sophisticated mass spectrometer combining the most 
advanced ion trap and Fourier Transform Ion Cyclotron Resonance technologies into a single 
instrument was used. Furthermore, the protein ratios were calculated using XPRESS software. 
These	adaptations	theoretically	bring	about	more	accurate	protein	identifications.
4.2	 Quantitative	proteomic	profiling	of	a	transgenic	mouse	line
Quantitative mass spectrometry using stable isotope-labeled tagging reagents such as ICAT 
has	emerged	as	a	powerful	 tool	 for	 the	 identification	and	 relative	quantification	of	proteins	
in current proteomic studies. In the past years a variety of large-scale quantitative proteomic 
profiles	have	been	published	using	ICAT	technology.	It	was	(Han	et	al.,	2001),	who	first	presented	
an	 approach	 to	 the	 systematic	 identification	 and	 quantification	 of	 proteins	 contained	 in	
subcellular	fractions.	They	identified	and	determined	the	abundance	ratios	of	491	microsomal	
proteins of naïve and in vitro - differentiated human myeloid leukemia (HL-60) cells. For most 
identified	proteins,	the	abundance	did	not	change	significantly.	Nevertheless,	they	found	that	
some	of	the	membrane-associated	signal	transduction	proteins	and	enzymes	showed	significant	
changes in their ratios with up to 20-fold variation. An ensuing report described the differences 
in protein expression comparing the PSDs isolated from rat forebrain and cerebellum (Cheng et 
al.,	2006).	PSD	protein	profiles	were	determined	using	the	cleavable	ICAT	strategy	and	LC-MS/
MS.	A	total	of	296	proteins	were	identified	and	quantified	with	43	proteins	exhibiting	statistically	
significant	 abundance	 change	 (with	 ratios	 >	 6-fold)	 between	 forebrain	 and	 cerebellum,	
indicating marked molecular heterogeneity of PSDs between different brain regions. 
In	this	work,	the	first	quantitative	proteomic	profiling	of	a	transgenic	mouse	line	is	presented.	We	
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isolated synaptosomes from whole brain and prepared two subcellular fractions of the isolated 
hippocampus.	Protein	profiles	were	determined	using	the	cleavable	ICAT	strategy	and	LC-MS/
MS.	Altogether,	761	synaptosomal	proteins	were	identified	of	which	66	had	an	abundance	ratio	
higher	than	1.2	in	P20	and	81	in	P40	animals.	In	the	hippocampus	1382	protein	identifications	
were	made	in	S2,	and	883	proteins	 in	P2.	365	overlapping	proteins	were	 identified	in	both	S2	
and P2 (Fig. 4.1). Totally 165 proteins were changed in S2 and P2. Data analysis revealed highly 
reliable	protein	identifications	and	quantification.	Firstly,	the	elution	profiles	of	the	biochemical	
fractionation using cation exchange chromatography indicated highly reproducible complexity 
reduction of resembling samples. Secondly, with a minimal probability of ≥ 0.95 that proteins are 
present in the sample, a  maximum of 0.5% incorrect protein assignments were estimated for 
all	samples	analyzed.	Yet	hundreds	of	protein	identifications	with	high	probability	scores	were	
quantitated.	Thirdly,	abundance	ratios	were	accurately	quantified	since	chromatographic	co-
elution	profiles	of	ICAT-labeled	peptides	were	observed.	Fourthly,	2D	reproduction	of	LC-MS/MS	
runs revealed that the samples are almost devoid of contaminating compounds and that the 
separation	of	peptides	eluting	from	the	RP-column	was	excellent	and	reproductive.	And	finally,	
computational	 analysis	 of	 the	peptide	 identifications	 of	 one	experiment	 indicated	a	 nearly	
complete trypsin digestion of the proteins; only in about 2% of all proteins one missed cleavage 
site was found. Furthermore, barely 2.5% of all peptides were singly charged, showing that 
the ionization during ESI was appropriate. The average delta error mass of the observed and 
calculated ions was within the range of the mass accuracy of the mass analyzer. Furthermore, 
the distribution of peptide length peaked at 13 amino acids, which is expected and the amino 
acid frequency suggested an accumulation of cysteines being an indicator for an enrichment 
of Cys-containing peptides. Taken together, many different proteins were accurately 
identified	 from	 synaptosomes	 and	 the	 hippocampus.	 Comparing	 the	 protein	 abundance	
ratios of wild-type and transgenic mice the changes are astonishingly subtle. Interestingly, 
neither	neurotrypsin	nor	agrin	could	be	 identified.	The	reason	for	 it	 is	as	yet	unclear.	Possibly,	
the traceable amounts of neurotrypsin even from the overexpressing mice were already lost 
during sample preparation. From what is known in our group, it is an extremely sticky molecule 
(unpublished	data).	Concerning	 the	missing	 identification	of	agrin	no	obvious	explanation	 is	
given. However, at the time when the database search was performed, entries for mouse mini-
agrin and the N-terminal NtA and TM domains were recorded only. Nevertheless, database 
entries for rat and human full-length agrin, were present and extremely homologous to the 
recently published mouse sequence. Therefore, the majority of the agrin peptides could still be 
assigned. Furthermore, both neurotrypsin and agrin had served as meaningful internal standards 
for	quantification.	Regarding	neurotrypsin	because	of	its	overexpression	in	the	transgenic	mice	
leading to a several fold increase in neurotrypsin expression compared to wild-type samples. 
Regarding agrin due to its increased processing by neurotrypsin and subsequent redistribution 
of the emerging fragments, which may lead to different quantities comparing wild-type and 
transgenic fractions, such as S2 or P2.
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4.3 Multifaceted neurotrypsin-dependent changes in protein 
expression
The	classification	of	all	protein	 identifications	 into	GO	terms	convincingly	 reflected	the	major	
classes of cellular compartments and molecular functions describing each subcellular fraction. 
A	 selective	 attribution	 of	 proteins	 to	 specific	 categories	 was	 observed.	 The	 fact	 that	 the	
‘membrane’ and the ‘mitochondria’ fractions were enriched in P2 as well as in the synaptosomes 
is absolutely expected. Evidentially the GO terms ‘transporter activity’, ‘structural component’, 
and	‘signal	transduction’	accounted	for	most	of	the	protein	identifications	from	P2.	And,	many	
proteins from S2 were assigned to ‘cytosol’, ‘enzyme regulator’, ‘structural constituent’ and 
‘nucleus’, from which proteins can translocate to the cytoplasma.
GO	 annotation	 of	 regulated	 proteins	 showed	 that,	 though	 moderate,	 specific	 biological	
processes are affected by neurotrypsin overexpression. Remarkably a lot of proteins with changed 
abundance ratios were involved in neuronal signal transduction mechanisms. In particular 
many of the proteins are involved in SNARE complex assembly or disassembly. Crucial factors 
for the regulation of SNARE complex formation and exocytosis are NSF proteins, SNAPs, Munc18-
1, complexins, and syntaxins all of which are down regulated in the transgenic S2 fraction of the 
hippocampus by 30 – 40%. Interestingly, NSF ATPase and Munc18-1 were additionally found in P2 
where	they	were	up	regulated	by	10	–	20%.	We	therefore	speculate	that	a	compartmentalization	
of proteins involved in the regulation of the fusion apparatus is taking place. Conclusively, an 
accumulation of SNARE fusion proteins associated to the plasma membrane possibly results 
in a perturbed exocytosis of neurotransmitter and a deregulated synaptic vesicle recycling. 
Furthermore, a reduced level of adequate protein supply for membrane docking and fusion 
might inhibit normal neuronal exocytosis. Changed expression levels were also found for dynamin 
1 and PACSIN 2 (down regulated by 20%), and amphiphysin 2 (up regulated by 40 – 50%), all of 
which	are	involved	in	endocytosis.	This	provides	another	hint	for	a	modified	vesicle	turnover.	Yet	
another	indication	for	a	disruption	of	synaptic	vesicle	trafficking	is	the	fact	that	small	GTPases,	
GDIs, and GAPs are affected. For instance we found more Rab3C protein in synaptosomes and 
hippocampal S2 of transgenic mice, while Rab GDI 1 and Rab3-GAP 1 levels were reduced, 
raising the possibility that in the neurotrypsin-overexpressing mouse Rab3C is preferentially found 
Figure 4.1     Intersection of protein identification comparing S2 and P2.
A total of 1593 hippocampal protein were identified and quantified using the ICAT strategy. 1382 proteins were found in S2 
and 887 in P2. Only 365 proteins were present in both fractions.
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in the GTP-bound, therefore active, form. Accumulating evidence suggests that Rab3C plays a 
key role in neurotransmitter release and synaptic plasticity. On top of that a mutation in the GDI1 
gene, which reduces binding and recycling of Rab3C, was linked to X-linked mental retardation 
associated with epileptic seizure (D’Adamo et al., 1998). Not only the exo- and endocytotic 
machinery was apparently affected, but also components of the postsynaptic density (PSD) 
like GluR3, SAP102 and SAPAP 4 were up regulated in transgenic by > 30% and α-CaMK II was 
reduced by up to 30%. Metabotropic GluR3 is a group II mGluR, which prevents the formation of 
cAMP, by activating G proteins that inhibit the enzyme adenylyl cyclase that forms cAMP from 
ATP (Chu and Hablitz, 2000). Found on both pre- and postsynaptic membranes, these receptors 
are involved in presynaptic inhibition and do not appear to affect postsynaptic membrane 
potentials by themselves (Endoh, 2004). Glutamate receptors in groups II and III reduce the 
activity of postsynaptic potentials, both excitatory and inhibitory, in the cortex. SAP102 couples 
the	NMDAR	to	specific	plasticity	pathways	and	learning	strategies	(Cuthbert	et	al.,	2007).	Since	
SAP102	was	also	more	abundant	in	transgenic	S2,	NMDAR	trafficking	might	indirectly	be	linked	
to neurotrypsin activity. In addition, mutations in the SAP102 gene cause nonsyndromic X-linked 
mental retardation (Tarpey et al., 2004). In conjunction with neurotransmitter turnover two 
important	molecules	were	found	in	the	proteomic	profiling,	both	of	which	are	primarily	found	
in astrocytes and for both the abundance was reduced in transgenic samples. Firstly, EAAT2 
transmembrane protein clears most of the glutamate from the synaptic cleft. It was down 
regulated by 25%. Acting as a symporter by cotransporting sodium with L-glutamate and also 
L- and D-aspartate, EAAT2 is essential for the termination of the postsynaptic action. Secondly, 
although	the	quantitative	differences	could	only	partially	be	confirmed,	it	is	glutamine	synthetase	
that catalyzes the conversion from glutamate, transported intracellularly by EAAT2, to glutamine 
under the consumption of ATP and ammonia. GS serves for two functions in parallel: one is to 
eliminate the glutamate and provide the glutamine, which can then diffuse from astrocytes 
to neurons to supply the neurotransmitter pool. The other function is to detoxify ammonia. On 
the one hand glutamate accumulates in the synaptic cleft and residual glutamate that is still 
removed	is	not	converted	into	glutamine	efficiently	enough.	Thus,	reduced	levels	of	EAAT2	and	
GS can consequently lead to epileptic seizure and excitotoxic cell death. On the other hand 
there is an acute intoxication with ammonia going on leading to rapid cell death. 
Nevertheless, critical integration points of multiple signaling pathways, also considered as 
molecular switches, such as PKC, MAPK and PAK proteins were also affected. Two isozymes 
of	 the	 PKC	 family	were	 identified	and	both	of	 them	were	down	 regulated	by	 roughly	 40%.	
PKCα, which belongs to the subfamily of the ‘conventional’ PKC, requiring Ca2+, DAG, and a 
phospholipid, and PKCε, a ‘novel’ PKC that is activated without Ca2+. Upon activation, PKCs 
are translocated to the plasma membrane by RACK proteins (membrane-bound receptor for 
activated protein kinase C proteins). PKCs are known for their long-term activation: they remain 
activated after the original activation signal until the Ca2+-wave is gone. This is presumably 
achieved by the production of diacylglycerol from phosphatidylcholine by phospholipase. Their 
substrates are myristoylated alanine-rich C-kinase substrate (MARCKS) proteins, MAP kinase, 
transcription factor inhibitor IκB, calpain, and the epidermal growth factor receptor. 
MAPK1 is a widely expressed protein kinase signaling molecule whose abundance was increased 
by 20 – 40% in samples of transgenic animals. MAPKs are involved in functions including the 
regulation of meiosis, mitosis, and postmitotic functions in differentiated cells. Many different 
stimuli, including growth factors, cytokines, virus infection, ligands for heterotrimeric G protein-
coupled receptors, and carcinogens, activate the MAPK pathway. In the MAPK pathway, 
Ras activates c-Raf, followed by MAPK/ERK kinase (MEK) and then MAPK1/2 (Itoh et al., 1993). 
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Phosphorylation of MAPKs leads to the activation of their kinase activity. Concerning the role 
of MAPKs in the hippocampus: they have recently been directly implicated in human learning 
through studies of a human mental retardation syndrome. A role of MAPKs in stabilizing structural 
changes	in	dendritic	spines	has	been	defined	as	well.	A	crucial	role	for	MAPKs	in	the	regulation	
of	local	dendritic	protein	synthesis	is	emerging.	And	finally,	the	importance	of	MAPK	interactions	
with scaffolding and structural proteins at the synapse is increasingly apparent (Sweatt, 2004). 
Also the protein level of PAK1 was elevated in synaptosomes and the hippocampus by 30 – 55%. 
PAK is a serine-threonine kinase that binds to and is activated by Rho family GTPases. PAK family 
members have an N-terminal kinase domain and a C-terminal p21 Rac and Cdc42-binding 
domain. Both p21-Rac and Cdc42 were up regulated in the P2 fraction of the hippocampus 
as well. The binding of Rho family GTPases results in autophosphorylation and activation of 
the kinase. PAK family members have been shown to play a role in actin polymerization and 
cytoskeletal dynamics (Brown et al., 1996). A primary role for dendritic spine defects was 
strengthened	by	the	recent	identification	of	a	set	of	genes	related	to	mental	retardation.	These	
mental retardation genes represent a cluster of proteins in the postsynaptic pathways regulating 
spine actin assembly and disassembly and spine morphogenesis. One of these proteins is PAK. 
Several other proteins whose expression was changed in transgenic mice were involved in the 
reorganization of the cytoskeleton. Strikingly, most of these were up regulated apart from F-
actin	capping	protein	alpha-2	 that	binds	 to	 the	barbed	end	of	actin	filaments	and	 thereby	
regulate	the	growth	of	the	actin	filament.	The	phenomenon	of	compartmentalization,	which	
was observed for synaptic vesicle proteins, also occurred in other disturbed functional entities 
such	as	cell	adhesion	and	cytoskeletal	rearrangements.	While	neural	cell	adhesion	molecules	
L1, NrCAM, ICAM-5, contactin 1 and others were down regulated in transgenic samples S2, L1 
was more abundant in P2 and contactin 1 was increased in synaptosomes. Basically, this speaks 
in	favor	of	the	fact	that	adhesion,	first	of	all	at	the	synaptic	plasma	membrane,	was	increased.	
Reduced levels of adhesion molecules in S2 however, suggests either that intracellular levels, 
possibly for the molecules that are about to be secreted, were less abundant or that cell 
adhesion elsewhere, e.g. extrasynaptic regions, is weakened. For L1 a cytoplasmic domain 
mutation was found leading to X-linked mental retardation due to impaired neural migration 
and axonal growth (Thelen et al., 2002).
Such systemic changes in the CNS of transgenic mice also require adaptations in metabolic 
pathways involved in the chemical conversion of carbohydrates, fats, and proteins into carbon 
dioxide and water to generate a usable form of energy, e.g. ATP. Consequently, the expression 
level of several proteins involved in the glycolysis, pyruvate oxidation or the tricarboxylic acid 
cycle were changed. From the data obtained by the ICAT screen it is yet too speculative to 
determine whether these individual metabolic reactions are stimulated or suppressed. Further 
experiments determining the metabolic rate would shed light on changes in the energy 
conversion in more detail.
Even though the abundance ratios determined by the ICAT experiment were small as compared 
to some previously published studies (Cheng et al., 2006; Han et al., 2001), there are several other 
publications presenting a similar range of relative abundance changes of proteins comparing 
two samples (Moron et al., 2007; Prokai et al., 2005; Zhang et al., 2005a; Zhang et al., 2005b). 
Likewise,	the	authors	of	these	studies	were	partially	successful	in	validating	the	findings	of	the	
ICAT-MS approach. From Hilgenberg’s study (Hilgenberg et al., 2006) it is known that binding of a 
C-terminal agrin fragment to alpha 3NKA induces Ca2+-influx.	Others	have	shown	that	clustering	
of	agrin	can	induce	filopodia	formation	(Annies	et	al.,	2006).	Based	on	this	and	the	findings	in	
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our study we hypothesize that neurotrypsin cleavage of agrin elicits Ca2+	influx,	possibly	through	
alpha3NKA, thereby activating α-CaMK II and MAPK signaling pathways, which in turn could 
lead to rearrangements of the cytoskeleton. Through this the expression level of Cdc42 , p21-
Rac, PAK1 are also affected.
With	 some	 exceptions	 the	 verification	 of	 our	 candidate	 proteins	 by	 Western	 blot	 analysis	
was	 often	marginal	 but	 sufficient.	 For	 instance	MAPK	 1	 was	 repeatedly	 more	 abundant	 in	
transgenic samples. Similarly, the expression level in P2 of N-copine, EEAT 2, and VDAC 1 was 
well	confirmed.	While	PAK1	and	GS	expression	was	validated	 in	one	mouse	 line	only,	 in	 the	
second line overexpressing neurotrypsin the endorsement failed. Merely the validation of the 
abundance ratios of adenosine kinase and of GS in S2 was contradictory and the amount of 
protein of alpha3NKA and RhoGDI was unchanged in wild-type and transgenic samples. The 
reason	 for	 this	might	 be	due	 to	 unspecific	 antibodies,	 intrinsic	 variation	 of	 the	Western	 blot	
technique from in vivo protein extracts, or false positives from the ICAT screen. However, the 
quantification	of	proteins	extracted	from	animal	tissue	with	differences	of	about	30	–	50%	might	
be	a	critical	undertaking	with	Western	blotting.	Other	reasons	like	the	intramolecular	location	
of the epitope from the antibodies used could lead to misinterpretations. E.g. the N-copine-
specific	antibody	 used	 in	 this	 study	 recognizes	 an	 epitope	 in	 the	N-terminus	 of	 the	protein,	
whereas	in	the	ICAT-MS	regulated	peptide	identifications	were	exclusively	from	the	C-terminal	
end.	Whether	the	abundance	changes	of	 the	C-terminus	were	found	due	to	fragmentation	
of	N-copine	by	neurotrypsin	is	unlikely,	since	no	putative	cleavage	site	was	identified.	The	fact	
is that the epitope of the antibody and the changed peptides do not overlap and therefore 
renders	any	conclusion	about	why	the	confirmation	failed	difficult.
The overall changes in protein abundance ratios comparing wild-type and neurotrypsin-
overexpressing samples were unexpectedly small. Almost no outstanding protein was found 
with a ratio far above 1 : 2, or vice versa. It might well be that neurotrypsin, like other serine 
peptidases such as tPA, has multiple molecular functions in different regions of the brain. On 
account of this we suggest that the effects of the neurotrypsin-dependent changes might 
be diluted out, analyzing e.g. synaptosomes isolated from whole brain. Therefore, the idea 
emerged to focus on the proteome of the hippocampus. But compensatory mechanisms might 
reduce putatively harmful regulatory anomalies in such a way that brings the system back into 
balance. On the other hand already small variations in protein expression levels sometimes 
shut the complex biological system up, resulting in disastrous consequences. For example in 
kainic-acid induced seizure endogenous upregulation of tPA mediates the progression of the 
seizure spreading (Yepes et al., 2002). Moreover, the tPA-plasmin system has been implicated 
in neuronal plasticity and degeneration. Expression of catalytically active tPA is transiently 
induced	in	CA1	pyramidal	neurons	but	its	expression	is	decreased	in	the	mossy	fiber	pathway	
after excitotoxic injury, indicatinig a complex control of tPA protein expression and enzymatic 
activity in the hippocampus (Salles and Strickland, 2002).
Immunohistochemical analysis of AK expression suggested an increase of AK- positive cells 
in cortical layers II, III and V. Adenosine is considered to be responsible for seizure arrest. In 
addition,	deficiencies	within	the	adenosine-based	neuromodulatory	system	may	contribute	to	
epileptogenesis (Boison, 2005). AK is the key enzyme that controls ambient levels of adenosine. 
Since adenosine can suppress seizures, an elevated level of AK might contribute to persistent 
seizure	 that itself results in neuronal cell death. This in turn might lead to the	 catastrophic 
damage	of cortical layer VI, which was observed in neurotrypsin-overexpressing mice. Indeed, 
adolescent transgenic mice suffered from chronic trembling, indicative for epileptogenic 
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seizures (eye-catching observation while handling with transgenic mice). Although, compared 
to	 tPA	 the	 specificity	 of	 neurotrypsin	 is	 probably	more	 confined,	 neurotrypsin	might	 likewise	
promote seizure. In case adequate inhibitors fail to restrain its elevated proteolytic activity that 
had become out of control due to overexpression, a deregulated cascade of proteolytic events 
and subsequent activation of signaling pathways like α-CaMK II and MAPK could possibly result 
in abnormal neuronal activity.
4.4 Pros and Cons of two proteomic approaches to investigate brain 
proteins of a transgenic mice
This	study	 is	 the	first	 large-scale	proteomic	analysis	of	a	transgenic	mouse	 line.	We	could	not	
conclude	that	a	complete	proteome	of	the	subcellular	fractions	was	identified	and	quantified.	
Indeed, a subset of proteins that lack cysteine residues, very low abundance proteins and 
very hydrophobic proteins will not be analyzed using this technique. The advantage of 
multidimensional ICAT analysis is that the complexity of the peptide mixture is reduced and thus 
analysis	of	a	higher	number	of	unique	proteins	and	associated	quantification	is	achieved	for	a	
given time during the automated LC-MS/MS procedure. As the technique selects for peptides 
that	contain	free	cysteine	residues	before	labeling,	it	was	relatively	rare	to	find	posttranslationally	
modified	 peptides.	 However,	 this	 lack	 of	 posttranslationally	 modified	 peptides	 could	 be	
overcome	 by	 simply	 analyzing	 avidin	 flow	 through	 peptides	 separately	 in	 a	MS	 approach.	
Nevertheless, from our analysis, it is apparent that ICAT analysis yields maximal information for 
protein	quantification,	whereas	studies	that	are	targeted	toward	posttranslational	modifications	
such as protein phosphorylation would require enrichment steps, as has been demonstrated  by 
(Zhou et al., 2001).
As	with	any	screening	method,	the	data	obtained	by	this	study	are	not	by	themselves	sufficient	to	
explain the mechanisms of neurotrypsin-dependent changes in the CNS. The data do, however, 
implicate new proteins in these processes and suggest that can subsequently be tested by 
hypothesis-driven research or by further large-scale experiments. The insights gained by the 
proteomic	profiling	also	do	not	explain	the	mechanisms	by	which	protein	concentrations	in	the	
CNS change. Changes in the rates of synthesis or degradation, the intracellular redistribution of 
a constant protein pool, or a combination of these factors could lead to the same apparent 
result.	 More	 extensive	 and	 repetitive	 experiments	 using	 ICAT	 protein	 profiling	 that	 include	
systemic subcellular fractions of brain tissue and additional time-resolved observations would 
be expected to differentiate the factors underlying the observed changes.
Four independent approaches to measure protein changes in E. coli treated with triclosan, 
an inhibitor of fatty acid biosynthesis were performed and more than 24’000 peptides were 
quantitated in an ICAT-MS experiment (Molloy et al., 2005). The results of this study demonstrated 
that	quantitatively,	 the	 technique	provided	good	 reproducibility,	and	on	average	 identified	
more than 450 unique proteins per experiment. However, the method was strongly biased to 
detect acidic proteins (pI < 7), underrepresented small proteins (<10 kDa) and failed to show 
clear superiority over 2DE methods in monitoring hydrophobic proteins from cell lysates.
Therefore, we complemented the ICAT-MS approach with the 2DE-MS method, which shows a 
preference	for	low	Mr	proteins	and	also	identifies	cysteine-free	proteins	that	were	transparent	
to	the	 ICAT	method.	Whereas	the	 ICAT-MS	method	quantifies	 the	sum	of	 the	protein	species	
of	one	gene	product,	the	2DE-MS	method	quantifies	at	the	level	of	resolved	protein	species,	
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including	 posttranslationally	 modified	 and	 processed	 polypeptides.	 Our	 data	 indicate	 that	
different proteomic technologies applied to the same sample may provide additional types of 
information that contribute to a more complete understanding of the biological system studied. 
On the other hand, we also conclude that the potential of 2DE-MS for complete proteome 
analysis	is	likewise	limited	and	is	preferentially	used	to	support	quantifications	from	LC-MS	based	
proteomics through stable isotope coding. Applying this technique alone limits the ability to 
analyze proteins of medium to low abundance. Due to the large range of protein expression 
levels	as	well	as	to	subtle	neurotrypsin-dependent	changes	 it	would	be	difficult	to	sufficiently	
resolve the perturbations of regulatory changes by 2DE alone.
In	conclusion	the	proteomic	profiling	of	subcellular	fractions	from	the	neurotrypsin-overexpressing	
mouse line provided insight into the complex interaction of a serine peptidases in the brain. Until 
now,	no	outstanding	change	in	any	of	the	protein	identification	was	recorded.	Two	reasons	might	
account for this. Either there is no bigger change than what we have found in our approach 
or,	more	 strongly	affected	proteins	with	 higher	abundance	 ratios	are	 not	 yet	 identified.	 It	 is	
known from the literature that serine peptidases potentially have different functions and even 
recognize different substrates depending either on the brain region or on the developmental 
stage (Samson and Medcalf, 2006). Thus, the effects might be diluted out or be too subtle in 
such a way that changes are scarcely detectable in a quantitative approach. Furthermore, 
the proteolytic overactivity might be inhibited by compensatory mechanisms operating in 
a temporally restricted manner such as an increase in the synthesis of inhibitors. Induction of 
endogenous inhibitors that limit the glaring damage potentially caused by overexpressed 
neurotrypsin during the time of active Thy-1.2 promotor might protect the brain from disastrous 
consequences. Of course technical improvements might as well lead to a more comprehensive 
proteome analysis. Due to redundant and incomplete database entries, still many uninterpreted 
good	quality	CID	spectra	are	left	over	in	shotgun	proteomics.	With	a	dynamic	spectrum	quality	
assessment and iterative computational analysis of proteomic data we would gain more 
efficient	identifications	of	posttranslational	modifications,	sequence	polymorphisms,	and	novel	
peptides (Nesvizhskii et al., 2006). 
In conclusion, minor proteome changes can technically be shown with differential isotope 
labeling	but	remain	difficult	to	be	verified	by	independent	methods.
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5. Material and Methods
5.1 Subcellular fractionation
5.1.1 Isolation of synaptosomes
Synaptosomes	were	prepared	as	described	by	Phelan	P.	&	Gorden-Weeks	P.R.	(in	Turner	A.J.	
and Bachelard H.S., Neurochemistry: A Practical Approach). Briefly,	whole	mouse	brains	were	
dissected and homogenized in a Potter-Elvehjem homogenizer (900 rpm, 12 up-and-down 
passes) in solution A (5 mM HEPES, 320 mM sucrose, pH 7.4). To remove cell debris and nuclei, 
the homogenate was centrifuged twice for 5 min at 1000 x gmax (Sorvall centrifuge, SS-34 rotor, 
DuPont Instruments) and the combined supernatants were centrifuged for 20 min at 12 000 
x gmax (Sorvall centrifuge, SS-34 rotor, DuPont Instruments). The resulting pellet had a colored 
layer at the bottom of the centrifuge tube, which was mainly composed of mitochondria, 
whereas the rest of the pellet was white and contained the majority of the synaptosomes. 
By careful whirl mixing the synaptosomes could be resuspended, whereas the major part of 
the mitochondrial pellet was left behind. This step was repeated once. The white part of the 
pellet was resuspended in 2.6 ml solution A in a handheld homogenizer, and layered carefully 
on top of a Ficoll gradient consisting of 4.8 ml 12% Ficoll overlaid with 4.8 ml 7.5% Ficoll in 13.2 
ml centrifuge tubes (Beckman Instruments). After centrifugation at 68 000 x gmax (Centrikon 
ultracentrifuge,	SW	41	Ti	rotor,	Beckman	Coulter),	for	1	hour,	the	synaptosomes	were	enriched	
as	a	cream-colored	band	at	the	7.5%/12%	Ficoll	interface.	A	myelin	layer	was	floating	on	top	
of the gradient and free mitochondria were in the pellet. The synaptosomes were recovered 
by aspiration, resuspended in Krebs’ solution (145 mM NaCl, 5 mM KCl, 1.2 mM CaCl2, 1.3 mM 
MgCl2×6H2O, 1.2 mM NaH2PO4×2H2O, 10 mM glucose and 20 mM HEPES, pH 7.5) and centrifuged 
for 20 min at 12 000 x gmax (Sorvall centrifuge, SS-34 rotor). The pellet was resuspended in solution 
A and stored at -80 °C.
5.1.2 Hippocampus fractionation
Mouse hippocampi were dissected and homogenized in a Potter-Elvehjem homogenizer (900 
rpm, 12 up-and-down passes) in solution A. To remove cell debris and nuclei, the homogenate 
was centrifuged twice for 10 min at 3000 x gmax (Eppendorf 5417R Microcentrifuge) and the 
combined supernatants were centrifuged for 45 min at 34 000 x gmax (Optima TLX Ultracentrifuge 
and TLA 100.3 rotor, Beckman Coulter). The resulting pellet was resuspended in solution A and 
termed P2, and the supernatant was collected and termed S2. Except for the ICAT experiment, 
both fractions were then incubated at 4 °C for 30 min with lysis buffer (20 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 1% Triton X-100 and 1x Roche complete Mini, EDTA free protease inhibitor cocktail) 
and stored at -80 °C until use.
5.2	 Isotope-coded	Affinity	Tag	(ICAT)
Between 0.5 and 1 mg proteins extracts from wild-type and transgenic sample were solubilized 
in 0.1% SDS, 200 mM Tris-HCl pH 8.3, 5 mM EDTA, 6 M urea. To reduce the disulphide bridges, 5 
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mM TCEP was added and the protein extract was incubated for 30 min at 37 °C. Equal amounts 
of proteins were labeled with cleavable light (12C) for wild-type and heavy (13C) ICAT reagent 
(Applied Biosystemss) for transgenic sample. In order to guarantee a complete labeling at 
least a two fold molar excess of reagent over free sulfhydryl groups was added to the sample 
for 90 min in the dark at room temperature with gentle agitation. The labeling reaction was 
quenched with ten fold molar excess of DTT over reagent. The labeled proteins were then 
combined,	diluted	down	to	a	final	urea	concentration	of	1	M,	and	digested	with	1	mg	trypsin	
(Promega) per 100 mg protein overnight at 37 °C. To reduce the complexity, the resulting 
peptide mixture was separated by strong cation exchange chromatography on an Ettan LC 
system (Amersham Biosciences) using a 2.1 mm x 20 cm Polysulfoethyl A column (PolyLC) at a 
flow	rate	of	0.2	ml/min.	The	buffers	used	were	5	mM KH2PO4 pH 3.0, 25% ACN for buffer A and 
5 mM KH2PO4 pH 3.0, 400mM KCl, 25% ACN for buffer B. The eluting salt gradient was up to 25% 
buffer B within 13.2 ml and up to 100% buffer B within 8.8 ml. In total, 62 fractions, 440 μl each, 
were collected. To neutralise the pH, 100 mM Na2HPO4 pH 10 was used. The labeled cysteine-
containing	peptides	were	then	isolated	manually	using	an	avidin	affinity	column	(ICAT	cartridge	
avidin, Applied Biosystems) according to the manufacturer’s instructions. After concentration 
of	the	avidin	purified	fractions,	the	biotin	tag	was	removed	by	acid	cleavage	using	cleaving	
reagent (Applied Biosystems) for 2 h at 37 °C. Finally, the peptides were cleaned-up for MS 
by	solid	phase	extraction	using	Sep-Pak	cartridges	(Waters).	The	samples	were	concentrated	
again, dissolved in 15 μl 0.2% acetic acid and stored at -80 °C until use.
5.3	 Mass	Spectrometry	(MS)
5.3.1 Reversed-Phase microcapillary Liquid Chromatography Electrospray 
Ionization	Mass	Spectrometry	(RP-µLC-ESI-MS)
RP-μLC-ESI-MS was performed coupling a Probot (LC-Packings/Dionex) autosampler system in-
line with an LCQ Deca quadrupole IT (ion trap) mass spectrometer (Thermo Finnigan). Samples 
were automatically injected into a 10 μl loop and loaded onto an analytical column (75 μm x 
8 cm column packed in-house with Magic C18 AQ beads 5 µm, 100 Å (Michrom)) prior to the 
ionization.	Peptide	mixtures	were	delivered	to	the	analytical	column	at	a	flow	rate	of	300	nl/min	
of buffer A (5% ACN, 0.2% formic acid) for 25 min and then eluted using a gradient of buffer B 
(80% ACN, 0.2% formic acid). 0 – 12%; 6%/min, 12 – 43%; 0.3%/min. Peptide ions were detected 
in a survey scan from 400 – 2000 a.m.u. followed by 3 MS/MS scans in an automated fashion. 
Alternatively, for the hippocampus S2 and P2 fraction an LTQ-FT mass spectrometer was used. 
Nanoflow-LC	MS/MS	was	performed	coupling	an	Agilent	1100	HPLC	(Agilent	Technologies)	to	
a 7-Tesla LTQ-FT mass spectrometer (Thermo). For peptide LC analytical columns (15 cm X 50 
µm) were packed in-house with ReproSil-Pur C18- AQ, 3 µm	(Dr.	Maisch	GmbH).	With	a	flow	
rate of 150 nl/min, peptides were transferred to the analytical column and eluted in a gradient 
of acetonitrile (1%/min) in 0.1 M acetic acid. The eluate was sprayed via emitter tips (New 
Objective), butt-connected to the analytical column. The mass spectrometer operated in 
data-dependent mode, automatically switching between MS and MS/MS acquisition for the 
three most abundant peaks in a given spectrum. The full-scan MS spectra were acquired in the 
Fourier transform-ion cyclotron resonance (FT-ICR) at a target value of 5 x 106 with a resolution 
of 20,000. The three most intense ions were then isolated for accurate mass measurements by 
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an FT-ICR-selected ion monitoring scan, which consisted of 10-Da mass range, at a resolution of 
50,000. These ions were then fragmented in the linear ion trap.
5.3.2	 Matrix-Assisted	 Laser	 Desorption/Ionization-Time-Of-Flight	 Mass	
Spectrometry	(MALDI-TOF	MS)
The samples were analyzed on a 4700 Proteomics Analyser MALDI TOF/TOF system (Applied 
Biosystems), which is equipped with a Nd:YAG laser operating at 200 Hz. All mass spectra were 
recorded	 in	positive	 reflector	mode,	and	 they	were	generated	by	accumulating	data	 from	
5000 laser pulses. First, MS spectra were recorded from the standard peptides on each of the 
six calibration spots, and the default calibration parameters of the instrument were updated. 
Subsequently, MS spectra were recorded for all sample spots and internally calibrated using 
signals from autoproteolytic fragments of trypsin if these signals were detectable. Up to four 
spectral peaks per spot that met the threshold criteria were included in the acquisition list for the 
MS/MS spectra. Peptide fragmentation was performed at collision energy of 1 kV and a collision 
gas pressure of approximately 2 x 10-7 Torr. Data from 2500 - 5000 laser pulses were summed up 
for each fragment ion spectrum.
5.3.3	 Protein	identification	and	quantification
5.3.3.1 Mascot search engine
For the database searches of MS/MS spectra of ICAT labeled hippocampal peptides collected 
with the LTQ FT-ICR, the peptide tolerance was set to 10 ppm and the MS/MS tolerance to 
0.5	Da.	Variable	modifications	on	cysteine	residues	of	the	ICAT	light	and	heavy	reagents	were	
chosen at 227.126991 and 236.157185, rsp. Oxidation of methionine, N-terminal pyroglutamic 
acid	and	N-acetylation	were	selected	as	variable	modifications.	A	human-mouse-rat	database	
downloaded from EBI (83028 sequences, release date: September 09, 2006) was used.
GPS (Global Proteome Server) Explorer Software version 3.5 (Applied Biosystemss) was used 
for submitting MS and MS/MS data for database searching from MALDI TOF-TOF experiments. 
Mascot version 2.1.0 (Matrix Science, London, UK) was utilized as the search engine (Perkins 
et al., 1999) and database searching was performed using a mouse protein database 
downloaded from the European Bioinformatics Institute (EBI) (32849 sequences, release date: 
March 25, 2006) Typically, the following search settings were used: maximum number of missed 
cleavages: 1; peptide tolerance: 35 ppm; MS/MS tolerance: 0.2 Da. Carboxyamidomethylation 
of	cysteine	was	set	as	fixed	modification,	and	oxidation	of	methionine	was	selected	as	variable	
modification.
5.3.3.2 SEQUEST search algorithm
The MS/MS spectra from the ESI-MS were used by SEQUEST algorithm (Eng et al., 1994) to search 
a protein sequence database. To identify the proteins from the synaptosomes, which were all 
recorded with an LCQ Deca mass spectrometer and proteins from the hippocampus fractions 
S2 and P2 that were measured with LTQ-FT mass spectrometer a the following settings were 
applied for SEQUEST analysis: the maximum number of missed cleavages was 1; the peptide 
tolerance was 3.0 Da; the fragment ion tolerance 1 Da. Different search options were selected 
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for	oxidation	of	methionine	and	9	Da	on	cysteine,	whereas	a	fixed	modification	of	227.13	was	
selected	for	cysteine	residues.	As	for	the	identification	of	hippocampal	proteins	a	human-mouse-
rat database downloaded from EBI (83028 sequences, release date: September 09, 2006) was 
used and the settings were taken as indicated above.
5.3.3.3 Peptide and Protein Probability Assignment
The statistical model PeptideProphet was used to assess the validity of peptide assignments 
from SEQUEST data set (Keller et al., 2002). From each data set, it learns the distribution of search 
scores and peptide properties among correct and incorrect peptides. Those distributions are 
used	to	compute	for	each	result	a	probability	that	it	is	correct.	This	analysis	allows	filtering	large	
volumes of MS/MS data with predictable false error rates and sensitivity values. A maximum 
error	rate	of	5%	was	chosen	for	peptides	to	pass	the	filter.	Protein	identifications	were	validated,	
using ProteinProphet,	 a	 statistical	 model	 that	 allows	 filtering	 large-scale	 proteomics	 data	
sets	with	predictable	 sensitivity	and	 false	positive	 identification	error	 rates.	Different	peptide	
identifications	allocated	to	the	same	protein	are	combined	to	estimate	the	probability	that	their	
corresponding protein is present in the sample (Nesvizhskii et al., 2003). A Minimal Probability 
Threshold (MPT) of 0.95 was chosen for ProteinProphet.
5.3.3.4	 Automated	Statistical	Analysis	on	Protein	Ratio	(ASAPRatio)
ASAPRatio	calculates	the	relative	abundance	of	proteins	and	the	corresponding	confidence	
intervals from ICAT-type LC ESI-MS data (Li et al., 2003). First, the software reconstructs single 
ion chromatogram (SIC) of a peptide and its partner, subtracts background noise from each 
chromatogram, and calculates light: heavy ratio, in one charge state. Second, the ratios of 
the same peptide in different charge states are averaged and weighted by the corresponding 
intensity to obtain the peptide light: heavy ratio and its error. Subsequently, all unique peptides 
identifications	 for	 a	 given	 protein	 are	 collected;	 their	 ratios	 and	 errors	 calculated,	 and	 the	
relative	protein	abundance	ratio	and	the	confidence	interval	are	computed,	applying	statistics	
for weighted samples. A by-product of the software is to identify outlier peptides that may 
be	misidentified	or,	more	 interestingly,	may	bear	unidentified	post-translational	modifications	
(PTM). 
5.3.3.5 XPRESS software
The XPRESS software automates protein expression calculations by accurately quantifying the 
relative	abundance	of	 ICAT-labeled	peptides	 from	 their	chromatographic	co-elution	profile.	
Starting	with	the	peptide	identification,	XPRESS	reconstructs	the	light	and	heavy	peptide	elution	
profiles	of	the	precursor	ions	and	determines	the	area	of	each	peptide	peak	and	calculates	
the protein abundance ratio based on these areas (Han et al., 2001). Furthermore, the program 
provides a graphical, interactive interface to the results. Averages plus standard deviations 
are calculated for each protein expression value when multiple peptide measurements are 
available. As opposed to ASAPRatio the mass tolerance is displayed and can be adjusted 
according to the mass accuracy of the mass spectrometer used. Accordingly, the mass 
tolerance was set to ± 0.5 units when using FT-ICR.
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5.4 2D Gel Electrophoresis
5.4.1	 First	Dimension:	Isoelectric	Focusing	(IEF)
IEF was performed using Immobiline Dry Strip pH 4 – 7, 24 cm. The strips were rehydrated in the 
Reswelling Tray (Amersham Biosciences) for 20 hours in 450 μl of rehydration buffer (7 M urea, 2 
M thiourea, 4% (w/v) CHAPS, 0.5% (v/v) IPG Buffer pH 4-7 (Amersham Biosciences), 1.2% (v/v) 
DeStreak Reagent (Amersham Biosciences), 0.002% bromphenol blue). 150 μg of protein was 
precipitated and interfering substances (salt, detergent) were removed with the 2D Clean-Up 
Kit (Amersham Biosciences). The proteins were dissolved in 50 μl of solubilization buffer (7 M urea, 
2 M thiourea, 40 mM DTT, 4% (w/v) CHAPS, 2% IPG Buffer pH 4-7) and cup-loaded onto the strips. 
For	the	first	dimension	the	Ettan IPGphor IEF System (Amersham Biosciences) was used with 
the following focusing steps: Step 1: 500 V, 1 min, gradient; Step 2: 500 V, 4 hours, step-and-hold; 
Step 3: 4000 V, 1.5 hours, gradient; Step 4: 8000 V, 45 kVh, step-and-hold. After the IEF the strips 
were frozen at -80 °C until use.
5.4.2 Second Dimension: SDS-PAGE
In-house casted 10% gels containing 10% acrylamide, 0.32% methylenebisacrylamide, 0.375 
M Tris/HCl (pH 8.8), 5% glycerol, 0.1% SDS, 0.05% ammonium persulfate, 0.0005% TEMED were 
casted in the Ettan Dalt II Gel Caster System (Amersham Biosciences). The Immobiline Dry Strips 
were	first	equilibrated	for	15	min	in	SDS-equilibration	buffer	(25	mM	Tris-base,	192	mM	glycine,	
01% (w/v) SDS) with 2% (w/v) DTT, followed by a 15 min equilibration in SDS-equilibration buffer 
containing 2.5% (w/v) iodacetamide, before placed on top of the gels. The Ettan Dalt II System 
(Amersham Biosciences) was used to run the gels in SDS-electrophoresis buffer containing 25 
mM	Tris-HCl	pH	8.3,	192	mM	glycine,	0.1%	SDS	with	constant	power	of	2.5	W/gel	for	30	min	for	a	
start	followed	by	12	W/gel	for	3	–	4	hours	to	separate	the	proteins	in	the	second	dimension.	The	
gels	were	fixed	in	30%	EtOH	and	10%	acetic	acid	overnight	and	washed	three	times	30	min	in	
20% EtOH. Ruthenium II tris (bathophenantroline disulfonate) (RuBP) was added to stain the gels 
as described by Lamanda et al., 2004 (Lamanda et al., 2004). The 2D gels were scanned using 
the Typhoon 9400 Variable Mode Imager (Molecular Dynamics) and Proteomeweaver software 
was used to analyze the gels.
5.4.3 2D Gel Analysis software
High-resolution	images	were	analyzed	using	Proteomweaver	v3.0	(Definiens).	Gel	images	were	
converted	 into	 8-bit	 TIF	 files	 and	 processed	 with	 Proteomweaver	 software,	 which	 allowed	
spot	 detection,	 gel	 matching,	 quantification,	 and	 statistical	 analysis.	 Different	 analysis	 sets	
were used for pairwise comparison of two protein-spots on the gels. The entire signal on each 
gel was normalized before the detection of spot boundaries and calculation of the intensity 
ratio for each spot pair was performed. Average abundance changes were calculated from 
regulation factors. Student’s t test was used for statistical analysis. Quality assurance statistics, 
which calculates the reliability of the regulation factor, indicated that a regulation factor for S2 
is suitable at 1.7 and for P2 it was above 2. Only spots with at least 1.5-fold change in intensity 
(P	≤	0.05)	and	a	coefficient	of	variation	of	less	than	25%	after	normalization	were	considered	as	
differentially expressed. 
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5.4.4	 Spot	Excision,	Digestion	and	Spotting	on	MALDI	target	plate
Protein spots from the 2D gels were excised with the GelPix Spot Picking Robot (Genetix). Before 
it, the gels were imaged using an on-board camera. The image was matched with pre-selected 
spots	from	analysis	sets	using	Proteomweaver.	In	this	way	a	user	defined	protein	target	excision	
list was generated. The protein spots were picked with an eight channel excision head. The 
gel slices were transferred to a V-shaped 96-well plate (Greiner) and stored in H2O	at -20 °C. 
In-gel	digestion,	extraction,	and	purification	of	peptides	with	subsequent	spotting	onto	MALDI	
target plates was performed using the fully automated Genesis ProTeam 150 Platform (TECAN). 
The	robot	was	configured	with	eight	liquid	handling	tips.	Four	nanopipetting	tips	were	used	to	
prepare excised gel samples for proteolytic digestion and four adaptor tips picked up ZipTips 
μ-C18 (Millipore) pipette tips in order to desalt peptide mixtures and to spot them onto MALDI 
target plates. In brief: The storage solution was removed and replaced by 80% ACN. After 10 
min, the ACN was removed and evaporated for additional 10 min. The dehydrated gel slices 
were	incubated	in	6.7	µg/µl	sequence	grade	modified	Trypsin	(Promega)	dissolved	in	5	mM	Tris-
HCl, pH 8.3 for 3 hours. The proteolysis was stopped by adding 1% TFA. The tryptic peptides were 
purified	and	spotted	onto	MALDI	target	plates	as	follows:	First,	the	ZipTips	were	pre-wetted	with	
80% ACN, 0.02% TFA and washed two times with 0.1% TFA. Second, the peptides were bound 
to the ZipTips by aspirating and dispensing the sample 5 – 7 cycles and washed again. Third, 
the peptides were spotted onto the target plate with MALDI matrix solution, containing 4 mg/
ml α-CCA in 65% ACN, 0.035% TFA. Finally, the samples were analyzed using 4700 Protoemics 
Analyser MALDI-TOF/TOF.
5.5 Antibodies
Polyclonal goat antibody G87 was generated against the protease domain of mouse 
neurotrypsin. G93 was raised against the full-length protein of mouse neurotrypsin. The R132 
polyclonal rabbit antibody was raised against the 80 kDa cleaved agrin fragment and R139 
was generated against the very C-terminal LG3 domain of rat agrin. G92 was produced using 
the same antigen but immunization was performed in a goat instead of a rabbit. All antibodies 
were	affinity	purified.	A	polyclonal	antibody	against	adenosine	 kinase	was	a	 kind	gift	of	Dr.	
D. Boison (Department of Pharmacology, University of Zurich). Monoclonal antibodies against 
α-CaMK II, clone 6G9 (ab2725), Na+/K+-ATPase-α3, clone XVIF9-G10 (ab2826) and polyclonal 
antibodies against Glutamine Synthetase (ab16802), Kinesin Heavy Chain 2 (ab3475) and PKC-
γ (ab4144) were all purchased from Abcam. The monoclonal antibody against phospho-α-
CaMK II	(pThr286),	clone	22B1	(MA-1-047)	was	from	Affinity	BioReagents.	Monoclonal	antibodies	
against CD81, clone Eat1 (559516), N-Copine (611588), Glutamate Receptor 2/3, clone 6C4 
(556341), Complexin 2, (610728), PSD-95 (610495), Rab3 (610379), and α-/ß-SNAP (611898) 
were all from BD Biosciences Pharmingen. Monoclonal antibodies against MAP-2, clone AP20 
(MAB3418), Synaptophysin, clone SY38 (MAB5258), NeuN (MAB377) and GFAP (MAB360) were 
from Chemicon. Polyclonal antibodies against Rho GDI (sc-360), PKC-ε (sc-214), Tenascin-C (sc-
20932), VDAC1 (sc-8828), MAP-1A (sc-8969), EAAT2/GLT-1 (sc-7760), PAK-1 (sc-882), Grp-78 (sc-
1050) were from Santa Cruz Biotechnology, Inc. Monoclonal antibodies agains ß-actin, clone 
AC-74 (A5316) and ß-COP (G6160) were from Sigma. The monoclonal antibody against Na+/K+-
ATPase-α1, clone C464.6 (05-369), and polyclonal antibodies against MAPK2 (06-333), phospho-
MAPK1/2 (07-467), and PP2A, A subunit (07-250) were from Upstate. And monoclonal antibody 
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against	Neurofilament-160	(NF-M),	clone	RMO-270	(13-0700)	was	from	Zymed	Laboratories	Inc.
5.6 Gel electrophoresis and immunoblotting
5.6.1 SDS-PAGE
Protein samples were boiled for 5 min in reducing SDS-PAGE loading buffer and electrophoretically 
separated on 7.5%, 10% or 12% polyacrylamide containing 0.1% SDS with constant current of 25 
mA/gel (Laemmli, 1970).
5.6.2 NuPAGE 4 – 12%  Bis-Tris and 10 – 20% Tricine Gel
Protein samples were dissolved in NuPAGE® LDS Sample Buffer or Novex® Tricine SDS Sample 
Buffer (Invitrogen) and incubated at 70 °C for 10 min or 85 °C for 2 min, respectively. The samples 
were loaded onto NuPAGE® 4-12% Bis-Tris or 10-20% Tricine Gels (Invitrogen) and separated at 
40 mA/gel.
5.6.3 Immunoblotting
Proteins resolved by gel electrophoresis were transferred to either nitrocellulose (Schleicher 
&	 Schuell)	 or	 PVDF	 (Millipore)	 membranes.	 For	 semi-dry	 Western	 blotting	 the	 proteins	 were	
transferred at constant voltage of 24 V for 1 hour in a BioRad Trans-Blot semi-dry power supply or 
the transfer was done at 30 V constant overnight in a Criterion Blotter (BioRad) for wet blotting. 
The	nitrocellulose	membranes	were	blocked	for	1	hour	in	PBS	containing	1%	Western	Blocking	
Reagent (Roche) and the PVDF membranes were rinsed in MetOH and let air-dry for blocking. 
Primary antibodies were incubated at room temperature for 2 hours or at 4 °C overnight, diluted 
in	 PBS	 and	 0.4%	 Western	 Blocking	 Reagent	 as	 indicated	 below.	 After	 washing,	 secondary	
antibodies conjugated to HRP were added for 45 min at room temperature as follows: anti-
goat-HRP (1:30,000), anti-rabbit-HRP (1:20,000) and anti-mouse-HRP (1:20,000). Finally, the blots 
were	developed	with	chemiluminescent	substrate	Chemiglow	(Witec	AG,	Littau,	Switzerland;	
Alpha	Innotech)	and	recorded	digitally	on	LAS-300	Luminscent	Image	Analyzer	(Fujifilm).
Antiobody	dilutions
name	 	 	 	 	 Preparation	 	 	 	 dilution
G87	 	 	 	 	 affinity-purified	 	 	 0.005	mg/ml
G93	 	 	 	 	 affinity-purified	 	 	 0.005	mg/ml
R132     serum (2nd boost)   1:3000
R139     serumm (2nd boost)   1:1000
anti-ß-actin	 	 	 	 ascites	fluid	 	 	 	 1:10000
anti-ADK	 	 	 	 affinity-purified	 	 	 1:3000
anti-ß-COP	 	 	 	 ascites	fluid	 	 	 	 1:10000
anti-α-CaMK II    IgG1     1:4000
anti-p-α-CaMK II   IgG1     1:2000
anti-EAAT2/GLT-1   IgG1     1:1000
anti-GFAP    IgG1     1:2000
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anti-GluR2    IgG2a     1:1000
anti-Glutamine Synthetase  IgG1     1:2000
anti-Grp-78    IgG1     1:1000
anti-MAPK2    IgG1     1:2000
anti-p-MAPK1/2   IgG1     1:2000
anti-Na+/K+-ATPase-α1		 	 ascites	fluid	 	 	 	 1:3000
anti-Na+/K+-ATPase-α3   IgG1     1:5000
anti-N-Copine    IgG1     1:2000
anti-Neurofilament		 	 	 IgG2a     1:2000
anti-PAK-1    IgG1     1:2000
anti-PSD-95    IgG1     1:2000
anti-Rho GDI    IgG1     1:1000
anti-Synaptophysin   IgG1     1:10000
anti-VDAC1    IgG1     1:1000
5.7	 Cleavage	of	 agrin	by	 co-expression	with	neurotrypsin	 in	HeLa	
cells
For expression ot neurotrypsin, the coding region of full-length human neurotrypsin (CAA04816) 
was inserted into pcDNA3.1 vector (Invitrogen). Catalytically inactive neurotrypsin (S/A) was 
generated by mutating Ser825 to Ala by means of overlapping extension PCR. For expression 
of membrane-bound full-length agrin, the coding sequence ranging from Met1 to Pro1959 of rat 
agrin (P25304, splice variant y4z8) was inserted into pcDNA3.1. HeLa cells were cultured to 60 
.	80%	confluency	 in	12-well	culture	plates	 (Corning)	with	DMEM	supplemented	with	10%	FCS	
(Biochrom). Polyethylenimine (PEI) was used as transfection reagent as described in (Baldi et 
al., 2005). The transfection mixture was removed 4 – 6 h after transfection by washing once with 
PBS. After 48 h in DMEM without FCS the medium was harvested and the cells were lysed in 150 
mM NaCl, 0.5 mM EDTA, 10% glycerol, 1% Triton-X-100 in 20mM Tris-HCl, pH 7,4. For the analysis of 
the cleavage products supernatants and cell lysates were separated on a 4 – 12% NuPAGE gel 
(Invitrogen) and analysed by immunodetection.
5.8 Immunohistochemistry
Animals	were	fixed	by	transcardiac	perfusion	using	a	perfusion	pump.	Freshly	prepared	fixative	
containing 4% PFA in Na+ phosphate buffer, pH 7.4, and 15% saturated picric acid was used to 
ensure preservation of the tissue and good antibody penetration. The brain was dissected out 
and	postifxed	in	the	same	fixative	for	1	hour	or	overnight	at	4	°C.	Cryoprotection	was	done	in	
ice-cold PBS with 10% (v/v) DMSO for 3 hours at 4 °C. The tissue was embedded in Tissue-Tek® 
O.C.T. Compound (Bayer) and was shock frozen in isopenthan and stored at -20 °C until use. 
Sectioning from frozen blocks was cut with LEICA CM3050 S sliding microtome at 40 μm. The 
tissue sections were either stained with immunoperoxidase (VECTASTAIN Elite ABC Kit VECTOR 
Laboratories)	method	or	with	immunofluorescence.
In brief, for immunoperoxidase staining the sections were blocked in Tris-Triton (0.05%) pH 7.4 
with 20% normal goat serum (NGS), 0.2% Triton X-100 for 1 hour and incubated with the primary 
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antibody diluted in Tris-Triton with 2% NGS and 0.1% Triton X-100 overnight. The next day, the 
sections were washed in TBS and biotinylated secondary antibodies were allowed to bind 
for 2 hours (Elite ABC Kit). After another wash step the ABC solution (Elite ABC Kit) containing 
avidin DH and biotinylated HRP H reagents was added for 1 hour, washed again, and then the 
sections were conditioned to pH 7.6 in 50 mM Tris buffer before the incubation with substrate 
solution DAB (0.5 mg/ml in TB, pH 7.6) for 30 min at dark. The reaction was catalyzed with 0.5% 
H2O2 until the sections had the appropriate color and stopped by transferring them into TB for 
two times 5 min and further into PBS before mounting the sections onto gelatinized glass slides. 
For dehydration they were shortly incubated in increasing vol.-% of EtOH (50, 70, 96 and 100%) 
followed by Xylene for 30 min before coverslipped with EUKITT mounting medium (Fluka).
For	 immunofluorescence	staining	the	sections	were	blocked	in	TBS	pH	7.4	with	20%	FCS,	0.2%	
Triton X-100 for 1 hour and incubated overnight with the primary antibody diluted in TBS with 
2% FCS and 0.1% Triton X-100, washed and incubated with the Cy3 or FITC labeled secondary 
antibody for 2 hours. After another washing step the sections were mounted using the 
Vectashield mounting medium (Vector Laboratories). The staining was either visualized under 
the	epifluorescent	microscope	LEITZ	DMRXE	(Leica)	or	by	confocal	microscopy	using	a	LEICA	SP1	
confocal microscope at the Center for Microscopy and Image Analysis, University of Zurich.
5.9	 Generation	 of	 transgenic	 mouse	 lines	 overexpressing	
neurotrypsin
Endogenous	expression	of	neurotrypsin	was	mainly	localized	to	specific	brain	regions	involved	
in learning and memory. It was also found that neurotrypsin is tightly regulated during postnatal 
development of the nervous system and its expression is reduced for the maintenance of the 
nervous	 system	during	adulthood	 (Gschwend	et	al.,	 1997;	Wolfer	et	al.,	 2001).	 The	 intriguing	
expression	pattern	and	the	finding	that	neurotrypsin	is	a	CNS	specific	serine	peptidase	suggests	
an important molecular function in processes such as synapse formation, elimination and 
synaptic plasticity. To shed light on the proteolytic and non-proteolytic activity of neurotrypsin 
transgenic	mouse	lines	overexpressing	neurotrypsin	under	the	control	of	the	brain	specific	Thy-1.2	
expression cassette were generated. The Thy-1.2 expression cassette drives strong constitutive 
expression	of	 transgenes	specifically	 in	neurons	of	 transgenic	mice	(Caroni,	1997).	Transgene	
expression begins at P6 - 10, at a time when it can affect activity-dependent rearrangements 
of synaptic connections and neuron-glia interactions during the late phase of nervous system 
development. The Thy-1.2 activity peaks at P12, with a subsequent sharp decline. The promotor 
activity remains relatively low thereafter (Radrizzani et al., 1995). These properties of the Thy-
1.2 promotor can be exploited to study the effects of neurotrypsin during late phase nervous 
system development and in the adult with the added possibility that different combinations of 
expressing and non-expressing neurons in transgenic animals derived from different founder 
lines	can	be	analyzed.	An	expression	construct	 including	a	floxed	STOP	cassette	followed	by	
the cDNA of human neurotrypsin (hNT) was ligated into the XhoI site of the promotor region, 
resulting in a dormant hNT expression cassette under the control of the Thy-1.2 promotor (Fig. 
5.1a). Removal of the STOP cassette can be used to activate the hNT transgene expression. This 
was achieved by crossing CMV-Cre with hNT (transgene494) transgenic mice. In the resulting 
double transgenic animals the Cre-recombinase removes the STOP cassette. Subsequent 
crossing with another hNT-CMV-Cre double transgenic mouse might occasionally result in a 
constitutively hNT overexpressing mouse line where the transgene has gone germline. In these 
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mice, termed Muslick 494 (M494), hNT expression is solely under the control of the Thy-1.2 
promotor (Fig. 5.1b). Transgenic mice derived from different founder lines, carrying the same 
expression constructs, called Muslick 491 (M491) strong expressor, or M491S, were also used in 
this report. Furthermore, two control lines were used. First, a transgenic mouse line still bearing 
the STOP cassette since it was not crossed with a CMV-Cre transgenic mouse, resulting in a 
transgenic	mouse	line	with	a	dormant	hNT	transgene	(floxed	494,	or	f494).	Second,	a	mouse	line	
overexpressing a proteolytically inactive form of mouse neurotrypsin, where the active serine 
of the catalytic triad was mutated to an alanine (S/A 785). Finally, a neurotrypsin knock-out 
(KO) mouse was used to check for protein expression levels (Zurlinden et al., submitted). Prior 
to use, all of the animals were tested for the presence of the transgene or the absence of the 
neurotrypsin	gene	by	PCR	using	specific	primers.
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Figure 5.1     Generation of a constitutively human neurotrypsin overexpressing mouse line.
(A) The mouse Thy-1.2 expression cassette is used to drive strong constitutive expression of transgenes specifically in 
neurons. The floxed STOP cassette followed by the human neurotrypsin (hNT) cDNA is cloned into the XhoI site of Thy-
1.2 expression cassette. For injection into mouse pronuclei EcoRI and PvuI sites, flanking the basic construct can be used 
to recover the 6.5 kb of the expression cassette plus transgene, resulting in a transgenic mouse line with a dormant hNT 
transgene. (B) Double transgenic mice are generated by crossing CMV-Cre and silent hNT transgenic mice (tg494). The Cre 
recombinase removes the STOP cassette and activates hNT expression. The subsequent crossing of two double transgenic 
mice may result in a constitutively hNT overexpressing mouse line under the control of  the Thy-1.2 promotor. This coinciden-
tally can occur when the Cre recombinase removes the STOP cassette in the germline to give rise to Muslick 494 (M494).
Material and Methods 
5.10	 Polymerase	Chain	Reaction	(PCR)
5.10.1 PCR genotyping
Genomic DNA was extracted with alkaline lysis from tail biopsies of offspring from hNT 
overexpressing mice crossed with wild-type Black/6 mice. 300 µl alkaline lysis reagent (25 mM 
NaOH; 0.2 mM Na-EDTA, pH 12.0) added to 0.5 cm tail biopsies and lysed for 45 min at 96°C. To 
stop the reaction 300 µl neutralizing reagent (400 mM Tris-HCl, pH 5.0) were added. 1µl extraction 
mixture was used for 20 µl reaction mix. For all PCR reactions the following reaction mix was 
prepared: 1x Buffer (Applied Biosystems), 0.25 mM dNTPs (Applied Biosystems), 1.5 mM MgCl2 
(Sigma) and 0.1 µl Taq-Polymerase (5 U/µl) (Applied Biosystems), 0.5 µM forward primer and 0.5 
µM reverse primer. The primer sequences and the PCR program for each mouse line is indicated 
below	(for	all	but	NTKO	TAG	was	used	as	a	positive	control	for	PCR	amplification,	PCR	products	
of NTKOF01 and NTKOR02 indicated NTKO and of NTKOF01 and NTKOR03 indicated wild-type 
allel:
m494,	m491s	and	f494
hNTSIIfor 5’-GCAATGTGCCAGATTCAGCAG-3’
Thy1back 5’-CCCATGTTCTGAGATATTGGAAG-3’
TAG83for 5’-GGAGGAGAGAGACCCCGTGAAA-3’
TAG82back 5’-ACACGAAGTGACGCCCAATCCGT-3’
PCR program: 1x (3’, 95°C), 40x (45’’, 95°C; 45’’ 63°C; 60’’, 72°C), 1x (5’ 72°C)
s/A	785
mNTIIfor 5’-CAATGTGCCAGACTAAGCACC-3’
Thy1back 5’-CCCATGTTCTGAGATATTGGAAG-3’
TAG83for 5’-GGAGGAGAGAGACCCCGTGAAA-3’
TAG82back 5’-ACACGAAGTGACGCCCAATCCGT-3’
PCR program: 1x (3’, 95°C), 40x (45’’, 95°C; 45’’ 56°C; 60’’, 72°C), 1x (5’ 72°C)
ntko
NTKOF01 5’-CAGAGCTCCTGGCGCTCATC-3’
NTKOR02 5’-GGAAGACAATAGCAGGCATGCTG-3’
NTKOR03 5’-CTCGCAGCTCAGCCCAACTG-3’
PCR program: 1x (3’, 95°C), 40x (45’’, 95°C; 45’’ 61°C; 60’’, 72°C), 1x (5’ 72°C)
5.10.2 Real-time PCR
Real-time PCR was performed to discriminate between heterozygous and homozygous 
transgenic	mice.	PCR	amplifications	were	measured	using	the	Applied	Biosystems	7500	Fast	Real-
Time PCR System. The primers and TaqMan® probes were all designed with Primer Express 2.0 
software (Applied Biosystems). The sequences of the primers and probes used for the amplicons 
of human NT were: forward primer: 5’-CAGTGGAAGTATATGCAAGTGGAGTT-3’, reverse primer: 5’-
GGTTTGTTTTGCTATTCCTTTTCCT-3’, TaqMan® probe: 5’-VIC-TCATTTGTCACCAGCTGCAGCTG GG-
TAMRA-3’, and of murine Tubulin -3 were: forward primer: 5’-TGCGGAAAGAGTGTGAGAATTG-
3’ and reverse primer: 5’-TCACGCACCTTGCTGA TGA-3’, TaqMan® probe: 5’-FAM-
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AGGGCTTCCAGCTGACACACTCA-TAMRA-3’. The real-time PCR was conducted in 10 μl 
reaction volume containing 100 ng template genomic DNA, 1x TaqMan® Fast Universal PCR 
Master Mix No AmpErase® UNG (Applied Biosystems), 900 nM each, forward and reverse primer, 
and 200 nM TaqMan® probes. PCR cycling conditions were as follows: 1 cycle at 95°C for 10 min, 
followed by 40 cycles at 95°C for 15 s and 58 °C for 1 min. The results were analysed on Applied 
Biosystems 7500 Real Time PCR system using Relative Quantitation (RQ) gene expression analysis 
software.
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